Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b,Condition 1c,Condition 2a,Condition 2b,Condition 3a,Condition 3b,Condition 4,Condition 5a,Condition 5b,Condition 6 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",spleen mass,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0000171,spleen wet weight,,,,0.708,g,0.0326,0.073,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 91 days),76115,vehicle control condition (for 91 days),,,,,,,,,, 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",blood total protein amount,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0000661,serum total protein level,,,,9.38,g/dl,0.6695,1.497,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 91 days),76125,vehicle control condition (for 91 days),,,,,,,,,, 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",blood cholesterol amount,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0000363,serum total cholesterol level,,,,68.12,mg/dl,6.422,14.36,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 91 days),76130,vehicle control condition (for 91 days),,,,,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",kidney superoxide dismutase activity,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0002229,kidney superoxide dismutase activity to total protein level ratio,,,,13.53,U/mg,0.8042,1.97,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 10 days),76187,vehicle control condition (for 10 days),,,,,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",kidney superoxide dismutase activity,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0002229,kidney superoxide dismutase activity to total protein level ratio,,,,8.13,U/mg,0.792,1.94,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) ,76188,vehicle control condition (for 10 days),,,cisplatin (7.5 mg/kg) ,,,,,,, 1543,"Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.",body mass,,RS:0002943,BluHsd:LE,male,70 days,8,,CMO:0000012,body weight,,,,353.1,g,10.8,30.547,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days),75955,vehicle control condition (for 30 days),controlled in utero environment (for 9 days),,maternal milk (for 21 days),,,,,,, 1543,"Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.",eating behavior trait,,RS:0002943,BluHsd:LE,male,98 days to 71 days,8,,CMO:0002178,total food calorie intake rate,,,,2995.2,kcal/d,187.0,528.9159,MMO:0000160,unspecified method,,0.0,,,,,controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days),76182,controlled in utero environment (for 9 days),vehicle control condition (for 30 days),,maternal milk (for 21 days),,controlled fat content diet (21.2 %) (for 28 days),,,,, 1543,"Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.",eating behavior trait,,RS:0002943,BluHsd:LE,male,98 days to 71 days,8,,CMO:0002209,food calorie intake level to change in body weight ratio,,,,10.1,kcal/g,0.3,0.8485,MMO:0000160,unspecified method,,0.0,,,,,controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days),76204,controlled in utero environment (for 9 days),vehicle control condition (for 30 days),,maternal milk (for 21 days),,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",catalase activity,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0002224,kidney catalase activity to total protein level ratio,,,,35.98,nmol/mg,0.8083,1.98,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 10 days),76234,vehicle control condition (for 10 days),,,,,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",catalase activity,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0002224,kidney catalase activity to total protein level ratio,,,,21.73,nmol/mg,0.6165,1.51,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) ,76235,vehicle control condition (for 10 days),,,cisplatin (7.5 mg/kg) ,,,,,,, 1543,"Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.",eating behavior trait,,RS:0002943,BluHsd:LE,male,98 days to 71 days,8,,CMO:0002212,food intake weight to change in body weight ratio,,,,6.7,g/g,0.3,0.8485,MMO:0000160,unspecified method,,0.0,,,,,controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days),76203,controlled in utero environment (for 9 days),vehicle control condition (for 30 days),,maternal milk (for 21 days),,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",body mass,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0000012,body weight,,,,140.6,g,0.5307,1.3,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition (for 10 days),75951,vehicle control condition (for 10 days),,,,,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",body mass,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0000012,body weight,,,,137.6,g,0.4491,1.1,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) ,75952,vehicle control condition (for 10 days),,,cisplatin (7.5 mg/kg) ,,,,,,, 1543,"Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.",body mass,,RS:0002943,BluHsd:LE,male,98 days,8,,CMO:0000012,body weight,,,,457.7,g,15.9,44.972,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days),75962,vehicle control condition (for 30 days),controlled in utero environment (for 9 days),,maternal milk (for 21 days),,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",urine output,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0000260,timed urine volume,,,,6.8,ml/d,0.6124,1.5,MMO:0000357,urine volume measurement method,,0.0,,,,,vehicle control condition (for 10 days),75965,vehicle control condition (for 10 days),,,,,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",urine output,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0000260,timed urine volume,,,,21.8,ml/d,1.3064,3.2,MMO:0000357,urine volume measurement method,,0.0,,,,,vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) ,75966,vehicle control condition (for 10 days),,,cisplatin (7.5 mg/kg) ,,,,,,, 1543,"Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.",body mass,,RS:0002943,BluHsd:LE,male,98 days to 71 days,8,,CMO:0000420,body weight gain,,,,104.6,g,5.9,16.6877,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days),75969,vehicle control condition (for 30 days),controlled in utero environment (for 9 days),,maternal milk (for 21 days),,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",blood creatinine amount,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0000057,serum creatinine level,,,,0.54,mg/dl,0.0122,0.03,MMO:0000271,serum creatinine analysis,,0.0,,,,,vehicle control condition (for 10 days),75972,vehicle control condition (for 10 days),,,,,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",blood creatinine amount,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0000057,serum creatinine level,,,,1.69,mg/dl,0.0572,0.14,MMO:0000271,serum creatinine analysis,,0.0,,,,,vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) ,75973,vehicle control condition (for 10 days),,,cisplatin (7.5 mg/kg) ,,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",blood urea nitrogen amount,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0000587,serum urea nitrogen level,,,,69.64,mg/dl,2.4985,6.12,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 10 days),75976,vehicle control condition (for 10 days),,,,,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",blood urea nitrogen amount,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0000587,serum urea nitrogen level,,,,96.11,mg/dl,1.9147,4.69,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) ,75977,vehicle control condition (for 10 days),,,cisplatin (7.5 mg/kg) ,,,,,,, 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",body mass,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0000012,body weight,,,,388,g,16.8152,37.6,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition (for 91 days),76041,vehicle control condition (for 91 days),,,,,,,,,, 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",body mass,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0002216,change in body weight to body weight ratio,,,,255,%,13.4164,30.0,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition (for 91 days),76065,vehicle control condition (for 91 days),,,,,,,,,, 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",kidney mass,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0000082,right kidney wet weight,,,,1.214,g,0.0371,0.083,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 91 days),76070,vehicle control condition (for 91 days),,,,,,,,,, 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",kidney mass,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0000083,left kidney wet weight,,,,1.192,g,0.0563,0.126,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 91 days),76075,vehicle control condition (for 91 days),,,,,,,,,, 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",kidney mass,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0001953,right kidney wet weight to body weight ratio,,,,3.138,mg/g,0.059,0.132,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 91 days),76080,vehicle control condition (for 91 days),,,,,,,,,, 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",kidney mass,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0001954,left kidney wet weight to body weight ratio,,,,3.072,mg/g,0.0711,0.159,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 91 days),76085,vehicle control condition (for 91 days),,,,,,,,,, 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",liver mass,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0000158,liver wet weight,,,,13.6,g,1.0465,2.34,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 91 days),76090,vehicle control condition (for 91 days),,,,,,,,,, 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",liver mass,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0000633,liver weight to body weight ratio,,,,34.846,g/kg,1.2093,2.704,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 91 days),76095,vehicle control condition (for 91 days),,,,,,,,,, 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",spleen mass,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0000149,spleen weight to body weight ratio,,,,0.1832,%,0.0084,0.0188,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 91 days),76120,vehicle control condition (for 91 days),,,,,,,,,, 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",blood triglyceride amount,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0000360,serum triglyceride level,,,,156.94,mg/dl,14.9307,33.386,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 91 days),76135,vehicle control condition (for 91 days),,,,,,,,,, 1543,"Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.",body mass,,RS:0002943,BluHsd:LE,male,70 days,8,,CMO:0000012,body weight,,,,345.8,g,13.1,37.0524,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days),76140,vehicle control condition (for 30 days),controlled in utero environment (for 9 days),,maternal milk (for 21 days),,,,,,, 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",blood calcium amount,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0000503,serum calcium level,,,,12.82,mg/dl,0.2375,0.531,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 91 days),76141,vehicle control condition (for 91 days),,,,,,,,,, 1543,"Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.",body mass,,RS:0002943,BluHsd:LE,male,98 days,8,,CMO:0000012,body weight,,,,491.1,g,20.4,57.6999,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days),76148,vehicle control condition (for 30 days),controlled in utero environment (for 9 days),,maternal milk (for 21 days),,controlled fat content diet (21.2 %) (for 28 days),,,,, 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",blood albumin amount,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0000550,serum albumin level,,,,0.04486,g/dl,0.0016,0.0036,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 91 days),76149,vehicle control condition (for 91 days),,,,,,,,,, 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",blood bilirubin amount,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0000376,serum total bilirubin level,,,,0.96,mg/dl,0.0747,0.167,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 91 days),76156,vehicle control condition (for 91 days),,,,,,,,,, 1543,"Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.",body mass,,RS:0002943,BluHsd:LE,male,98 days to 71 days,8,,CMO:0000420,body weight gain,,,,145.3,g,9.3,26.3044,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days),76161,vehicle control condition (for 30 days),controlled in utero environment (for 9 days),,maternal milk (for 21 days),,controlled fat content diet (21.2 %) (for 28 days),,,,, 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",blood urea nitrogen amount,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0000587,serum urea nitrogen level,,,,77.76,mg/dl,3.1797,7.11,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 91 days),76164,vehicle control condition (for 91 days),,,,,,,,,, 1543,"Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.",eating behavior trait,,RS:0002943,BluHsd:LE,male,98 days to 71 days,8,,CMO:0002178,total food calorie intake rate,,,,2103.7,kcal/d,62.9,177.9081,MMO:0000160,unspecified method,,0.0,,,,,vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days),76169,vehicle control condition (for 30 days),controlled in utero environment (for 9 days),,maternal milk (for 21 days),,,,,,, 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",blood creatinine amount,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0000057,serum creatinine level,,,,0.68,mg/dl,0.0492,0.11,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 91 days),76170,vehicle control condition (for 91 days),,,,,,,,,, 1545,"Yildiz N and Barlas N, Hum Exp Toxicol. 2013 Jul;32(7):675-86. doi: 10.1177/0960327112464796.",blood lactate dehydrogenase amount,,RS:0001014,Hsd:WI,male,126 days to 119 days,5,,CMO:0000668,serum lactate dehydrogenase activity level,,,,1068,U/l,313.2284,700.4,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 91 days),76177,vehicle control condition (for 91 days),,,,,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",kidney glutathione peroxidase activity,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0002227,kidney glutathione peroxidase activity to total protein level ratio,,,,22.63,U/mg,1.3472,3.3,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 10 days),76191,vehicle control condition (for 10 days),,,,,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",kidney glutathione peroxidase activity,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0002227,kidney glutathione peroxidase activity to total protein level ratio,,,,7.54,U/mg,0.5062,1.24,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) ,76192,vehicle control condition (for 10 days),,,cisplatin (7.5 mg/kg) ,,,,,,, 1543,"Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.",eating behavior trait,,RS:0002943,BluHsd:LE,male,98 days to 71 days,8,,CMO:0002212,food intake weight to change in body weight ratio,,,,4.7,g/g,0.2,0.5657,MMO:0000160,unspecified method,,0.0,,,,,controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days),76197,controlled in utero environment (for 9 days),vehicle control condition (for 30 days),,maternal milk (for 21 days),,controlled fat content diet (21.2 %) (for 28 days),,,,, 1543,"Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.",eating behavior trait,,RS:0002943,BluHsd:LE,male,98 days to 71 days,8,,CMO:0002209,food calorie intake level to change in body weight ratio,,,,10.4,kcal/g,0.3,0.8485,MMO:0000160,unspecified method,,0.0,,,,,controlled in utero environment (for 9 days) and vehicle control condition (for 30 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days),76198,controlled in utero environment (for 9 days),vehicle control condition (for 30 days),,maternal milk (for 21 days),,controlled fat content diet (21.2 %) (for 28 days),,,,, 1543,"Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.",testis mass,,RS:0002943,BluHsd:LE,male,98 days,8,,CMO:0000175,both testes wet weight,,,,3.4,g,0.3,0.8485,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days),76233,vehicle control condition (for 30 days),controlled in utero environment (for 9 days),,maternal milk (for 21 days),,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",kidney glutathione amount,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0002235,kidney glutathione level,,,,12384.996,ug/g,257.1989,630.006,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 10 days),76238,vehicle control condition (for 10 days),,,,,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",kidney glutathione amount,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0002235,kidney glutathione level,,,,7882.758,ug/g,178.1573,436.3944,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) ,76239,vehicle control condition (for 10 days),,,cisplatin (7.5 mg/kg) ,,,,,,, 1543,"Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.",testis mass,,RS:0002943,BluHsd:LE,male,98 days,8,,CMO:0000175,both testes wet weight,,,,3.4,g,0.2,0.5657,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days),76249,vehicle control condition (for 30 days),controlled in utero environment (for 9 days),,maternal milk (for 21 days),,controlled fat content diet (21.2 %) (for 28 days),,,,, 1543,"Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.",blood testosterone amount,,RS:0002943,BluHsd:LE,male,98 days,8,,CMO:0000568,serum testosterone level,,,,7.3,ng/ml,1.5,4.2426,MMO:0000073,radioimmunoassay,,0.0,tritium-based,,,,vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days),76252,vehicle control condition (for 30 days),controlled in utero environment (for 9 days),,maternal milk (for 21 days),,,,,,, 1543,"Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.",blood testosterone amount,,RS:0002943,BluHsd:LE,male,98 days,8,,CMO:0000568,serum testosterone level,,,,10,ng/ml,1.2,3.3941,MMO:0000073,radioimmunoassay,,0.0,tritium-based,,,,vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days),76253,vehicle control condition (for 30 days),controlled in utero environment (for 9 days),,maternal milk (for 21 days),,controlled fat content diet (21.2 %) (for 28 days),,,,, 1543,"Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.",blood estradiol amount,,RS:0002943,BluHsd:LE,male,98 days,8,,CMO:0000564,serum estradiol level,,,,370,pg/ml,120.0,339.4113,MMO:0000073,radioimmunoassay,,0.0,tritium-based,,,,vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days),76254,vehicle control condition (for 30 days),controlled in utero environment (for 9 days),,maternal milk (for 21 days),,,,,,, 1543,"Nanjappa MK, et al., Toxicol Lett. 2014 Mar 21;225(3):479-87. doi: 10.1016/j.toxlet.2014.01.024. Epub 2014 Jan 26.",blood estradiol amount,,RS:0002943,BluHsd:LE,male,98 days,8,,CMO:0000564,serum estradiol level,,,,290,pg/ml,10.0,28.2843,MMO:0000073,radioimmunoassay,,0.0,tritium-based,,,,vehicle control condition (for 30 days) and controlled in utero environment (for 9 days) then maternal milk (for 21 days) then controlled fat content diet (21.2 %) (for 28 days),76255,vehicle control condition (for 30 days),controlled in utero environment (for 9 days),,maternal milk (for 21 days),,controlled fat content diet (21.2 %) (for 28 days),,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",kidney lipid peroxide amount,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0002246,kidney lipid peroxide level,,,,0.75,nmol/mg,0.0163,0.04,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 10 days),76256,vehicle control condition (for 10 days),,,,,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",kidney lipid peroxide amount,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0002246,kidney lipid peroxide level,,,,1.51,nmol/mg,0.0327,0.08,MMO:0000329,liquid phase colorimetry,,0.0,,,,,vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) ,76257,vehicle control condition (for 10 days),,,cisplatin (7.5 mg/kg) ,,,,,,, 1558,"Jenkins S, et al., Environ Health Perspect. 2009 Jun;117(6):910-5. doi: 10.1289/ehp.11751. Epub 2009 Jan 7.",blood estradiol amount,,RS:0000064,Crl:CD(SD),female,50 days,32,,CMO:0000564,serum estradiol level,,,,34.4,pg/ml,2.7,15.2735,MMO:0000073,radioimmunoassay,,0.0,,,,,maternal milk (for 20 days) and vehicle control condition (for 15 days),76260,maternal milk (for 20 days),vehicle control condition (for 15 days),,,,,,,,, 1558,"Jenkins S, et al., Environ Health Perspect. 2009 Jun;117(6):910-5. doi: 10.1289/ehp.11751. Epub 2009 Jan 7.",blood progesterone amount,,RS:0000064,Crl:CD(SD),female,50 days,32,,CMO:0000566,serum progesterone level,,,,12.5,ng/ml,2.8,15.8392,MMO:0000073,radioimmunoassay,,0.0,,,,,maternal milk (for 20 days) and vehicle control condition (for 15 days),76262,maternal milk (for 20 days),vehicle control condition (for 15 days),,,,,,,,, 1558,"Jenkins S, et al., Environ Health Perspect. 2009 Jun;117(6):910-5. doi: 10.1289/ehp.11751. Epub 2009 Jan 7.",mammary gland integrity trait,,RS:0000064,Crl:CD(SD),female,365 days to 0 days,32,,CMO:0000343,mammary tumor number,,,,2.84,,0.31,1.7536,MMO:0000158,manual palpation method,,0.0,,,,,"maternal milk (for 20 days) and vehicle control condition (for 15 days) then 7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days)",76264,maternal milk (for 20 days),vehicle control condition (for 15 days),,"7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days)",,,,,,, 1558,"Jenkins S, et al., Environ Health Perspect. 2009 Jun;117(6):910-5. doi: 10.1289/ehp.11751. Epub 2009 Jan 7.",mammary gland integrity trait,,RS:0000064,Crl:CD(SD),female,365 days to 0 days,32,,CMO:0000345,post-insult time to mammary tumor formation,,,median,65,d,,,MMO:0000158,manual palpation method,,0.0,,,,,"maternal milk (for 20 days) and vehicle control condition (for 15 days) then 7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days)",76267,maternal milk (for 20 days),vehicle control condition (for 15 days),,"7,12-dimethyltetraphene (DMBA) (30 mg/kg) (for 1 days)",,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",body mass,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0000420,body weight gain,,G7-G21,,82.4,g,6.2225,26.4,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition (for 14 days),76270,vehicle control condition (for 14 days),,,,,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",kidney mass,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0000085,both kidneys wet weight,,,,0.82,g,0.0245,0.06,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 10 days),75956,vehicle control condition (for 10 days),,,,,,,,,, 1544,"Prabhu VV, et al., Pharmacol Rep. 2013;65(4):980-90.",kidney mass,,RS:0001014,Hsd:WI,male,0 days,6,,CMO:0000085,both kidneys wet weight,,,,1.2,g,0.0531,0.13,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 10 days) then cisplatin (7.5 mg/kg) ,75957,vehicle control condition (for 10 days),,,cisplatin (7.5 mg/kg) ,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",body mass,,RS:0001592,HanTac:WH,male,1 days,17,,CMO:0000012,body weight,,,,6.2,g,0.1213,0.5,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition (for 1 days),96612,vehicle control condition (for 1 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",body mass,,RS:0001592,HanTac:WH,female,17 days to 16 days,15,,CMO:0000012,body weight,,,,29.1,g,0.6713,2.6,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition (between 16 and 17 days),96687,vehicle control condition (between 16 and 17 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",stillborn offspring quantity,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0002383,number of fetuses lost perinatally to litter size ratio,,,,8.5,%,1.8856,8.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,vehicle control condition (for 14 days),96592,vehicle control condition (for 14 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",total life span,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0002384,number of perinatal live-born offspring deaths to litter size ratio,,,,3.2,%,1.2728,5.4,MMO:0000163,in vivo visual assessment,,0.0,,,,,vehicle control condition (for 14 days),96602,vehicle control condition (for 14 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",perineum length,,RS:0001592,HanTac:WH,male,1 days,17,,CMO:0002385,anogenital distance,,,,4.1,mm,0.017,0.07,MMO:0000417,in vivo stereo light microscopy,,0.0,,,,,vehicle control condition (for 1 days),96617,vehicle control condition (for 1 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",testis mass,,RS:0001592,HanTac:WH,male,17 days to 16 days,18,,CMO:0000177,right testis wet weight,,,,51.3,mg,1.7913,7.6,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (between 16 and 17 days),96637,vehicle control condition (between 16 and 17 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",epididymis mass,,RS:0001592,HanTac:WH,male,17 days to 16 days,18,,CMO:0001606,both epididymides wet weight,,,,0.0228,g,9.0E-4,0.0038,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (between 16 and 17 days),96652,vehicle control condition (between 16 and 17 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",seminal gland mass,,RS:0001592,HanTac:WH,male,17 days to 16 days,18,,CMO:0001605,both seminal vesicles wet weight,,,,7.1,mg,0.4714,2.0,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (between 16 and 17 days),96657,vehicle control condition (between 16 and 17 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",skeletal muscle mass,,RS:0001592,HanTac:WH,male,17 days to 16 days,18,,CMO:0002387,combined levator ani and bulbocavernosus muscle weight,,,,26,mg,1.0371,4.4,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (between 16 and 17 days),96662,vehicle control condition (between 16 and 17 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",liver mass,,RS:0001592,HanTac:WH,male,17 days to 16 days,18,,CMO:0000158,liver wet weight,,,,0.7537,g,0.027,0.1147,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (between 16 and 17 days),96672,vehicle control condition (between 16 and 17 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",adrenal gland mass,,RS:0001592,HanTac:WH,male,17 days to 16 days,18,,CMO:0000164,both adrenal glands wet weight,,,,7.5,mg,0.495,2.1,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (between 16 and 17 days),96677,vehicle control condition (between 16 and 17 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",ovary mass,,RS:0001592,HanTac:WH,female,17 days to 16 days,15,,CMO:0002491,left ovary wet weight,,left ovary,,3.2,mg,0.2685,1.04,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (between 16 and 17 days),96697,vehicle control condition (between 16 and 17 days),,,,,,,,,, 1120,"Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20.",arterial blood pressure trait,,RS:0000771,WKY/Izm,male,98 days,6,,CMO:0000533,absolute change in mean arterial blood pressure,,,,27,mmHg,3.0,7.3485,MMO:0000011,vascular indwelling catheter method,,0.0,,,,,vehicle control condition (2 ul) (for 0 hours) then air-jet exposure (for 0 hours) then angiotensin II (20 ng) ,84566,vehicle control condition (2 ul) (for 0 hours),,,air-jet exposure (for 0 hours),,angiotensin II (20 ng) ,,,,, 1120,"Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20.",arterial blood pressure trait,,RS:0001054,WKY.SHRSP-(D1Wox29-D1Arb21)/Izm,male,98 days,6,,CMO:0000533,absolute change in mean arterial blood pressure,,,,32,mmHg,2.0,4.899,MMO:0000011,vascular indwelling catheter method,,0.0,,,,,vehicle control condition (2 ul) (for 0 hours) then air-jet exposure (for 0 hours) then angiotensin II (20 ng) ,84568,vehicle control condition (2 ul) (for 0 hours),,,air-jet exposure (for 0 hours),,angiotensin II (20 ng) ,,,,, 1120,"Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20.",arterial blood pressure trait,,RS:0000771,WKY/Izm,male,98 days,6,,CMO:0000533,absolute change in mean arterial blood pressure,,,,50,mmHg,2.0,4.899,MMO:0000011,vascular indwelling catheter method,,0.0,,,,,vehicle control condition (2 ul) (for 0 hours) then air-jet exposure (for 0 hours) then angiotensin II (20 ng) then phenylephrine (3 ug) ,84570,vehicle control condition (2 ul) (for 0 hours),,,air-jet exposure (for 0 hours),,angiotensin II (20 ng) ,,phenylephrine (3 ug) ,,, 1120,"Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20.",arterial blood pressure trait,,RS:0001054,WKY.SHRSP-(D1Wox29-D1Arb21)/Izm,male,98 days,6,,CMO:0000533,absolute change in mean arterial blood pressure,,,,50,mmHg,3.0,7.3485,MMO:0000011,vascular indwelling catheter method,,0.0,,,,,vehicle control condition (2 ul) (for 0 hours) then air-jet exposure (for 0 hours) then angiotensin II (20 ng) then phenylephrine (3 ug) ,84572,vehicle control condition (2 ul) (for 0 hours),,,air-jet exposure (for 0 hours),,angiotensin II (20 ng) ,,phenylephrine (3 ug) ,,, 1601,"McGill MR, et al., Toxicol Appl Pharmacol. 2012 Nov 1;264(3):387-94. doi: 10.1016/j.taap.2012.08.015. Epub 2012 Aug 23.",blood alanine transaminase amount,,RS:0000363,F344/NHsd,not specified,84 days to 56 days,4,,CMO:0000575,serum alanine aminotransferase activity level,,,,35,U/l,11.0,22.0,MMO:0000173,spectrophotometry,,0.0,,,,,fasting (between 12 and 15 hours) then vehicle control condition (for 1 days),84754,fasting (between 12 and 15 hours),,,vehicle control condition (for 1 days),,,,,,, 1120,"Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20.",arterial blood pressure trait,,RS:0000771,WKY/Izm,male,98 days,6,,CMO:0000533,absolute change in mean arterial blood pressure,,,,-3,mmHg,2.0,4.899,MMO:0000011,vascular indwelling catheter method,,0.0,,,,,air-jet exposure (for 0 hours) then vehicle control condition (2 ul) (for 0 hours),84553,air-jet exposure (for 0 hours),,,vehicle control condition (2 ul) (for 0 hours),,,,,,, 1120,"Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20.",arterial blood pressure trait,,RS:0001054,WKY.SHRSP-(D1Wox29-D1Arb21)/Izm,male,98 days,6,,CMO:0000533,absolute change in mean arterial blood pressure,,,,-1,mmHg,2.0,4.899,MMO:0000011,vascular indwelling catheter method,,0.0,,,,,air-jet exposure (for 0 hours) then vehicle control condition (2 ul) (for 0 hours),84555,air-jet exposure (for 0 hours),,,vehicle control condition (2 ul) (for 0 hours),,,,,,, 1120,"Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20.",heart pumping trait,,RS:0000771,WKY/Izm,male,98 days,6,,CMO:0000534,absolute change in heart rate,,,,0,beats/min,6.0,14.6969,MMO:0000011,vascular indwelling catheter method,,0.0,,,,,air-jet exposure (for 0 hours) then vehicle control condition (2 ul) (for 0 hours),84562,air-jet exposure (for 0 hours),,,vehicle control condition (2 ul) (for 0 hours),,,,,,, 1120,"Yamazato M, et al., Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R709-14. Epub 2005 Oct 20.",heart pumping trait,,RS:0001054,WKY.SHRSP-(D1Wox29-D1Arb21)/Izm,male,98 days,6,,CMO:0000534,absolute change in heart rate,,,,-5,beats/min,7.0,17.1464,MMO:0000011,vascular indwelling catheter method,,0.0,,,,,air-jet exposure (for 0 hours) then vehicle control condition (2 ul) (for 0 hours),84564,air-jet exposure (for 0 hours),,,vehicle control condition (2 ul) (for 0 hours),,,,,,, 1601,"McGill MR, et al., Toxicol Appl Pharmacol. 2012 Nov 1;264(3):387-94. doi: 10.1016/j.taap.2012.08.015. Epub 2012 Aug 23.",blood alanine transaminase amount,,RS:0000698,Hsd:SD,not specified,84 days to 56 days,4,,CMO:0000575,serum alanine aminotransferase activity level,,,,30,U/l,1.0,2.0,MMO:0000173,spectrophotometry,,0.0,,,,,fasting (between 12 and 15 hours) then vehicle control condition (for 1 days),84757,fasting (between 12 and 15 hours),,,vehicle control condition (for 1 days),,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",gestation period duration,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0000467,gestation period length,,,,23,d,0.1414,0.6,MMO:0000163,in vivo visual assessment,,0.0,,,,,vehicle control condition (for 14 days),96583,vehicle control condition (for 14 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",single birth offspring quantity,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0000642,litter size,,,,11.8,,0.7778,3.3,MMO:0000163,in vivo visual assessment,,0.0,,,,,vehicle control condition (for 14 days),96597,vehicle control condition (for 14 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",single birth offspring quantity,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0002494,number of male offspring to litter size ratio,,(number of males to litter size) ratio),,50.5,%,4.3605,18.5,MMO:0000163,in vivo visual assessment,,0.0,,,,,vehicle control condition (for 14 days),96607,vehicle control condition (for 14 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",perineum length,,RS:0001592,HanTac:WH,female,1 days,17,,CMO:0002385,anogenital distance,,,,2.2,mm,0.0243,0.1,MMO:0000417,in vivo stereo light microscopy,,0.0,,,,,vehicle control condition (for 1 days),96622,vehicle control condition (for 1 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",nipple quantity,,RS:0001592,HanTac:WH,male,14 days,17,,CMO:0002386,areola mammae/nipple number,,,,0.1,,0.0485,0.2,MMO:0000163,in vivo visual assessment,,0.0,,,,,vehicle control condition (for 14 days),96627,vehicle control condition (for 14 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",body mass,,RS:0001592,HanTac:WH,male,17 days to 16 days,18,,CMO:0000012,body weight,,,,28.6,g,1.0842,4.6,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition (between 16 and 17 days),96632,vehicle control condition (between 16 and 17 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",testis mass,,RS:0001592,HanTac:WH,male,17 days to 16 days,18,,CMO:0000178,left testis wet weight,,,,50.9,mg,1.7442,7.4,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (between 16 and 17 days),96642,vehicle control condition (between 16 and 17 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",ventral prostate mass,,RS:0001592,HanTac:WH,male,17 days to 16 days,18,,CMO:0000850,ventral prostate gland wet weight,,,,0.0117,g,8.0E-4,0.0036,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (between 16 and 17 days),96647,vehicle control condition (between 16 and 17 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",ovary mass,,RS:0001592,HanTac:WH,female,17 days to 16 days,15,,CMO:0002490,right ovary wet weight,,right ovary,,2.9,mg,0.1988,0.77,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (between 16 and 17 days),96692,vehicle control condition (between 16 and 17 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",thyroid gland mass,,RS:0001592,HanTac:WH,female,17 days to 16 days,15,,CMO:0002392,thyroid gland wet weight,,left ovary,,4.7,mg,0.2324,0.9,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (between 16 and 17 days),96707,vehicle control condition (between 16 and 17 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",retroperitoneal fat pad mass,,RS:0001592,HanTac:WH,female,17 days to 16 days,15,,CMO:0000356,retroperitoneal fat pad weight,,,,0.0295,g,0.0032,0.0123,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (between 16 and 17 days),96712,vehicle control condition (between 16 and 17 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",embryonic growth trait,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0002382,number of blastocysts/embryos lost postimplantation to litter size ratio,,,,7.9,%,2.7106,11.5,MMO:0000160,unspecified method,,0.0,,,,,vehicle control condition (for 14 days),96588,vehicle control condition (for 14 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",bulbourethral gland mass,,RS:0001592,HanTac:WH,male,17 days to 16 days,18,,CMO:0002395,bulbourethral gland wet weight,,,,1.7,mg,0.0943,0.4,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (between 16 and 17 days),96667,vehicle control condition (between 16 and 17 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",retroperitoneal fat pad mass,,RS:0001592,HanTac:WH,male,17 days to 16 days,18,,CMO:0000356,retroperitoneal fat pad weight,,,,0.038,g,0.0026,0.0112,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (between 16 and 17 days),96682,vehicle control condition (between 16 and 17 days),,,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",liver mass,,RS:0001592,HanTac:WH,female,17 days to 16 days,15,,CMO:0000158,liver wet weight,,,,0.7988,g,0.0172,0.0667,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (between 16 and 17 days),96702,vehicle control condition (between 16 and 17 days),,,,,,,,,, 2160,"Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.",heart left ventricular blood pressure trait,,RS:0000681,SD,male,0 days,6,,CMO:0000606,left ventricular end-diastolic blood pressure,,,,13,mmHg,2.0,4.899,MMO:0000014,vascular transducer tipped catheter,,1.0,,ACF,2,days,artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours),98826,artificial aortocaval fistula (for 2 days),,,vehicle control condition (for 2 days),,ketamine (80 mg/kg) (for 0 hours),xylazine (10 mg/kg) (for 0 hours),,,, 2160,"Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.",heart left ventricular blood pressure trait,,RS:0000681,SD,male,0 days,6,,CMO:0000606,left ventricular end-diastolic blood pressure,,,,3,mmHg,1.0,2.4495,MMO:0000014,vascular transducer tipped catheter,,1.0,,sham ACF,2,days,sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) ,98827,sham surgical control condition (for 2 days),,,vehicle control condition (for 2 days),,ketamine (80 mg/kg) (for 0 hours),xylazine (10 mg/kg) ,,,, 2160,"Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.",heart left ventricular blood pressure trait,,RS:0000681,SD,male,0 days,6,,CMO:0000605,left ventricular end-systolic blood pressure,,,,56,mmHg,3.0,7.3485,MMO:0000014,vascular transducer tipped catheter,,1.0,,ACF,2,days,artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours),98838,artificial aortocaval fistula (for 2 days),,,vehicle control condition (for 2 days),,ketamine (80 mg/kg) (for 0 hours),xylazine (10 mg/kg) (for 0 hours),,,, 2160,"Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.",heart left ventricular blood pressure trait,,RS:0000681,SD,male,0 days,6,,CMO:0000605,left ventricular end-systolic blood pressure,,,,64,mmHg,3.0,7.3485,MMO:0000014,vascular transducer tipped catheter,,1.0,,sham ACF,2,days,sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) ,98839,sham surgical control condition (for 2 days),,,vehicle control condition (for 2 days),,ketamine (80 mg/kg) (for 0 hours),xylazine (10 mg/kg) ,,,, 2160,"Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.",heart left ventricle mass,,RS:0000681,SD,male,0 days,6,,CMO:0000530,heart left ventricle weight to body weight ratio,g/g*103,,,2.6,mg/g,0.1,0.2449,MMO:0000005,post excision weight measurement,,1.0,,ACF,2,days,artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days),98874,artificial aortocaval fistula (for 2 days),,,vehicle control condition (for 2 days),,,,,,, 2160,"Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.",heart left ventricle mass,,RS:0000681,SD,male,0 days,6,,CMO:0000530,heart left ventricle weight to body weight ratio,g/g*103,,,2.3,mg/g,0.1,0.2449,MMO:0000005,post excision weight measurement,,1.0,,sham ACF,2,days,sham surgical control condition (for 2 days) then vehicle control condition (for 2 days),98875,sham surgical control condition (for 2 days),,,vehicle control condition (for 2 days),,,,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",glomerular filtration trait,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0000765,creatinine clearance,,,,3.1,ml/min,0.5,1.3229,MMO:0000275,urine creatinine analysis,,0.0,,,,,standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99179,standard rat chow (for 8 days),,,vehicle control condition (0.5 ml) (for 8 days),,,,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",glomerular filtration trait,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0000765,creatinine clearance,,,,3.5,ml/min,0.3,0.7937,MMO:0000275,urine creatinine analysis,,0.0,,,,,controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99181,controlled sodium content diet (8 %) (for 8 days),,,0.9% sodium chloride solution (0.9 %) (for 8 days),,vehicle control condition (0.5 ml) (for 8 days),,,,, 2160,"Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.",heart left ventricular blood pressure trait,,RS:0000681,SD,male,0 days,6,,CMO:0001745,maximum rate of positive change in left ventricular blood pressure,,,,8259,mmHg/s,325.0,796.0842,MMO:0000014,vascular transducer tipped catheter,,1.0,,ACF,2,days,artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours),98886,artificial aortocaval fistula (for 2 days),,,vehicle control condition (for 2 days),,ketamine (80 mg/kg) (for 0 hours),xylazine (10 mg/kg) (for 0 hours),,,, 2160,"Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.",heart left ventricular blood pressure trait,,RS:0000681,SD,male,0 days,6,,CMO:0001745,maximum rate of positive change in left ventricular blood pressure,,,,8231,mmHg/s,423.0,1036.1342,MMO:0000014,vascular transducer tipped catheter,,1.0,,sham ACF,2,days,sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) ,98887,sham surgical control condition (for 2 days),,,vehicle control condition (for 2 days),,ketamine (80 mg/kg) (for 0 hours),xylazine (10 mg/kg) ,,,, 2160,"Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.",heart left ventricular blood pressure trait,,RS:0000681,SD,male,0 days,6,,CMO:0001746,maximum rate of negative change in left ventricular blood pressure,,,,-6032,mmHg/s,387.0,947.9525,MMO:0000014,vascular transducer tipped catheter,,1.0,,ACF,2,days,artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours),98890,artificial aortocaval fistula (for 2 days),,,vehicle control condition (for 2 days),,ketamine (80 mg/kg) (for 0 hours),xylazine (10 mg/kg) (for 0 hours),,,, 2160,"Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.",heart left ventricular blood pressure trait,,RS:0000681,SD,male,0 days,6,,CMO:0001746,maximum rate of negative change in left ventricular blood pressure,,,,-7197,mmHg/s,303.0,742.1954,MMO:0000014,vascular transducer tipped catheter,,1.0,,sham ACF,2,days,sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) ,98891,sham surgical control condition (for 2 days),,,vehicle control condition (for 2 days),,ketamine (80 mg/kg) (for 0 hours),xylazine (10 mg/kg) ,,,, 2160,"Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.",heart pumping trait,,RS:0000681,SD,male,0 days,6,,CMO:0000002,heart rate,,,,420,beats/min,14.0,34.2929,MMO:0000107,HP Sonos 5500 echo ultrasound,,1.0,,ACF,2,days,artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) ,98801,artificial aortocaval fistula (for 2 days),,,vehicle control condition (for 2 days),,ketamine (80 mg/kg) (for 0 hours),xylazine (10 mg/kg) ,,,, 2160,"Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.",heart pumping trait,,RS:0000681,SD,male,0 days,6,,CMO:0000002,heart rate,,,,380,beats/min,10.0,24.4949,MMO:0000107,HP Sonos 5500 echo ultrasound,,1.0,,sham ACF,2,days,sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours),98802,sham surgical control condition (for 2 days),,,vehicle control condition (for 2 days),,ketamine (80 mg/kg) (for 0 hours),xylazine (10 mg/kg) (for 0 hours),,,, 2160,"Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.",arterial blood pressure trait,,RS:0000681,SD,male,0 days,6,,CMO:0000009,mean arterial blood pressure,,,,72,mmHg,2.0,4.899,MMO:0000014,vascular transducer tipped catheter,,1.0,,ACF,2,days,artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours),98814,artificial aortocaval fistula (for 2 days),,,vehicle control condition (for 2 days),,ketamine (80 mg/kg) (for 0 hours),xylazine (10 mg/kg) (for 0 hours),,,, 2160,"Seqqat R, et al., J Mol Cell Cardiol. 2012 Aug;53(2):240-9. doi: 10.1016/j.yjmcc.2012.05.004. Epub 2012 May 15.",arterial blood pressure trait,,RS:0000681,SD,male,0 days,6,,CMO:0000009,mean arterial blood pressure,,,,86,mmHg,4.0,9.798,MMO:0000014,vascular transducer tipped catheter,,1.0,,sham ACF,2,days,sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) ,98815,sham surgical control condition (for 2 days),,,vehicle control condition (for 2 days),,ketamine (80 mg/kg) (for 0 hours),xylazine (10 mg/kg) ,,,, 2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",blood glucose amount,,RS:0000742,WKY,male,156 days,10,,CMO:0000046,blood glucose level,,,,160.56,mg/dl,8.64,27.3221,MMO:0000073,radioimmunoassay,,0.0,,,,days,vehicle control condition (1 null) ,99101,vehicle control condition (1 null) ,,,,,,,,,, 2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",body mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000012,body weight,,,,450.39,g,9.36,29.5989,MMO:0000016,body weighing method,,0.0,,,,days,vehicle control condition (1 null) ,99107,vehicle control condition (1 null) ,,,,,,,,,, 2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",kidney mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000622,single kidney wet weight to body weight ratio,,,,3.41,g/kg,0.34,1.0752,MMO:0000005,post excision weight measurement,,0.0,,,,days,vehicle control condition (1 null) ,99113,vehicle control condition (1 null) ,,,,,,,,,, 2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",urine output,,RS:0000742,WKY,male,156 days,10,,CMO:0000260,timed urine volume,,,,17.1,ml/d,1.57,4.9648,MMO:0000357,urine volume measurement method,,0.0,,,,days,vehicle control condition (1 null) ,99119,vehicle control condition (1 null) ,,,,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",blood glucose amount,,RS:0000742,WKY,male,0 days,11,,CMO:0000046,blood glucose level,,,,76,mg/dl,1.0,3.3166,MMO:0000190,machine read blood glucose test strip,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99970,unilateral nephrectomy (for 28 days),,,vehicle control condition,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",blood glucose amount,,RS:0000742,WKY,male,0 days,17,,CMO:0000046,blood glucose level,,,,324,mg/dl,13.0,53.6004,MMO:0000190,machine read blood glucose test strip,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99971,unilateral nephrectomy (for 28 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,11,,CMO:0000037,hematocrit,,,,45.2,%,1.4,4.6433,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99975,unilateral nephrectomy (for 28 days),,,vehicle control condition,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,17,,CMO:0000037,hematocrit,,,,44.8,%,0.6,2.4739,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99976,unilateral nephrectomy (for 28 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,11,,CMO:0002783,glomerular filtration rate to body weight ratio,,,,0.517,ml/min/100g,0.011,0.0365,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99980,unilateral nephrectomy (for 28 days),,,vehicle control condition,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,17,,CMO:0002783,glomerular filtration rate to body weight ratio,,,,0.496,ml/min/100g,0.029,0.1196,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99981,unilateral nephrectomy (for 28 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,11,,CMO:0002943,renal filtration fraction,,,,0.23,,0.01,0.0332,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99985,unilateral nephrectomy (for 28 days),,,vehicle control condition,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,17,,CMO:0002943,renal filtration fraction,,,,0.293,,0.011,0.0454,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99986,unilateral nephrectomy (for 28 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney plasma flow trait,,RS:0000742,WKY,male,0 days,11,,CMO:0002782,renal plasma flow to body weight ratio,,,,2.28,ml/min/100g,0.07,0.2322,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99990,unilateral nephrectomy (for 28 days),,,vehicle control condition,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney plasma flow trait,,RS:0000742,WKY,male,0 days,17,,CMO:0002782,renal plasma flow to body weight ratio,,,,1.72,ml/min/100g,0.11,0.4535,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99991,unilateral nephrectomy (for 28 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,11,,CMO:0001898,renal vascular resistance,,,,6.3,mmHg/ml/min,0.4,1.3266,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99995,unilateral nephrectomy (for 28 days),,,vehicle control condition,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,17,,CMO:0001898,renal vascular resistance,,,,16.7,mmHg/ml/min,1.4,5.7723,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99996,unilateral nephrectomy (for 28 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",urine output,,RS:0000742,WKY,male,0 days,11,,CMO:0000260,timed urine volume,,,,11.664,ml/d,1.008,3.3432,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then vehicle control condition,100000,unilateral nephrectomy (for 28 days),,,vehicle control condition,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",urine output,,RS:0000742,WKY,male,0 days,17,,CMO:0000260,timed urine volume,,,,39.456,ml/d,4.608,18.9993,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,100001,unilateral nephrectomy (for 28 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart left ventricle end-diastolic diameter,,RS:0003075,SS-Nppbem2Mcwi-/-,male,84 days,7,,CMO:0000982,heart left ventricle end-diastolic diameter,,,,7.52,mm,0.32,0.8466,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99768,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart left ventricle end-diastolic diameter,,RS:0003075,SS-Nppbem2Mcwi-/-,male,168 days,7,,CMO:0000982,heart left ventricle end-diastolic diameter,,,,8.68,mm,0.33,0.8731,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99770,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart left ventricle end-diastolic diameter,,RS:0003075,SS-Nppbem2Mcwi-/-,male,252 days,7,,CMO:0000982,heart left ventricle end-diastolic diameter,,,,7.99,mm,0.62,1.6404,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99772,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart left ventricle posterior wall thickness,,RS:0003075,SS-Nppbem2Mcwi-/-,male,84 days,7,,CMO:0002597,heart left ventricle end-diastolic posterior wall thickness,,,,2.03,mm,0.06,0.1587,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99774,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart left ventricle posterior wall thickness,,RS:0003075,SS-Nppbem2Mcwi-/-,male,84 days,7,,CMO:0001840,heart left ventricle end-systolic posterior wall thickness,,,,3.29,mm,0.19,0.5027,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99792,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart left ventricle end-diastolic diameter,,RS:0003075,SS-Nppbem2Mcwi-/-,male,84 days,7,,CMO:0000985,heart left ventricle fractional shortening,,,,47.3,%,4.1,10.8476,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99804,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",arterial blood pressure trait,,RS:0003075,SS-Nppbem2Mcwi-/-,male,84 days,7,,CMO:0000005,diastolic blood pressure,,,serial mean,128,mmHg,22.0,58.2065,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition,99822,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",arterial blood pressure trait,,RS:0003075,SS-Nppbem2Mcwi-/-,male,168 days,7,,CMO:0000005,diastolic blood pressure,,,serial mean,142,mmHg,28.0,74.081,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition,99824,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",arterial blood pressure trait,,RS:0003075,SS-Nppbem2Mcwi-/-,male,252 days,7,,CMO:0000005,diastolic blood pressure,,,serial mean,145,mmHg,31.0,82.0183,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition,99826,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",arterial blood pressure trait,,RS:0003075,SS-Nppbem2Mcwi-/-,male,84 days,7,,CMO:0000004,systolic blood pressure,,,serial mean,172,mmHg,13.0,34.3948,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition,99828,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",arterial blood pressure trait,,RS:0003075,SS-Nppbem2Mcwi-/-,male,168 days,7,,CMO:0000004,systolic blood pressure,,,serial mean,195,mmHg,30.0,79.3725,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition,99830,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",arterial blood pressure trait,,RS:0003075,SS-Nppbem2Mcwi-/-,male,252 days,7,,CMO:0000004,systolic blood pressure,,,serial mean,197,mmHg,26.0,68.7895,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition,99832,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",arterial blood pressure trait,,RS:0003075,SS-Nppbem2Mcwi-/-,male,84 days,7,,CMO:0000009,mean arterial blood pressure,,,serial mean,142,mmHg,12.0,31.749,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition,99834,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",arterial blood pressure trait,,RS:0003075,SS-Nppbem2Mcwi-/-,male,168 days,7,,CMO:0000009,mean arterial blood pressure,,,serial mean,158,mmHg,27.0,71.4353,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition,99836,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",arterial blood pressure trait,,RS:0003075,SS-Nppbem2Mcwi-/-,male,252 days,7,,CMO:0000009,mean arterial blood pressure,,,serial mean,162,mmHg,29.0,76.7268,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition,99838,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",urine output,,RS:0003075,SS-Nppbem2Mcwi-/-,male,84 days,7,,CMO:0000260,timed urine volume,,,,14.7,ml/d,2.6,6.879,MMO:0000357,urine volume measurement method,,0.0,,,,,vehicle control condition,99840,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",urine output,,RS:0003075,SS-Nppbem2Mcwi-/-,male,168 days,7,,CMO:0000260,timed urine volume,,,,21.1,ml/d,7.6,20.1077,MMO:0000357,urine volume measurement method,,0.0,,,,,vehicle control condition,99842,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",urine output,,RS:0003075,SS-Nppbem2Mcwi-/-,male,252 days,7,,CMO:0000260,timed urine volume,,,,19.5,ml/d,4.6,12.1705,MMO:0000357,urine volume measurement method,,0.0,,,,,vehicle control condition,99844,vehicle control condition,,,,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,7,,CMO:0000012,body weight,,,,268,g,13.0,34.3948,MMO:0000016,body weighing method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99935,unilateral nephrectomy (for 28 days),,,vehicle control condition,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,8,,CMO:0000012,body weight,,,,215,g,10.0,28.2843,MMO:0000016,body weighing method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99936,unilateral nephrectomy (for 28 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",blood glucose amount,,RS:0000742,WKY,male,0 days,7,,CMO:0000046,blood glucose level,,,,74,mg/dl,2.0,5.2915,MMO:0000190,machine read blood glucose test strip,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99940,unilateral nephrectomy (for 28 days),,,vehicle control condition,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",blood glucose amount,,RS:0000742,WKY,male,0 days,8,,CMO:0000046,blood glucose level,,,,350,mg/dl,18.0,50.9117,MMO:0000190,machine read blood glucose test strip,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99941,unilateral nephrectomy (for 28 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,7,,CMO:0002783,glomerular filtration rate to body weight ratio,,,,0.494,ml/min/100g,0.03,0.0794,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99945,unilateral nephrectomy (for 28 days),,,vehicle control condition,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002783,glomerular filtration rate to body weight ratio,,,,0.792,ml/min/100g,0.03,0.0849,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99946,unilateral nephrectomy (for 28 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney plasma flow trait,,RS:0000742,WKY,male,0 days,7,,CMO:0002782,renal plasma flow to body weight ratio,,,,2.16,ml/min/100g,0.18,0.4762,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99950,unilateral nephrectomy (for 28 days),,,vehicle control condition,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney plasma flow trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002782,renal plasma flow to body weight ratio,,,,3.09,ml/min/100g,0.18,0.5091,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99951,unilateral nephrectomy (for 28 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,7,,CMO:0002943,renal filtration fraction,,,,0.233,,0.013,0.0344,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99955,unilateral nephrectomy (for 28 days),,,vehicle control condition,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002943,renal filtration fraction,,,,0.26,,0.013,0.0368,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99956,unilateral nephrectomy (for 28 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,7,,CMO:0001898,renal vascular resistance,,,,10,mmHg/ml/min,0.6,1.5875,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99960,unilateral nephrectomy (for 28 days),,,vehicle control condition,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,8,,CMO:0001898,renal vascular resistance,,,,9,mmHg/ml/min,0.4,1.1314,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99961,unilateral nephrectomy (for 28 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",urine output,,RS:0000742,WKY,male,0 days,7,,CMO:0000260,timed urine volume,,,,12.384,ml/d,2.016,5.3338,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99965,unilateral nephrectomy (for 28 days),,,vehicle control condition,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",urine output,,RS:0000742,WKY,male,0 days,8,,CMO:0000260,timed urine volume,,,,23.472,ml/d,1.728,4.8875,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99966,unilateral nephrectomy (for 28 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart left ventricle posterior wall thickness,,RS:0003075,SS-Nppbem2Mcwi-/-,male,168 days,7,,CMO:0001840,heart left ventricle end-systolic posterior wall thickness,,,,3.17,mm,0.17,0.4498,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99794,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart left ventricle posterior wall thickness,,RS:0003075,SS-Nppbem2Mcwi-/-,male,252 days,7,,CMO:0001840,heart left ventricle end-systolic posterior wall thickness,,,,3.41,mm,0.5,1.3229,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99796,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",cardiac output trait,,RS:0003075,SS-Nppbem2Mcwi-/-,male,84 days,7,,CMO:0000180,ejection fraction,,,,83.3,%,4.3,11.3767,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99798,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",cardiac output trait,,RS:0003075,SS-Nppbem2Mcwi-/-,male,168 days,7,,CMO:0000180,ejection fraction,,,,80.2,%,3.4,8.9956,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99800,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",cardiac output trait,,RS:0003075,SS-Nppbem2Mcwi-/-,male,252 days,7,,CMO:0000180,ejection fraction,,,,77.4,%,6.0,15.8745,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99802,vehicle control condition,,,,,,,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",skin chloride amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0002770,skin chloride level to skin dry weight ratio,,skin cl mmol/g,,0.051,mmol/g,0.003,0.0079,MMO:0000584,ex vivo analysis of atomic composition following dry ashing,,0.0,ashed skin,,,,standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99135,standard rat chow (for 8 days),,,vehicle control condition (0.5 ml) (for 8 days),,,,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",skin chloride amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0002770,skin chloride level to skin dry weight ratio,,skin cl mmol/g,,0.068,mmol/g,0.006,0.0159,MMO:0000584,ex vivo analysis of atomic composition following dry ashing,,0.0,ashed skin,,,,controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99137,controlled sodium content diet (8 %) (for 8 days),,,0.9% sodium chloride solution (0.9 %) (for 8 days),,vehicle control condition (0.5 ml) (for 8 days),,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",skin water amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0002771,skin water level to skin dry weight ratio,,skin h2o ml/g,,1.432,ml/g,0.032,0.0847,MMO:0000584,ex vivo analysis of atomic composition following dry ashing,,0.0,ashed skin,,,,controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99141,controlled sodium content diet (8 %) (for 8 days),,,0.9% sodium chloride solution (0.9 %) (for 8 days),,vehicle control condition (0.5 ml) (for 8 days),,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",skin mineral amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0002772,skin potassium level plus skin sodium level to skin water level ratio,,skin na+k/h2o,,0.17,,0.001,0.0026,MMO:0000584,ex vivo analysis of atomic composition following dry ashing,,0.0,ashed skin,,,,standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99143,standard rat chow (for 8 days),,,vehicle control condition (0.5 ml) (for 8 days),,,,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",skin mineral amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0002772,skin potassium level plus skin sodium level to skin water level ratio,,skin na+k/h2o,,0.176,,0.008,0.0212,MMO:0000584,ex vivo analysis of atomic composition following dry ashing,,0.0,ashed skin,,,,controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99145,controlled sodium content diet (8 %) (for 8 days),,,0.9% sodium chloride solution (0.9 %) (for 8 days),,vehicle control condition (0.5 ml) (for 8 days),,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",skin chloride amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0002775,skin chloride level to skin water level ratio,,skin na/h2o,,90,mmol/l,0.8,2.1166,MMO:0000584,ex vivo analysis of atomic composition following dry ashing,,0.0,ashed skin,,,,standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99147,standard rat chow (for 8 days),,,vehicle control condition (0.5 ml) (for 8 days),,,,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",skin chloride amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0002775,skin chloride level to skin water level ratio,,skin na/h2o,,101,mmol/l,3.9,10.3184,MMO:0000584,ex vivo analysis of atomic composition following dry ashing,,0.0,ashed skin,,,,controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99149,controlled sodium content diet (8 %) (for 8 days),,,0.9% sodium chloride solution (0.9 %) (for 8 days),,vehicle control condition (0.5 ml) (for 8 days),,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",skin chloride amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0002775,skin chloride level to skin water level ratio,,skin cl/h2o,,42,mmol/l,2.4,6.3498,MMO:0000584,ex vivo analysis of atomic composition following dry ashing,,0.0,ashed skin,,,,standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99151,standard rat chow (for 8 days),,,vehicle control condition (0.5 ml) (for 8 days),,,,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",skin chloride amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0002775,skin chloride level to skin water level ratio,,skin cl/h2o,,48,mmol/l,4.8,12.6996,MMO:0000584,ex vivo analysis of atomic composition following dry ashing,,0.0,ashed skin,,,,controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99153,controlled sodium content diet (8 %) (for 8 days),,,0.9% sodium chloride solution (0.9 %) (for 8 days),,vehicle control condition (0.5 ml) (for 8 days),,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",skin potassium amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0002773,skin potassium level to skin water level ratio,,skin k/h2o,,80,mmol/l,1.1,2.9103,MMO:0000584,ex vivo analysis of atomic composition following dry ashing,,0.0,ashed skin,,,,standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99155,standard rat chow (for 8 days),,,vehicle control condition (0.5 ml) (for 8 days),,,,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",skin potassium amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0002773,skin potassium level to skin water level ratio,,skin k/h2o,,71,mmol/l,3.0,7.9373,MMO:0000584,ex vivo analysis of atomic composition following dry ashing,,0.0,ashed skin,,,,controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99157,controlled sodium content diet (8 %) (for 8 days),,,0.9% sodium chloride solution (0.9 %) (for 8 days),,vehicle control condition (0.5 ml) (for 8 days),,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",blood sodium amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0000060,plasma sodium level,,,,143.7,mmol/l,4.4,11.6413,MMO:0000037,automated blood electrolyte analysis,,0.0,,,,,standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99159,standard rat chow (for 8 days),,,vehicle control condition (0.5 ml) (for 8 days),,,,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",blood sodium amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0000060,plasma sodium level,,,,141.4,mmol/l,2.1,5.5561,MMO:0000037,automated blood electrolyte analysis,,0.0,,,,,controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99161,controlled sodium content diet (8 %) (for 8 days),,,0.9% sodium chloride solution (0.9 %) (for 8 days),,vehicle control condition (0.5 ml) (for 8 days),,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",blood potassium amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0000061,plasma potassium level,,,,3.9,mmol/l,0.2,0.5292,MMO:0000037,automated blood electrolyte analysis,,0.0,,,,,standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99163,standard rat chow (for 8 days),,,vehicle control condition (0.5 ml) (for 8 days),,,,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",blood potassium amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0000061,plasma potassium level,,,,4.2,mmol/l,0.3,0.7937,MMO:0000037,automated blood electrolyte analysis,,0.0,,,,,controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99165,controlled sodium content diet (8 %) (for 8 days),,,0.9% sodium chloride solution (0.9 %) (for 8 days),,vehicle control condition (0.5 ml) (for 8 days),,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",blood chloride amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0000059,plasma chloride level,,,,98.2,mmol/l,1.1,2.9103,MMO:0000037,automated blood electrolyte analysis,,0.0,,,,,standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99167,standard rat chow (for 8 days),,,vehicle control condition (0.5 ml) (for 8 days),,,,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",blood creatinine amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0000537,plasma creatinine level,,,,0.30882306,mg/dl,0.0102,0.0269,MMO:0000306,plasma creatinine analysis,,0.0,,,,,standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99171,standard rat chow (for 8 days),,,vehicle control condition (0.5 ml) (for 8 days),,,,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",blood creatinine amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0000537,plasma creatinine level,,,,0.30090452,mg/dl,0.0079,0.021,MMO:0000306,plasma creatinine analysis,,0.0,,,,,controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99173,controlled sodium content diet (8 %) (for 8 days),,,0.9% sodium chloride solution (0.9 %) (for 8 days),,vehicle control condition (0.5 ml) (for 8 days),,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",blood cystatin C amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0002778,plasma cystatin C level,,,,4,mg/l,0.6,1.5875,MMO:0000352,automated plasma protein analysis,,0.0,,,,,standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99175,standard rat chow (for 8 days),,,vehicle control condition (0.5 ml) (for 8 days),,,,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",blood cystatin C amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0002778,plasma cystatin C level,,,,3.5,mg/l,0.2,0.5292,MMO:0000352,automated plasma protein analysis,,0.0,,,,,controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99177,controlled sodium content diet (8 %) (for 8 days),,,0.9% sodium chloride solution (0.9 %) (for 8 days),,vehicle control condition (0.5 ml) (for 8 days),,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart left ventricle end-diastolic diameter,,RS:0003075,SS-Nppbem2Mcwi-/-,male,168 days,7,,CMO:0000985,heart left ventricle fractional shortening,,,,44.3,%,2.8,7.4081,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99806,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart left ventricle end-diastolic diameter,,RS:0003075,SS-Nppbem2Mcwi-/-,male,252 days,7,,CMO:0000985,heart left ventricle fractional shortening,,,,41.6,%,5.6,14.8162,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99808,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart left ventricle mass,,RS:0003075,SS-Nppbem2Mcwi-/-,male,84 days,7,,CMO:0000776,heart left ventricle weight,,,,1.53,g,0.08,0.2117,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99810,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart left ventricle mass,,RS:0003075,SS-Nppbem2Mcwi-/-,male,168 days,7,,CMO:0000776,heart left ventricle weight,,,,1.67,g,0.06,0.1587,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99812,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart left ventricle mass,,RS:0003075,SS-Nppbem2Mcwi-/-,male,252 days,7,,CMO:0000776,heart left ventricle weight,,,,1.78,g,0.04,0.1058,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99814,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart pumping trait,,RS:0003075,SS-Nppbem2Mcwi-/-,male,84 days,7,,CMO:0000002,heart rate,,,,382,beats/min,45.0,119.0588,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99816,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart pumping trait,,RS:0003075,SS-Nppbem2Mcwi-/-,male,168 days,7,,CMO:0000002,heart rate,,,,349,beats/min,20.0,52.915,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99818,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart pumping trait,,RS:0003075,SS-Nppbem2Mcwi-/-,male,252 days,7,,CMO:0000002,heart rate,,,,327,beats/min,19.0,50.2693,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99820,vehicle control condition,,,,,,,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",skin sodium amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0002769,skin sodium level to skin dry weight ratio,,mmol/g,,0.11,REQUEST NEW VALUE,0.003,0.0079,MMO:0000584,ex vivo analysis of atomic composition following dry ashing,,0.0,ashed skin,,,,standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99131,standard rat chow (for 8 days),,,vehicle control condition (0.5 ml) (for 8 days),,,,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",skin sodium amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0002769,skin sodium level to skin dry weight ratio,,mmol/g,,0.144,REQUEST NEW VALUE,0.005,0.0132,MMO:0000584,ex vivo analysis of atomic composition following dry ashing,,0.0,ashed skin,,,,controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99133,controlled sodium content diet (8 %) (for 8 days),,,0.9% sodium chloride solution (0.9 %) (for 8 days),,vehicle control condition (0.5 ml) (for 8 days),,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",blood chloride amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0000059,plasma chloride level,,,,104.8,mmol/l,1.8,4.7624,MMO:0000037,automated blood electrolyte analysis,,0.0,,,,,controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99169,controlled sodium content diet (8 %) (for 8 days),,,0.9% sodium chloride solution (0.9 %) (for 8 days),,vehicle control condition (0.5 ml) (for 8 days),,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",urine sodium amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0000760,urine sodium excretion rate,,mmol/d,,1,mEq/d,0.2,0.5292,MMO:0000434,urine sodium analysis,,0.0,,,,,standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99183,standard rat chow (for 8 days),,,vehicle control condition (0.5 ml) (for 8 days),,,,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",urine sodium amount,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0000760,urine sodium excretion rate,,,,41.9,mEq/d,5.2,13.7579,MMO:0000434,urine sodium analysis,,0.0,,,,,controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99185,controlled sodium content diet (8 %) (for 8 days),,,0.9% sodium chloride solution (0.9 %) (for 8 days),,vehicle control condition (0.5 ml) (for 8 days),,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",arterial blood pressure trait,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0000009,mean arterial blood pressure,,,,101,mmHg,0.9,2.3812,MMO:0000577,intra-aortic radiotelemetry,,0.0,,,,,standard rat chow (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99187,standard rat chow (for 8 days),,,vehicle control condition (0.5 ml) (for 8 days),,,,,,, 2238,"Lankhorst S, et al., Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.",arterial blood pressure trait,,RS:0000916,WKY/NHsd,male,0 days,7,,CMO:0000009,mean arterial blood pressure,,,,116,mmHg,1.0,2.6458,MMO:0000577,intra-aortic radiotelemetry,,0.0,,,,,controlled sodium content diet (8 %) (for 8 days) then 0.9% sodium chloride solution (0.9 %) (for 8 days) then vehicle control condition (0.5 ml) (for 8 days),99189,controlled sodium content diet (8 %) (for 8 days),,,0.9% sodium chloride solution (0.9 %) (for 8 days),,vehicle control condition (0.5 ml) (for 8 days),,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart right ventricular blood pressure trait,,RS:0000811,SS/JrHsdMcwi,male,56 days,6,,CMO:0003281,right ventricular end-systolic blood pressure,,,,26,mmHg,0.99,2.425,MMO:0000013,vascular fluid filled catheter,,0.0,,,,,vehicle control condition,106796,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart right ventricular blood pressure trait,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,15,,CMO:0003281,right ventricular end-systolic blood pressure,,,,25.1,mmHg,0.53,2.0527,MMO:0000013,vascular fluid filled catheter,,0.0,,,,,vehicle control condition,106797,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",body mass,,RS:0003075,SS-Nppbem2Mcwi-/-,male,168 days,7,,CMO:0000012,body weight,,,,425,g,22.0,58.2065,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition,99758,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",body mass,,RS:0003075,SS-Nppbem2Mcwi-/-,male,252 days,7,,CMO:0000012,body weight,,,,452,g,21.0,55.5608,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition,99760,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart ventricle septum thickness,,RS:0003075,SS-Nppbem2Mcwi-/-,male,84 days,7,,CMO:0002791,heart interventricular end-diastolic septal wall thickness,,,,2.01,mm,0.08,0.2117,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99762,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart ventricle septum thickness,,RS:0003075,SS-Nppbem2Mcwi-/-,male,168 days,7,,CMO:0002791,heart interventricular end-diastolic septal wall thickness,,,,1.92,mm,0.12,0.3175,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99764,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart ventricle septum thickness,,RS:0003075,SS-Nppbem2Mcwi-/-,male,252 days,7,,CMO:0002791,heart interventricular end-diastolic septal wall thickness,,,,2.26,mm,0.23,0.6085,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99766,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart left ventricle posterior wall thickness,,RS:0003075,SS-Nppbem2Mcwi-/-,male,168 days,7,,CMO:0002597,heart left ventricle end-diastolic posterior wall thickness,,,,1.89,mm,0.16,0.4233,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99776,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart left ventricle posterior wall thickness,,RS:0003075,SS-Nppbem2Mcwi-/-,male,252 days,7,,CMO:0002597,heart left ventricle end-diastolic posterior wall thickness,,,,2.17,mm,1.94,5.1328,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99778,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart ventricle septum thickness,,RS:0003075,SS-Nppbem2Mcwi-/-,male,84 days,7,,CMO:0002792,heart interventricular end-systolic septal wall thickness,,,,3.19,mm,0.2,0.5292,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99780,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart ventricle septum thickness,,RS:0003075,SS-Nppbem2Mcwi-/-,male,168 days,7,,CMO:0002792,heart interventricular end-systolic septal wall thickness,,,,3.24,mm,0.21,0.5556,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99782,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart ventricle septum thickness,,RS:0003075,SS-Nppbem2Mcwi-/-,male,252 days,7,,CMO:0002792,heart interventricular end-systolic septal wall thickness,,,,3.48,mm,0.26,0.6879,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99784,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart left ventricle end-systolic diameter,,RS:0003075,SS-Nppbem2Mcwi-/-,male,84 days,7,,CMO:0000983,heart left ventricle end-systolic diameter,,,,3.98,mm,0.45,1.1906,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99786,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart left ventricle end-systolic diameter,,RS:0003075,SS-Nppbem2Mcwi-/-,male,168 days,7,,CMO:0000983,heart left ventricle end-systolic diameter,,,,4.83,mm,0.35,0.926,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99788,vehicle control condition,,,,,,,,,, 2319,"Holditch SJ, et al., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.",heart left ventricle end-systolic diameter,,RS:0003075,SS-Nppbem2Mcwi-/-,male,252 days,7,,CMO:0000983,heart left ventricle end-systolic diameter,,,,4.67,mm,0.74,1.9579,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition,99790,vehicle control condition,,,,,,,,,, 2581,"Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.",body mass,,RS:0000592,MW,male,0 days,7,,CMO:0000012,body weight,,,,220,g,9.0,23.8118,MMO:0000119,body measuring method,,0.0,,unx,14,days,unilateral nephrectomy (for 14 days) then vehicle control condition,101142,unilateral nephrectomy (for 14 days),,,vehicle control condition,,,,,,, 2581,"Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.",body mass,,RS:0000592,MW,male,0 days,7,,CMO:0000012,body weight,,,,260,g,6.0,15.8745,MMO:0000119,body measuring method,,0.0,,unx,42,days,unilateral nephrectomy (for 14 days) then vehicle control condition,101146,unilateral nephrectomy (for 14 days),,,vehicle control condition,,,,,,, 2581,"Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.",body mass,,RS:0000592,MW,male,0 days,7,,CMO:0000012,body weight,,,,286,g,9.0,23.8118,MMO:0000119,body measuring method,,0.0,,unx,70,days,unilateral nephrectomy (for 70 days) then vehicle control condition,101154,unilateral nephrectomy (for 70 days),,,vehicle control condition,,,,,,, 2581,"Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.",arterial blood pressure trait,,RS:0000592,MW,male,0 days,7,,CMO:0000004,systolic blood pressure,undefined,,,118,mmHg,2.0,5.2915,MMO:0000031,tail cuff plethysmography,,0.0,,unx,14,days,unilateral nephrectomy (for 14 days) then vehicle control condition,101159,unilateral nephrectomy (for 14 days),,,vehicle control condition,,,,,,, 2581,"Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.",arterial blood pressure trait,,RS:0000592,MW,male,0 days,7,,CMO:0000004,systolic blood pressure,undefined,,,118,mmHg,2.0,5.2915,MMO:0000031,tail cuff plethysmography,,0.0,,unx,42,days,unilateral nephrectomy (for 14 days) then vehicle control condition,101163,unilateral nephrectomy (for 14 days),,,vehicle control condition,,,,,,, 2581,"Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.",arterial blood pressure trait,,RS:0000592,MW,male,0 days,7,,CMO:0000004,systolic blood pressure,undefined,,,122,mmHg,2.0,5.2915,MMO:0000031,tail cuff plethysmography,,0.0,,unx,70,days,unilateral nephrectomy (for 70 days) then vehicle control condition,101168,unilateral nephrectomy (for 70 days),,,vehicle control condition,,,,,,, 2581,"Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.",arterial blood pressure trait,,RS:0000592,MW,male,0 days,7,,CMO:0000009,mean arterial blood pressure,undefined,,,108,mmHg,2.0,5.2915,MMO:0000011,vascular indwelling catheter method,,0.0,,unx,70,days,unilateral nephrectomy (for 70 days) then vehicle control condition,101173,unilateral nephrectomy (for 70 days),,,vehicle control condition,,,,,,, 2581,"Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.",blood urea nitrogen amount,,RS:0000592,MW,male,0 days,7,,CMO:0000049,blood urea nitrogen level,,,,25,mg/dl,1.0,2.6458,MMO:0000253,blood urea nitrogen analysis,,0.0,,unx,14,days,unilateral nephrectomy (for 14 days) then vehicle control condition,101178,unilateral nephrectomy (for 14 days),,,vehicle control condition,,,,,,, 2581,"Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.",blood urea nitrogen amount,,RS:0000592,MW,male,0 days,7,,CMO:0000049,blood urea nitrogen level,,,,25,mg/dl,3.0,7.9373,MMO:0000253,blood urea nitrogen analysis,,0.0,,unx,42,days,unilateral nephrectomy (for 14 days) then vehicle control condition,101182,unilateral nephrectomy (for 14 days),,,vehicle control condition,,,,,,, 2581,"Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.",blood urea nitrogen amount,,RS:0000592,MW,male,0 days,7,,CMO:0000049,blood urea nitrogen level,,,,26,mg/dl,1.0,2.6458,MMO:0000253,blood urea nitrogen analysis,,0.0,,unx,70,days,unilateral nephrectomy (for 70 days) then vehicle control condition,101187,unilateral nephrectomy (for 70 days),,,vehicle control condition,,,,,,, 2581,"Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.",total urine protein amount,,RS:0000592,MW,male,0 days,7,,CMO:0000756,urine total protein excretion rate,,,,11,mg/d,2.0,5.2915,MMO:0000426,Bradford protein assay,,0.0,,unx,14,days,unilateral nephrectomy (for 14 days) then vehicle control condition,101192,unilateral nephrectomy (for 14 days),,,vehicle control condition,,,,,,, 2581,"Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.",total urine protein amount,,RS:0000592,MW,male,0 days,7,,CMO:0000756,urine total protein excretion rate,,,,23,mg/d,2.0,5.2915,MMO:0000426,Bradford protein assay,,0.0,,unx,42,days,unilateral nephrectomy (for 14 days) then vehicle control condition,101196,unilateral nephrectomy (for 14 days),,,vehicle control condition,,,,,,, 2581,"Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.",total urine protein amount,,RS:0000592,MW,male,0 days,7,,CMO:0000756,urine total protein excretion rate,,,,18,mg/d,4.0,10.583,MMO:0000426,Bradford protein assay,,0.0,,unx,70,days,unilateral nephrectomy (for 70 days) then vehicle control condition,101200,unilateral nephrectomy (for 70 days),,,vehicle control condition,,,,,,, 2581,"Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.",total urine protein amount,,RS:0000592,MW,male,0 days,18,,CMO:0000756,urine total protein excretion rate,,,,8,mg/d,2.0,8.4853,MMO:0000426,Bradford protein assay,,0.0,,control,29,days,vehicle control condition,101203,vehicle control condition,,,,,,,,,, 2581,"Fogo A, et al., J Clin Invest. 1988 Jul;82(1):322-30.",glomerular filtration trait,,RS:0000592,MW,male,0 days,7,,CMO:0000490,glomerular filtration rate,,,,1.46,ml/min,0.08,0.2117,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,70,days,unilateral nephrectomy (for 70 days) then vehicle control condition,101205,unilateral nephrectomy (for 70 days),,,vehicle control condition,,,,,,, 2583,"Kohara K, et al., Hypertension. 1993 Jun;21(6 Pt 2):975-9.",blood sodium amount,,RS:0000752,SHR/NCrlCrlj,male,126 days,5,,CMO:0000499,blood sodium level,,,,140,mmol/l,1.0,2.2361,MMO:0000142,automated serum sodium test,,0.0,,unx,42,days,unilateral nephrectomy (for 42 days) then vehicle control condition (for 28 days),101238,unilateral nephrectomy (for 42 days),,,vehicle control condition (for 28 days),,,,,,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001840,Crlj:WI,male,16 days,6,,CMO:0000009,mean arterial blood pressure,undefined,,,138,mmHg,9.0,22.0454,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours),103015,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,,,,,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001840,Crlj:WI,male,16 days,7,,CMO:0000009,mean arterial blood pressure,undefined,,,128,mmHg,9.0,23.8118,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours),103016,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,,,,,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001299,GK,male,16 days,5,,CMO:0000009,mean arterial blood pressure,undefined,,,137,mmHg,6.0,13.4164,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours),103017,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,,,,,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001299,GK,male,16 days,7,,CMO:0000009,mean arterial blood pressure,undefined,,,147,mmHg,7.0,18.5203,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours),103018,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,,,,,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001840,Crlj:WI,male,16 days,6,,CMO:0000009,mean arterial blood pressure,undefined,,,90,mmHg,8.0,19.5959,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours),103019,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,,,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001840,Crlj:WI,male,16 days,7,,CMO:0000009,mean arterial blood pressure,undefined,,,96,mmHg,8.0,21.166,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours),103020,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,,,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001299,GK,male,16 days,5,,CMO:0000009,mean arterial blood pressure,undefined,,,108,mmHg,8.0,17.8885,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours),103021,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,,,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001299,GK,male,16 days,7,,CMO:0000009,mean arterial blood pressure,undefined,,,111,mmHg,5.0,13.2288,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours),103022,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,,,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001840,Crlj:WI,male,16 days,6,,CMO:0000009,mean arterial blood pressure,undefined,,,99,mmHg,7.0,17.1464,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),103023,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001840,Crlj:WI,male,16 days,7,,CMO:0000009,mean arterial blood pressure,undefined,,,109,mmHg,10.0,26.4575,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),103024,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001299,GK,male,16 days,7,,CMO:0000009,mean arterial blood pressure,undefined,,,123,mmHg,5.0,13.2288,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),103026,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001840,Crlj:WI,male,16 days,6,,CMO:0000009,mean arterial blood pressure,undefined,,,155,mmHg,10.0,24.4949,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) then meclofenamate (3 mg/kg) (for 0.5 hours),103027,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours),,meclofenamate (3 mg/kg) (for 0.5 hours) 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001840,Crlj:WI,male,16 days,7,,CMO:0000009,mean arterial blood pressure,undefined,,,136,mmHg,13.0,34.3948,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours),103028,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours),meclofenamate (3 mg/kg) (for 0.5 hours), 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001299,GK,male,16 days,5,,CMO:0000009,mean arterial blood pressure,undefined,,,151,mmHg,1.0,2.2361,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours),103029,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours),meclofenamate (3 mg/kg) (for 0.5 hours), 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001299,GK,male,16 days,7,,CMO:0000009,mean arterial blood pressure,undefined,,,140,mmHg,8.0,21.166,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours),103030,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours),meclofenamate (3 mg/kg) (for 0.5 hours), 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001840,Crlj:WI,male,16 days,6,,CMO:0000009,mean arterial blood pressure,undefined,,,120,mmHg,7.0,17.1464,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours),103031,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours),meclofenamate (3 mg/kg) (for 0.5 hours),acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001840,Crlj:WI,male,16 days,7,,CMO:0000009,mean arterial blood pressure,undefined,,,102,mmHg,11.0,29.1033,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours),103032,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours),meclofenamate (3 mg/kg) (for 0.5 hours),acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001299,GK,male,16 days,5,,CMO:0000009,mean arterial blood pressure,undefined,,,137,mmHg,3.0,6.7082,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours),103033,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours),meclofenamate (3 mg/kg) (for 0.5 hours),acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001299,GK,male,16 days,7,,CMO:0000009,mean arterial blood pressure,undefined,,,143,mmHg,3.0,7.9373,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours),103034,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours),meclofenamate (3 mg/kg) (for 0.5 hours),acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001840,Crlj:WI,male,16 days,6,,CMO:0000002,heart rate,,,,372,beats/min,11.0,26.9444,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours),103035,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,,,,,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001840,Crlj:WI,male,16 days,7,,CMO:0000002,heart rate,,,,415,beats/min,10.0,26.4575,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours),103036,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,,,,,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001299,GK,male,16 days,5,,CMO:0000002,heart rate,,,,395,beats/min,17.0,38.0132,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours),103037,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,,,,,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001299,GK,male,16 days,7,,CMO:0000002,heart rate,,,,147,beats/min,7.0,18.5203,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours),103038,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,,,,,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001840,Crlj:WI,male,16 days,6,,CMO:0000002,heart rate,,,,90,beats/min,15.0,36.7423,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours),103039,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,,,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001840,Crlj:WI,male,16 days,7,,CMO:0000002,heart rate,,,,380,beats/min,18.0,47.6235,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours),103040,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,,,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001299,GK,male,16 days,5,,CMO:0000002,heart rate,,,,366,beats/min,17.0,38.0132,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours),103041,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,,,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001840,Crlj:WI,male,16 days,7,,CMO:0000002,heart rate,,,,379,beats/min,9.0,23.8118,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),103042,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001840,Crlj:WI,male,16 days,6,,CMO:0000002,heart rate,,,,351,beats/min,19.0,46.5403,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),103043,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001840,Crlj:WI,male,16 days,7,,CMO:0000002,heart rate,,,,384,beats/min,17.0,44.9778,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),103044,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001299,GK,male,16 days,5,,CMO:0000002,heart rate,,,,366,beats/min,17.0,38.0132,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),103045,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001299,GK,male,16 days,7,,CMO:0000002,heart rate,,,,390,beats/min,10.0,26.4575,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),103046,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001840,Crlj:WI,male,16 days,6,,CMO:0000002,heart rate,,,,288,beats/min,11.0,26.9444,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) then meclofenamate (3 mg/kg) (for 0.5 hours),103047,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours),,meclofenamate (3 mg/kg) (for 0.5 hours) 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001840,Crlj:WI,male,16 days,7,,CMO:0000002,heart rate,,,,287,beats/min,7.0,18.5203,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours),103048,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours),meclofenamate (3 mg/kg) (for 0.5 hours), 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001299,GK,male,16 days,5,,CMO:0000002,heart rate,,,,301,beats/min,21.0,46.9574,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours),103049,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours),meclofenamate (3 mg/kg) (for 0.5 hours), 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001299,GK,male,16 days,7,,CMO:0000002,heart rate,,,,344,beats/min,11.0,29.1033,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours),103050,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours),meclofenamate (3 mg/kg) (for 0.5 hours), 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001840,Crlj:WI,male,16 days,6,,CMO:0000002,heart rate,,,,275,beats/min,8.0,19.5959,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours),103051,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours),meclofenamate (3 mg/kg) (for 0.5 hours),acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001840,Crlj:WI,male,16 days,7,,CMO:0000002,heart rate,,,,264,beats/min,9.0,23.8118,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours),103052,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours),meclofenamate (3 mg/kg) (for 0.5 hours),acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001299,GK,male,16 days,5,,CMO:0000002,heart rate,,,,252,beats/min,25.0,55.9017,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours),103053,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours),meclofenamate (3 mg/kg) (for 0.5 hours),acetylcholine (5 ug/kg/min) (for 0.1 hours) 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",heart pumping trait,,RS:0001299,GK,male,16 days,7,,CMO:0000002,heart rate,,,,279,beats/min,17.0,44.9778,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (5 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours) then NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours) and meclofenamate (3 mg/kg) (for 0.5 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours),103054,air oxygen content (5 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),NG-nitroarginine methyl ester (50 mg/kg) (for 0.5 hours),meclofenamate (3 mg/kg) (for 0.5 hours),acetylcholine (5 ug/kg/min) (for 0.1 hours) 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",heart pumping trait,,RS:0001299,GK,male,168 days,6,,CMO:0000002,heart rate,,nighttime measurement,,323,beats/min,8.0,19.5959,MMO:0000070,intra-aortic abdominal radiotelemetry,,,measured 12 hr/night for 4 weeks,,,,vehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours),103568,vehicle control condition (for 28 days),dark phase of controlled light/dark cycle (for 12 hours),,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",voluntary movement trait,,RS:0000731,WKY/NCrl,male,168 days,6,,CMO:0003644,number of spontaneous locomotor movements per unit time,,number of spontaneous locomotor movements per unit time (CMO:0003644),,0.9,/min,0.1,0.2449,MMO:0000070,intra-aortic abdominal radiotelemetry,,,measured 12 hr/day for 4 weeks,,,,vehicle control condition (between 1 and 28 days) and light phase of controlled light/dark cycle (for 12 hours),103574,vehicle control condition (between 1 and 28 days),light phase of controlled light/dark cycle (for 12 hours),,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",voluntary movement trait,,RS:0001299,GK,male,168 days,6,,CMO:0003644,number of spontaneous locomotor movements per unit time,,number of spontaneous locomotor movements per unit time (CMO:0003644),,0.9,/min,0.1,0.2449,MMO:0000070,intra-aortic abdominal radiotelemetry,,,measured 12 hr/day for 4 weeks,,,,vehicle control condition (between 1 and 28 days) and light phase of controlled light/dark cycle (for 12 hours),103576,vehicle control condition (between 1 and 28 days),light phase of controlled light/dark cycle (for 12 hours),,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",voluntary movement trait,,RS:0000731,WKY/NCrl,male,168 days,6,,CMO:0003644,number of spontaneous locomotor movements per unit time,,number of spontaneous locomotor movements per unit time (CMO:0003644),,2.8,/min,0.3,0.7348,MMO:0000070,intra-aortic abdominal radiotelemetry,,,measured 12 hr/night for 4 weeks,,,,vehicle control condition (between 1 and 28 days) and dark phase of controlled light/dark cycle,103582,vehicle control condition (between 1 and 28 days),dark phase of controlled light/dark cycle,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",voluntary movement trait,,RS:0001299,GK,male,168 days,6,,CMO:0003644,number of spontaneous locomotor movements per unit time,,number of spontaneous locomotor movements per unit time (CMO:0003644),,2.9,/min,0.1,0.2449,MMO:0000070,intra-aortic abdominal radiotelemetry,,,measured 12 hr/night for 4 weeks,,,,vehicle control condition (between 1 and 28 days) and dark phase of controlled light/dark cycle,103584,vehicle control condition (between 1 and 28 days),dark phase of controlled light/dark cycle,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",vasodilation trait,,RS:0000731,WKY/NCrl,male,168 days,7,,CMO:0000725,logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-7.07,,0.054,0.1429,MMO:0000342,wire myography,,,,,,,vehicle control condition (for 28 days),103586,vehicle control condition (for 28 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",vasodilation trait,,RS:0001299,GK,male,168 days,8,,CMO:0000725,logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-7.29,,0.092,0.2602,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),103588,vehicle control condition (for 28 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",vasodilation trait,,RS:0000731,WKY/NCrl,male,168 days,7,,CMO:0000731,acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,89.88,%,2.56,6.7731,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),103590,vehicle control condition (for 28 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",vasodilation trait,,RS:0001299,GK,male,168 days,8,,CMO:0000731,acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,67.1,%,3.32,9.3904,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),103592,vehicle control condition (for 28 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",vasodilation trait,,RS:0000731,WKY/NCrl,male,168 days,7,,CMO:0000727,logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-8.058,,0.048,0.127,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),103594,vehicle control condition (for 28 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",vasodilation trait,,RS:0001299,GK,male,168 days,8,,CMO:0000727,logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-7.96,,0.048,0.1358,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),103596,vehicle control condition (for 28 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",vasodilation trait,,RS:0000731,WKY/NCrl,male,168 days,7,,CMO:0000732,sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,97.56,%,1.02,2.6987,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),103598,vehicle control condition (for 28 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",vasodilation trait,,RS:0001299,GK,male,168 days,8,,CMO:0000732,sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,94.07,%,1.125,3.182,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),103600,vehicle control condition (for 28 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",vasodilation trait,,RS:0000731,WKY/NCrl,male,168 days,7,,CMO:0000725,logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-7.6,,0.05,0.1323,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),103602,vehicle control condition (for 28 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",vasodilation trait,,RS:0001299,GK,male,168 days,8,,CMO:0000725,logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-7.39,,0.04,0.1131,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),103604,vehicle control condition (for 28 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",vasodilation trait,,RS:0000731,WKY/NCrl,male,168 days,7,,CMO:0000731,acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,99.75,%,2.32,6.1381,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),103606,vehicle control condition (for 28 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",vasodilation trait,,RS:0001299,GK,male,168 days,8,,CMO:0000731,acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,96.96,%,2.2,6.2225,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),103608,vehicle control condition (for 28 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",vasodilation trait,,RS:0000731,WKY/NCrl,male,168 days,7,,CMO:0000727,logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-8.15,,0.089,0.2355,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),103610,vehicle control condition (for 28 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",vasodilation trait,,RS:0001299,GK,male,168 days,8,,CMO:0000727,logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-8.74,,0.57,1.6122,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),103612,vehicle control condition (for 28 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",vasodilation trait,,RS:0000731,WKY/NCrl,male,168 days,7,,CMO:0000732,sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,96.54,%,1.9,5.0269,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),103614,vehicle control condition (for 28 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",vasodilation trait,,RS:0001299,GK,male,168 days,8,,CMO:0000732,sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,86.87,%,3.06,8.655,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),103616,vehicle control condition (for 28 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",artery molecular composition trait,,RS:0000731,WKY/NCrl,male,175 days,7,,CMO:0002853,aorta wall phosphorylated eNOS level to total eNOS level ratio,,,,1.45,,0.21,0.5556,MMO:0000669,western blot assay,,0.0,,,,,vehicle control condition (for 35 days),103618,vehicle control condition (for 35 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",artery molecular composition trait,,RS:0001299,GK,male,175 days,8,,CMO:0002853,aorta wall phosphorylated eNOS level to total eNOS level ratio,,,,1.61,,0.3,0.8485,MMO:0000669,western blot assay,,0.0,,,,,vehicle control condition (for 35 days),103620,vehicle control condition (for 35 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",artery molecular composition trait,,RS:0000731,WKY/NCrl,male,175 days,7,,CMO:0002852,mesenteric artery phosphorylated eNOS level to total eNOS level ratio,,,,0.94,,0.13,0.3439,MMO:0000669,western blot assay,,0.0,,,,,vehicle control condition (for 35 days),103622,vehicle control condition (for 35 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",artery molecular composition trait,,RS:0001299,GK,male,175 days,8,,CMO:0002852,mesenteric artery phosphorylated eNOS level to total eNOS level ratio,,,,0.9,,0.07,0.198,MMO:0000669,western blot assay,,0.0,,,,,vehicle control condition (for 35 days),103624,vehicle control condition (for 35 days),,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",blood glucose amount,,RS:0001366,LL/Mav,male,56 days to 49 days,13,,CMO:0000046,blood glucose level,,,,65,mg/dl,1.0,3.6056,MMO:0000112,blood glucose analysis,,0.0,,,,,vehicle control condition then fasting (for 16 hours),102656,vehicle control condition,,,fasting (for 16 hours),,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",blood glucose amount,,RS:0000556,LH/Mav,male,56 days to 49 days,8,,CMO:0000046,blood glucose level,,,,67,mg/dl,1.0,2.8284,MMO:0000112,blood glucose analysis,,0.0,,,,,vehicle control condition then fasting (for 16 hours),102657,vehicle control condition,,,fasting (for 16 hours),,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",blood glucose amount,,RS:0001366,LL/Mav,male,56 days to 49 days,13,,CMO:0000046,blood glucose level,,,,132,mg/dl,4.0,14.4222,MMO:0000112,blood glucose analysis,,0.0,,,,,vehicle control condition then fasting (for 16 hours) then glucose (2 g/kg) (for 1 hours),102659,vehicle control condition,,,fasting (for 16 hours),,glucose (2 g/kg) (for 1 hours),,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",blood glucose amount,,RS:0000556,LH/Mav,male,56 days to 49 days,8,,CMO:0000046,blood glucose level,,,,121,mg/dl,6.0,16.9706,MMO:0000112,blood glucose analysis,,0.0,,,,,vehicle control condition then fasting (for 16 hours) then glucose (2 g/kg) (for 1 hours),102660,vehicle control condition,,,fasting (for 16 hours),,glucose (2 g/kg) (for 1 hours),,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",blood cholesterol amount,,RS:0001366,LL/Mav,male,112 days,13,,CMO:0000585,plasma total cholesterol level,,,,50.5791,mg/dl,2.7027,9.7447,MMO:0000491,blood cholesterol analysis,,0.0,,,,,vehicle control condition,102662,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",blood cholesterol amount,,RS:0000556,LH/Mav,male,112 days,8,,CMO:0000585,plasma total cholesterol level,,,,66.4092,mg/dl,5.4054,15.2888,MMO:0000491,blood cholesterol analysis,,0.0,,,,,vehicle control condition,102663,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",blood triglyceride amount,,RS:0001366,LL/Mav,male,112 days,13,,CMO:0000548,plasma triglyceride level,,,,1.58,mmol/l,0.13,0.4687,MMO:0000234,plasma triglyceride analysis,,0.0,,,,,vehicle control condition,102668,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",blood triglyceride amount,,RS:0000556,LH/Mav,male,112 days,8,,CMO:0000548,plasma triglyceride level,,,,1.57,mmol/l,0.06,0.1697,MMO:0000234,plasma triglyceride analysis,,0.0,,,,,vehicle control condition,102669,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",blood creatinine amount,,RS:0001366,LL/Mav,male,112 days,13,,CMO:0000537,plasma creatinine level,,,,0.518,mg/dl,0.01,0.0361,MMO:0000306,plasma creatinine analysis,,0.0,,,,,vehicle control condition,102674,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",blood creatinine amount,,RS:0000554,LH/MavRrrc,male,112 days,8,,CMO:0000537,plasma creatinine level,,,,0.53,mg/dl,0.012,0.0339,MMO:0000306,plasma creatinine analysis,,0.0,,,,,vehicle control condition,102675,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",heart left ventricle mass,,RS:0001366,LL/Mav,male,112 days,13,,CMO:0000530,heart left ventricle weight to body weight ratio,,,,20.4,mg/g,0.1,0.3606,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,102680,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",heart left ventricle mass,,RS:0000554,LH/MavRrrc,male,112 days,8,,CMO:0000530,heart left ventricle weight to body weight ratio,,,,23,mg/g,0.2,0.5657,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,102681,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",aorta mass,,RS:0001366,LL/Mav,male,112 days,13,,CMO:0003216,aorta weight to body weight ratio,,,,11.6,mg/100g,0.3,1.0817,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,102686,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",aorta mass,,RS:0000554,LH/MavRrrc,male,112 days,8,,CMO:0003216,aorta weight to body weight ratio,,,,12.2,mg/100g,0.2,0.5657,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,102687,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",kidney mass,,RS:0001366,LL/Mav,male,112 days,13,,CMO:0000340,both kidneys wet weight to body weight ratio,,,,6.53,g/kg,0.04,0.1442,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,102692,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",kidney mass,,RS:0000554,LH/MavRrrc,male,112 days,8,,CMO:0000340,both kidneys wet weight to body weight ratio,,,,6.36,g/kg,0.08,0.2263,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,102693,vehicle control condition,,,,,,,,,, 2520,"Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.",arterial blood pressure trait,,RS:0004500,SD-Nfe2l2em1Mcwi+/+,male,11 days to 9 days,4,,CMO:0000009,mean arterial blood pressure,,,,95,mmHg,3.9,7.8,MMO:0000013,vascular fluid filled catheter,,0.0,,,,,controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days),100739,controlled sodium content diet (0.4 %) (between 70 and 84 days),,,controlled sodium content diet (4 %) (for 6 days),,vehicle control condition (for 3 days),,,,, 2520,"Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.",arterial blood pressure trait,,RS:0004501,SD-Nfe2l2em1Mcwi-/-,male,11 days to 9 days,3,,CMO:0000009,mean arterial blood pressure,,,,102,mmHg,3.0,5.1962,MMO:0000013,vascular fluid filled catheter,,0.0,,,,,controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days),100740,controlled sodium content diet (0.4 %) (between 70 and 84 days),,,controlled sodium content diet (4 %) (for 6 days),,vehicle control condition (for 3 days),,,,, 2520,"Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.",cerebral artery size trait,,RS:0004500,SD-Nfe2l2em1Mcwi+/+,male,11 days to 9 days,5,,CMO:0001128,middle cerebral artery inner diameter,,max dilation,,246,um,4.8,10.7331,MMO:0000027,ex vivo method,,0.0,,,,,controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then controlled calcium ion content physiological salt solution perfusate (0 %) ,100745,controlled sodium content diet (0.4 %) (between 70 and 84 days),,,controlled sodium content diet (4 %) (for 6 days),,vehicle control condition (for 3 days),,controlled calcium ion content physiological salt solution perfusate (0 %) ,,, 2520,"Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.",cerebral artery size trait,,RS:0004501,SD-Nfe2l2em1Mcwi-/-,male,11 days to 9 days,4,,CMO:0001128,middle cerebral artery inner diameter,,max dilation,,248,um,9.0,18.0,MMO:0000027,ex vivo method,,0.0,,,,,controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then controlled calcium ion content physiological salt solution perfusate (0 %) ,100746,controlled sodium content diet (0.4 %) (between 70 and 84 days),,,controlled sodium content diet (4 %) (for 6 days),,vehicle control condition (for 3 days),,controlled calcium ion content physiological salt solution perfusate (0 %) ,,, 2520,"Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.",cerebral artery size trait,,RS:0004500,SD-Nfe2l2em1Mcwi+/+,male,11 days to 9 days,5,,CMO:0001128,middle cerebral artery inner diameter,,resting diameter,,145,um,12.5,27.9508,MMO:0000027,ex vivo method,,0.0,,,,,controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then physiological salt solution perfusate,100751,controlled sodium content diet (0.4 %) (between 70 and 84 days),,,controlled sodium content diet (4 %) (for 6 days),,vehicle control condition (for 3 days),,physiological salt solution perfusate,,, 2520,"Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.",cerebral artery size trait,,RS:0004501,SD-Nfe2l2em1Mcwi-/-,male,11 days to 9 days,4,,CMO:0001128,middle cerebral artery inner diameter,,resting diameter,,154,um,15.0,30.0,MMO:0000027,ex vivo method,,0.0,,,,,controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then physiological salt solution perfusate,100752,controlled sodium content diet (0.4 %) (between 70 and 84 days),,,controlled sodium content diet (4 %) (for 6 days),,vehicle control condition (for 3 days),,physiological salt solution perfusate,,, 2520,"Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.",cerebral artery size trait,,RS:0004500,SD-Nfe2l2em1Mcwi+/+,male,11 days to 9 days,5,,CMO:0001190,percent change in middle cerebral artery inner diameter,,tone,,41.4,%,4.47,9.9952,MMO:0000027,ex vivo method,,0.0,,,,,controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then physiological salt solution perfusate,100757,controlled sodium content diet (0.4 %) (between 70 and 84 days),,,controlled sodium content diet (4 %) (for 6 days),,vehicle control condition (for 3 days),,physiological salt solution perfusate,,, 2520,"Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.",cerebral artery size trait,,RS:0004501,SD-Nfe2l2em1Mcwi-/-,male,11 days to 9 days,4,,CMO:0001190,percent change in middle cerebral artery inner diameter,,tone,,37.4,%,6.53,13.06,MMO:0000027,ex vivo method,,0.0,,,,,controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days) then physiological salt solution perfusate,100758,controlled sodium content diet (0.4 %) (between 70 and 84 days),,,controlled sodium content diet (4 %) (for 6 days),,vehicle control condition (for 3 days),,physiological salt solution perfusate,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",blood cholesterol amount,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,6,,CMO:0000363,serum total cholesterol level,,,,333,mg/dl,15.6,38.212,MMO:0000132,serum total cholesterol measurement test,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),101941,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",blood LDL cholesterol amount,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,6,,CMO:0000362,serum low density lipoprotein cholesterol level,,,,102.5,mg/dl,9.37,22.9517,MMO:0000134,serum low-density lipoprotein-cholesterol measurement test,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),101944,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",blood HDL cholesterol amount,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,6,,CMO:0000361,serum high density lipoprotein cholesterol level,,,,97.25,mg/dl,15.33,37.5507,MMO:0000133,serum high-density lipoprotein-cholesterol measurement test,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),101947,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",blood triglyceride amount,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,6,,CMO:0000360,serum triglyceride level,,,,2196.13,mg/dl,204.52,500.9696,MMO:0000136,serum triglyceride analysis,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),101950,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",blood free fatty acid amount,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,6,,CMO:0000547,serum free fatty acids level,,,,1.42,mmol/l,0.14,0.3429,MMO:0000308,serum free fatty acid analysis,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),101953,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",blood glucose amount,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,6,,CMO:0000543,serum glucose level,,,,149.4,mg/dl,12.36,30.2757,MMO:0000316,serum glucose analysis,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),101956,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",blood insulin amount,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,6,,CMO:0000358,serum insulin level,,,,0.000807,mg/dl,1.0E-4,2.0E-4,MMO:0000322,serum insulin analysis,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),101959,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",body mass,,RS:0001366,LL/Mav,male,56 days to 49 days,13,,CMO:0000012,body weight,,,,219,g,5.0,18.0278,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition,102641,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",body mass,,RS:0000556,LH/Mav,male,56 days to 49 days,8,,CMO:0000012,body weight,,,,232,g,6.0,16.9706,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition,102642,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",arterial blood pressure trait,,RS:0001366,LL/Mav,male,56 days to 49 days,13,,CMO:0000004,systolic blood pressure,undefined,,,115,mmHg,3.0,10.8167,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition,102644,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",arterial blood pressure trait,,RS:0000556,LH/Mav,male,56 days to 49 days,8,,CMO:0000004,systolic blood pressure,undefined,,,136,mmHg,3.0,8.4853,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition,102645,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",urine output,,RS:0001366,LL/Mav,male,56 days to 49 days,13,,CMO:0000260,timed urine volume,,,,8.4,ml/d,0.3,1.0817,MMO:0000357,urine volume measurement method,,0.0,,,,,vehicle control condition,102647,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",urine output,,RS:0000556,LH/Mav,male,56 days to 49 days,8,,CMO:0000260,timed urine volume,,,,8.7,ml/d,0.6,1.6971,MMO:0000357,urine volume measurement method,,0.0,,,,,vehicle control condition,102648,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",urine creatinine amount,,RS:0001366,LL/Mav,male,56 days to 49 days,13,,CMO:0000764,urine creatinine excretion rate,,,,7.1,mg/d,0.3,1.0817,MMO:0000275,urine creatinine analysis,,0.0,,,,,vehicle control condition,102650,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",urine creatinine amount,,RS:0000556,LH/Mav,male,56 days to 49 days,8,,CMO:0000764,urine creatinine excretion rate,,,,8,mg/d,0.3,0.8485,MMO:0000275,urine creatinine analysis,,0.0,,,,,vehicle control condition,102651,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",total urine protein amount,,RS:0001366,LL/Mav,male,56 days to 49 days,13,,CMO:0002758,urine protein level to urine creatinine level ratio,,,,2.7,,0.1,0.3606,MMO:0000334,urine protein analysis,,0.0,,,,,vehicle control condition,102653,vehicle control condition,,,,,,,,,, 2703,"Emonnot L, et al., Am J Hypertens. 2008 Jun;21(6):657-62. doi: 10.1038/ajh.2008.155. Epub 2008 Apr 3.",total urine protein amount,,RS:0000556,LH/Mav,male,56 days to 49 days,8,,CMO:0002758,urine protein level to urine creatinine level ratio,,,,5.9,,0.5,1.4142,MMO:0000334,urine protein analysis,,0.0,,,,,vehicle control condition,102654,vehicle control condition,,,,,,,,,, 2541,"Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.",body mass,,RS:0003240,MWF/ZtmRrrc,male,126 days,8,,CMO:0000012,body weight,,,,378,g,10.6066,30.0,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition,100901,vehicle control condition,,,,,,,,,, 2541,"Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.",body mass,,RS:0003240,MWF/ZtmRrrc,male,126 days,7,,CMO:0000012,body weight,,,,385,g,11.3389,30.0,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition,100903,vehicle control condition,,,,,,,,,, 2541,"Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.",body mass,,RS:0003240,MWF/ZtmRrrc,male,246 days,8,,CMO:0000012,body weight,,,,433,g,9.1924,26.0,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition,100905,vehicle control condition,,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",tibia length,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,13,,CMO:0001731,tibia straight segment length,,,,34.62,mm,0.15,0.5408,MMO:0000119,body measuring method,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),101971,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",heart mass,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,13,,CMO:0001198,heart weight to tibia length ratio,,,,0.4295,g/cm,0.0115,0.0415,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),101974,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",heart left ventricle mass,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,13,,CMO:0002787,heart left ventricle weight to tibia length ratio,,lv/tl,,0.3101,g/cm,0.009,0.0324,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),101977,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",retroperitoneal fat pad mass,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,13,,CMO:0002990,retroperitoneal fat pad weight to tibia length ratio,,rf/tl,,429.56,mg/mm,13.64,49.1797,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),101980,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",epididymal fat pad mass,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,13,,CMO:0001201,epididymal fat pad weight to tibia length ratio,,ef/tl,,3.5481,g/cm,0.0975,0.3515,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),101983,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",mesenteric fat pad mass,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,13,,CMO:0003286,mesenteric fat pad weight to tibia length ratio,,mf/tl,,364.22,mg/mm,10.33,37.2453,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),101986,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",inguinal fat pad mass,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,13,,CMO:0002991,inguinal fat pad weight to tibia length ratio,,if/tl,,1501.32,mg/mm,68.53,247.0884,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),101989,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",heart left ventricle wall thickness,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,13,,CMO:0000987,heart ventricle septal wall thickness,,,,0.206,cm,0.003,0.0108,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),101992,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",heart left ventricle end-diastolic diameter,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,13,,CMO:0000982,heart left ventricle end-diastolic diameter,,,,8.27,mm,0.13,0.4687,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),101995,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2684,"Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.",body mass,,RS:0003328,SS/NEisSlc,male,126 days,8,,CMO:0000012,body weight,,,,361,g,9.0,25.4558,MMO:0000016,body weighing method,,0.0,,,,,controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days),102311,controlled sodium content diet (0.3 %) (for 42 days),,,controlled sodium content diet (8 %) (for 77 days),,vehicle control condition (for 49 days),,,,, 2684,"Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.",arterial blood pressure trait,,RS:0003328,SS/NEisSlc,male,126 days,8,,CMO:0000004,systolic blood pressure,undefined,,,226,mmHg,11.0,31.1127,MMO:0000031,tail cuff plethysmography,,0.0,,,,,controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days),102314,controlled sodium content diet (0.3 %) (for 42 days),,,controlled sodium content diet (8 %) (for 77 days),,vehicle control condition (for 49 days),,,,, 2684,"Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.",heart left ventricle end-diastolic diameter,,RS:0003328,SS/NEisSlc,male,126 days,8,,CMO:0000985,heart left ventricle fractional shortening,,,,24.8,%,1.2,3.3941,MMO:0000002,transthoracic echocardiography,,0.0,,,,,controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days),102317,controlled sodium content diet (0.3 %) (for 42 days),,,controlled sodium content diet (8 %) (for 77 days),,vehicle control condition (for 49 days),,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",arterial blood pressure trait,,RS:0000731,WKY/NCrl,male,168 days,6,,CMO:0000004,systolic blood pressure,,daytime measurement,,121,mmHg,3.0,7.3485,MMO:0000070,intra-aortic abdominal radiotelemetry,,,measured 12 hr/day for 4 weeks,,,,vehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours),103526,vehicle control condition (for 28 days),light phase of controlled light/dark cycle (for 12 hours),,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",arterial blood pressure trait,,RS:0001299,GK,male,168 days,6,,CMO:0000004,systolic blood pressure,,daytime measurement,,145,mmHg,4.0,9.798,MMO:0000070,intra-aortic abdominal radiotelemetry,,,measured 12 hr/day for 4 weeks,,,,vehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours),103528,vehicle control condition (for 28 days),light phase of controlled light/dark cycle (for 12 hours),,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",arterial blood pressure trait,,RS:0000731,WKY/NCrl,male,168 days,6,,CMO:0000004,systolic blood pressure,,nighttime measurement,,126,mmHg,3.0,7.3485,MMO:0000070,intra-aortic abdominal radiotelemetry,,,measured 12 hr/night for 4 weeks,,,,vehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours),103534,vehicle control condition (for 28 days),dark phase of controlled light/dark cycle (for 12 hours),,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",arterial blood pressure trait,,RS:0001299,GK,male,168 days,6,,CMO:0000004,systolic blood pressure,,nighttime measurement,,145,mmHg,4.0,9.798,MMO:0000070,intra-aortic abdominal radiotelemetry,,,measured 12 hr/night for 4 weeks,,,,vehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours),103536,vehicle control condition (for 28 days),dark phase of controlled light/dark cycle (for 12 hours),,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",arterial blood pressure trait,,RS:0000731,WKY/NCrl,male,168 days,6,,CMO:0000005,diastolic blood pressure,,daytime measurement,,85,mmHg,3.0,7.3485,MMO:0000070,intra-aortic abdominal radiotelemetry,,,measured 12 hr/day for 4 weeks,,,,vehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours),103542,vehicle control condition (for 28 days),light phase of controlled light/dark cycle (for 12 hours),,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",arterial blood pressure trait,,RS:0001299,GK,male,168 days,6,,CMO:0000005,diastolic blood pressure,,daytime measurement,,98,mmHg,2.0,4.899,MMO:0000070,intra-aortic abdominal radiotelemetry,,,measured 12 hr/day for 4 weeks,,,,vehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours),103544,vehicle control condition (for 28 days),light phase of controlled light/dark cycle (for 12 hours),,,,,,,,, 2844,"Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.",neuron morphology trait,,RS:0001013,WI,male,547 days,4,,CMO:0002832,neuron mitochondrion area to neuron cytoplasm area ratio,,mito/cyto,,10.4,%,0.16,0.32,MMO:0000221,ex vivo electron microscopy with digital image analysis,,0.0,,,,,vehicle control condition (for 180 days),103644,vehicle control condition (for 180 days),,,,,,,,,, 2844,"Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.",neuron morphology trait,,RS:0000634,OXYS/Nov,male,547 days,4,,CMO:0002832,neuron mitochondrion area to neuron cytoplasm area ratio,,mito/cyto,,3.6,%,0.1,0.2,MMO:0000221,ex vivo electron microscopy with digital image analysis,,0.0,,,,,vehicle control condition (for 180 days),103645,vehicle control condition (for 180 days),,,,,,,,,, 2844,"Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.",neuron morphology trait,,RS:0001013,WI,male,547 days,4,,CMO:0002836,neuron lysosome area to neuron cytoplasm area ratio,,lys/cyto,,8.3,%,0.19,0.38,MMO:0000221,ex vivo electron microscopy with digital image analysis,,0.0,,,,,vehicle control condition (for 180 days),103647,vehicle control condition (for 180 days),,,,,,,,,, 2844,"Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.",neuron morphology trait,,RS:0000634,OXYS/Nov,male,547 days,4,,CMO:0002836,neuron lysosome area to neuron cytoplasm area ratio,,lys/cyto,,11.9,%,0.39,0.78,MMO:0000221,ex vivo electron microscopy with digital image analysis,,0.0,,,,,vehicle control condition (for 180 days),103648,vehicle control condition (for 180 days),,,,,,,,,, 2844,"Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.",neuron morphology trait,,RS:0001013,WI,male,547 days,4,,CMO:0002840,neuron golgi apparatus area to neuron cytoplasm area ratio,,ga/cyto,,1.05,%,0.04,0.08,MMO:0000221,ex vivo electron microscopy with digital image analysis,,0.0,,,,,vehicle control condition (for 180 days),103650,vehicle control condition (for 180 days),,,,,,,,,, 2844,"Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.",neuron morphology trait,,RS:0000634,OXYS/Nov,male,547 days,4,,CMO:0002840,neuron golgi apparatus area to neuron cytoplasm area ratio,,ga/cyto,,1.2,%,0.04,0.08,MMO:0000221,ex vivo electron microscopy with digital image analysis,,0.0,,,,,vehicle control condition (for 180 days),103651,vehicle control condition (for 180 days),,,,,,,,,, 2844,"Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.",neuron morphology trait,,RS:0001013,WI,male,547 days,4,,CMO:0002844,neuron rough endoplasmic reticulum area to neuron cytoplasm area ratio,,rer/cyto,,27.4,%,0.51,1.02,MMO:0000221,ex vivo electron microscopy with digital image analysis,,0.0,,,,,vehicle control condition (for 180 days),103653,vehicle control condition (for 180 days),,,,,,,,,, 2844,"Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.",neuron morphology trait,,RS:0000634,OXYS/Nov,male,547 days,4,,CMO:0002844,neuron rough endoplasmic reticulum area to neuron cytoplasm area ratio,,rer/cyto,,11.2,%,0.33,0.66,MMO:0000221,ex vivo electron microscopy with digital image analysis,,0.0,,,,,vehicle control condition (for 180 days),103654,vehicle control condition (for 180 days),,,,,,,,,, 2844,"Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.",neuron morphology trait,,RS:0001013,WI,male,547 days,4,,CMO:0002848,neuron vacuole area to neuron cytoplasm area ratio,,v/cyto,,3.97,%,0.34,0.68,MMO:0000221,ex vivo electron microscopy with digital image analysis,,0.0,,,,,vehicle control condition (for 180 days),103656,vehicle control condition (for 180 days),,,,,,,,,, 2844,"Stefanova NA, et al., J Pineal Res. 2015 Sep;59(2):163-77. doi: 10.1111/jpi.12248. Epub 2015 Jun 8.",neuron morphology trait,,RS:0000634,OXYS/Nov,male,547 days,4,,CMO:0002848,neuron vacuole area to neuron cytoplasm area ratio,,v/cyto,,8.23,%,0.4,0.8,MMO:0000221,ex vivo electron microscopy with digital image analysis,,0.0,,,,,vehicle control condition (for 180 days),103657,vehicle control condition (for 180 days),,,,,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",heart mass,,RS:0000760,SHRSP/Gcrc,male,126 days,N/A,,CMO:0000074,heart weight to body weight ratio,,,,4.66,g/kg,0.4,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102100,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",heart mass,,RS:0000761,WKY/Gcrc,male,126 days,N/A,,CMO:0000074,heart weight to body weight ratio,,,,3.48,g/kg,0.26,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102101,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",heart mass,,RS:0003568,SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc,male,126 days,N/A,,CMO:0000074,heart weight to body weight ratio,,,,4.03,g/kg,0.28,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102102,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",heart mass,,RS:0004553,SHRSP.WKY-(D3Wox20-D3Rat114)/Gcrc,male,126 days,6,,CMO:0000074,heart weight to body weight ratio,,,,4.47,g/kg,0.27,0.6614,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102103,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",heart mass,,RS:0004554,SHRSP.WKY-(D3Mgh16-D3Rat80)/Gcrc,male,126 days,N/A,,CMO:0000074,heart weight to body weight ratio,,,,3.88,g/kg,0.12,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102104,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",heart mass,,RS:0004555,SHRSP.WKY-(D3Mgh16-D3Wox3)/Gcrc,male,126 days,7,,CMO:0000074,heart weight to body weight ratio,,,,4.07,g/kg,0.17,0.4498,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102105,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",heart mass,,RS:0004556,SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc,male,126 days,N/A,,CMO:0000074,heart weight to body weight ratio,,,,4.26,g/kg,0.3,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102106,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",heart mass,,RS:0004557,SHRSP.WKY-(D3Mgh16-rs197649383)/Gcrc,male,126 days,N/A,,CMO:0000074,heart weight to body weight ratio,,,,4.72,g/kg,0.64,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102107,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine urea amount,,RS:0000760,SHRSP/Gcrc,male,126 days,17,,CMO:0002926,urine urea level to urine creatinine level ratio,,,,112.69,,29.95,123.487,MMO:0000676,urine urea analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),103791,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine urea amount,,RS:0000761,WKY/Gcrc,male,126 days,18,,CMO:0002926,urine urea level to urine creatinine level ratio,,,,68.85,,9.11,38.6505,MMO:0000676,urine urea analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),103792,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine urea amount,,RS:0003568,SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc,male,126 days,9,,CMO:0002926,urine urea level to urine creatinine level ratio,,,,87.33,,12.81,38.43,MMO:0000676,urine urea analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),103793,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine urea amount,,RS:0004556,SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc,male,126 days,7,,CMO:0002926,urine urea level to urine creatinine level ratio,,,,101.15,,8.47,22.4095,MMO:0000676,urine urea analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),103794,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine urea amount,,RS:0004558,SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc,male,126 days,6,,CMO:0002926,urine urea level to urine creatinine level ratio,,,,76.34,,4.14,10.1409,MMO:0000676,urine urea analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),103795,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",heart mass,,RS:0004558,SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc,male,126 days,N/A,,CMO:0000074,heart weight to body weight ratio,,,,4.67,g/kg,0.4,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102108,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",heart left ventricle mass,,RS:0000760,SHRSP/Gcrc,male,126 days,N/A,,CMO:0000530,heart left ventricle weight to body weight ratio,,,,3.64,mg/g,0.39,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102109,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",heart left ventricle mass,,RS:0000761,WKY/Gcrc,male,126 days,N/A,,CMO:0000530,heart left ventricle weight to body weight ratio,,,,2.52,mg/g,0.2,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102110,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",heart left ventricle mass,,RS:0003568,SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc,male,126 days,N/A,,CMO:0000530,heart left ventricle weight to body weight ratio,,,,3.04,mg/g,0.29,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102111,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",heart left ventricle mass,,RS:0004553,SHRSP.WKY-(D3Wox20-D3Rat114)/Gcrc,male,126 days,6,,CMO:0000530,heart left ventricle weight to body weight ratio,,,,3.33,mg/g,0.33,0.8083,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102112,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",heart left ventricle mass,,RS:0004554,SHRSP.WKY-(D3Mgh16-D3Rat80)/Gcrc,male,126 days,N/A,,CMO:0000530,heart left ventricle weight to body weight ratio,,,,2.79,mg/g,0.14,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102113,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",heart left ventricle mass,,RS:0004555,SHRSP.WKY-(D3Mgh16-D3Wox3)/Gcrc,male,126 days,7,,CMO:0000530,heart left ventricle weight to body weight ratio,,,,3,mg/g,0.11,0.291,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102114,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",heart left ventricle mass,,RS:0004556,SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc,male,126 days,N/A,,CMO:0000530,heart left ventricle weight to body weight ratio,,,,3.12,mg/g,0.24,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102115,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",heart left ventricle mass,,RS:0004557,SHRSP.WKY-(D3Mgh16-rs197649383)/Gcrc,male,126 days,N/A,,CMO:0000530,heart left ventricle weight to body weight ratio,,,,3.57,mg/g,0.66,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102116,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",heart left ventricle mass,,RS:0004558,SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc,male,126 days,N/A,,CMO:0000530,heart left ventricle weight to body weight ratio,,,,3.28,mg/g,0.19,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102117,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",kidney mass,,RS:0000760,SHRSP/Gcrc,male,126 days,N/A,,CMO:0000340,both kidneys wet weight to body weight ratio,,,,4.11,g/kg,0.25,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102118,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",kidney mass,,RS:0000761,WKY/Gcrc,male,126 days,N/A,,CMO:0000340,both kidneys wet weight to body weight ratio,,,,2.87,g/kg,0.23,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102119,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",kidney mass,,RS:0003568,SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc,male,126 days,N/A,,CMO:0000340,both kidneys wet weight to body weight ratio,,,,3.65,g/kg,0.2,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102120,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",kidney mass,,RS:0004553,SHRSP.WKY-(D3Wox20-D3Rat114)/Gcrc,male,126 days,6,,CMO:0000340,both kidneys wet weight to body weight ratio,,,,3.78,g/kg,0.18,0.4409,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102121,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",kidney mass,,RS:0004554,SHRSP.WKY-(D3Mgh16-D3Rat80)/Gcrc,male,126 days,N/A,,CMO:0000340,both kidneys wet weight to body weight ratio,,,,3.77,g/kg,0.12,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102122,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",kidney mass,,RS:0004556,SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc,male,126 days,N/A,,CMO:0000340,both kidneys wet weight to body weight ratio,,,,4.16,g/kg,0.4,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102123,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",blood albumin amount,,RS:0002216,Slc:W,male,105 days,N/A,,CMO:0002898,blood glycated albumin level,,glycated albumin n=4-6,,1.5,%,0.05,,MMO:0000166,blood protein analysis,,0.0,,,,,vehicle control condition (for 21 days),102874,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",blood albumin amount,,RS:0000482,GK/Slc,male,105 days,N/A,,CMO:0002898,blood glycated albumin level,,glycated albumin n=4-6,,2.3,%,0.07,,MMO:0000166,blood protein analysis,,0.0,,,,,vehicle control condition (for 21 days),102876,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",blood hemoglobin amount,,RS:0002216,Slc:W,male,105 days,N/A,,CMO:0002786,blood hemoglobin A1c level,,HbA1c n=4-6,,5.32,%,0.13,,MMO:0000295,blood hemoglobin analysis,,0.0,,,,,vehicle control condition (for 21 days),102878,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",blood hemoglobin amount,,RS:0000482,GK/Slc,male,105 days,N/A,,CMO:0002786,blood hemoglobin A1c level,,HbA1c n=4-6,,5.21,%,0.12,,MMO:0000295,blood hemoglobin analysis,,0.0,,,,,vehicle control condition (for 21 days),102880,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",blood free fatty acid amount,,RS:0002216,Slc:W,male,105 days,N/A,,CMO:0000117,blood free fatty acids level,,ueq/l = umol/l,,9.99485,mg/dl,0.7204,,MMO:0000216,blood free fatty acid analysis,,0.0,,,,,vehicle control condition (for 21 days),102882,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",blood free fatty acid amount,,RS:0000482,GK/Slc,male,105 days,N/A,,CMO:0000117,blood free fatty acids level,,ueq/l = umol/l,,12.551475,mg/dl,0.517,,MMO:0000216,blood free fatty acid analysis,,0.0,,,,,vehicle control condition (for 21 days),102884,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",blood triglyceride amount,,RS:0002216,Slc:W,male,105 days,N/A,,CMO:0000118,blood triglyceride level,,n=4-6,,119.5,mg/dl,12.4,,MMO:0000233,blood triglyceride analysis,,0.0,,,,,vehicle control condition (for 21 days),102886,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",blood triglyceride amount,,RS:0000482,GK/Slc,male,105 days,N/A,,CMO:0000118,blood triglyceride level,,n=4-6,,52.3,mg/dl,7.4,,MMO:0000233,blood triglyceride analysis,,0.0,,,,,vehicle control condition (for 21 days),102888,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",blood cholesterol amount,,RS:0002216,Slc:W,male,105 days,N/A,,CMO:0000051,blood total cholesterol level,,n=4-6,,67,mg/dl,3.5,,MMO:0000491,blood cholesterol analysis,,0.0,,,,,vehicle control condition (for 21 days),102890,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",blood cholesterol amount,,RS:0000482,GK/Slc,male,105 days,N/A,,CMO:0000051,blood total cholesterol level,,n=4-6,,77.8,mg/dl,5.2,,MMO:0000491,blood cholesterol analysis,,0.0,,,,,vehicle control condition (for 21 days),102892,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",blood HDL cholesterol amount,,RS:0002216,Slc:W,male,105 days,N/A,,CMO:0000052,blood high density lipoprotein cholesterol level,,n=4-6,,4.2,mg/dl,0.3,,MMO:0000278,blood high-density lipoprotein-cholesterol measurement test,,0.0,,,,,vehicle control condition (for 21 days),102894,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",blood HDL cholesterol amount,,RS:0000482,GK/Slc,male,105 days,N/A,,CMO:0000052,blood high density lipoprotein cholesterol level,,n=4-6,,9,mg/dl,0.9,,MMO:0000278,blood high-density lipoprotein-cholesterol measurement test,,0.0,,,,,vehicle control condition (for 21 days),102896,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",blood LDL cholesterol amount,,RS:0002216,Slc:W,male,105 days,N/A,,CMO:0000053,blood low density lipoprotein cholesterol level,,n=4-6,,26.8,mg/dl,1.4,,MMO:0000279,blood low-density lipoprotein-cholesterol measurement test,,0.0,,,,,vehicle control condition (for 21 days),102898,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",blood LDL cholesterol amount,,RS:0000482,GK/Slc,male,105 days,N/A,,CMO:0000053,blood low density lipoprotein cholesterol level,,n=4-6,,24.3,mg/dl,1.8,,MMO:0000279,blood low-density lipoprotein-cholesterol measurement test,,0.0,,,,,vehicle control condition (for 21 days),102900,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",blood urea nitrogen amount,,RS:0002216,Slc:W,male,105 days,N/A,,CMO:0000049,blood urea nitrogen level,,n=4-6,,19.8,mg/dl,0.6,,MMO:0000253,blood urea nitrogen analysis,,0.0,,,,,vehicle control condition (for 21 days),102902,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",blood urea nitrogen amount,,RS:0000482,GK/Slc,male,105 days,N/A,,CMO:0000049,blood urea nitrogen level,,n=4-6,,15.7,mg/dl,1.2,,MMO:0000253,blood urea nitrogen analysis,,0.0,,,,,vehicle control condition (for 21 days),102904,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",blood creatinine amount,,RS:0002216,Slc:W,male,105 days,N/A,,CMO:0000538,blood creatinine level,,n=4-6,,0.33,mg/dl,0.01,,MMO:0000270,blood creatinine analysis,,0.0,,,,,vehicle control condition (for 21 days),102906,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",blood creatinine amount,,RS:0000482,GK/Slc,male,105 days,N/A,,CMO:0000538,blood creatinine level,,n=4-6,,0.26,mg/dl,0.02,,MMO:0000270,blood creatinine analysis,,0.0,,,,,vehicle control condition (for 21 days),102908,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",urine ketone body amount,,RS:0002216,Slc:W,male,105 days,N/A,,CMO:0002897,urine acetoacetone level,,n=4-6,,50.3,umol/l,2.6,,MMO:0000147,urine analysis,,0.0,,,,,vehicle control condition (for 21 days),102914,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",urine ketone body amount,,RS:0000482,GK/Slc,male,105 days,N/A,,CMO:0002897,urine acetoacetone level,,n=4-6,,91.5,umol/l,39.9,,MMO:0000147,urine analysis,,0.0,,,,,vehicle control condition (for 21 days),102916,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",urine ketone body amount,,RS:0002216,Slc:W,male,105 days,N/A,,CMO:0002896,urine 3-hydroxybutyrate level,,n=4-6,,265.3,umol/l,11.7,,MMO:0000147,urine analysis,,0.0,,,,,vehicle control condition (for 21 days),102918,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",urine ketone body amount,,RS:0000482,GK/Slc,male,105 days,N/A,,CMO:0002896,urine 3-hydroxybutyrate level,,n=4-6,,323.3,umol/l,92.7,,MMO:0000147,urine analysis,,0.0,,,,,vehicle control condition (for 21 days),102920,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",urine output,,RS:0002216,Slc:W,male,105 days,N/A,,CMO:0000260,timed urine volume,,n=4-6,,11.2,ml/d,0.5,,MMO:0000357,urine volume measurement method,,0.0,,,,,vehicle control condition (for 21 days),102922,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",urine output,,RS:0000482,GK/Slc,male,105 days,N/A,,CMO:0000260,timed urine volume,,n=4-6,,9.6,ml/d,0.7,,MMO:0000357,urine volume measurement method,,0.0,,,,,vehicle control condition (for 21 days),102924,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",urine glucose amount,,RS:0002216,Slc:W,male,105 days,N/A,,CMO:0000383,urine glucose level,,n=4-6,,31.8,mg/dl,3.4,,MMO:0000165,blood glucose test strip read by electrochemical glucometer,,0.0,,,,,vehicle control condition (for 21 days),102926,vehicle control condition (for 21 days),,,,,,,,,, 2781,"Iuchi H, et al., Sci Rep. 2017 Sep 19;7(1):11906. doi: 10.1038/s41598-017-12106-y.",urine glucose amount,,RS:0000482,GK/Slc,male,105 days,N/A,,CMO:0000383,urine glucose level,,n=4-6,,588.3,mg/dl,349.4,,MMO:0000165,blood glucose test strip read by electrochemical glucometer,,0.0,,,,,vehicle control condition (for 21 days),102928,vehicle control condition (for 21 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",arterial blood pressure trait,,RS:0000731,WKY/NCrl,male,168 days,6,,CMO:0000005,diastolic blood pressure,,nighttime measurement,,89,mmHg,3.0,7.3485,MMO:0000070,intra-aortic abdominal radiotelemetry,,,measured 12 hr/night for 4 weeks,,,,vehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours),103550,vehicle control condition (for 28 days),dark phase of controlled light/dark cycle (for 12 hours),,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",arterial blood pressure trait,,RS:0001299,GK,male,168 days,6,,CMO:0000005,diastolic blood pressure,,nighttime measurement,,104,mmHg,2.0,4.899,MMO:0000070,intra-aortic abdominal radiotelemetry,,,measured 12 hr/night for 4 weeks,,,,vehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours),103552,vehicle control condition (for 28 days),dark phase of controlled light/dark cycle (for 12 hours),,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",heart pumping trait,,RS:0000731,WKY/NCrl,male,168 days,6,,CMO:0000002,heart rate,,daytime measurement,,294,beats/min,5.0,12.2474,MMO:0000070,intra-aortic abdominal radiotelemetry,,,measured 12 hr/day for 4 weeks,,,,vehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours),103558,vehicle control condition (for 28 days),light phase of controlled light/dark cycle (for 12 hours),,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",heart pumping trait,,RS:0001299,GK,male,168 days,6,,CMO:0000002,heart rate,,daytime measurement,,279,beats/min,3.0,7.3485,MMO:0000070,intra-aortic abdominal radiotelemetry,,,measured 12 hr/day for 4 weeks,,,,vehicle control condition (for 28 days) and light phase of controlled light/dark cycle (for 12 hours),103560,vehicle control condition (for 28 days),light phase of controlled light/dark cycle (for 12 hours),,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",heart pumping trait,,RS:0000731,WKY/NCrl,male,168 days,6,,CMO:0000002,heart rate,,nighttime measurement,,344,beats/min,5.0,12.2474,MMO:0000070,intra-aortic abdominal radiotelemetry,,,measured 12 hr/night for 4 weeks,,,,vehicle control condition (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours),103566,vehicle control condition (for 28 days),dark phase of controlled light/dark cycle (for 12 hours),,,,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricle mass,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0002787,heart left ventricle weight to tibia length ratio,,lv/tl,,0.2,g/cm,0.005,0.015,MMO:0000005,post excision weight measurement,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101695,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricle mass,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0002787,heart left ventricle weight to tibia length ratio,,lv/tl,,0.28,g/cm,0.007,0.0198,MMO:0000005,post excision weight measurement,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101697,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",retroperitoneal fat pad mass,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0002990,retroperitoneal fat pad weight to tibia length ratio,,vf/tl,,105,mg/mm,9.0,27.0,MMO:0000005,post excision weight measurement,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101699,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",retroperitoneal fat pad mass,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0002990,retroperitoneal fat pad weight to tibia length ratio,,vf/tl,,482,mg/mm,18.0,50.9117,MMO:0000005,post excision weight measurement,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101701,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",inguinal fat pad mass,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0002991,inguinal fat pad weight to tibia length ratio,,sf/tl,,32,mg/mm,3.0,9.0,MMO:0000005,post excision weight measurement,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101703,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",inguinal fat pad mass,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0002991,inguinal fat pad weight to tibia length ratio,,sf/tl,,209,mg/mm,12.0,33.9411,MMO:0000005,post excision weight measurement,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101705,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricle wall thickness,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0000987,heart ventricle septal wall thickness,,,,0.158,cm,0.003,0.009,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101707,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricle wall thickness,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0000987,heart ventricle septal wall thickness,,,,0.205,cm,0.004,0.0113,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101709,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",kidney mass,,RS:0000742,WKY,male,252 days to 238 days,15,,CMO:0000082,right kidney wet weight,,,,1.3533,g,0.0439,0.17,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100373,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",urine output,,RS:0000742,WKY,male,252 days to 238 days,7,,CMO:0000260,timed urine volume,,,,10.6,ml/d,2.2,5.8207,MMO:0000357,urine volume measurement method,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100376,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",blood creatinine amount,,RS:0000742,WKY,male,252 days to 238 days,6,,CMO:0000537,plasma creatinine level,,,,0.52,mg/dl,0.04,0.098,MMO:0000306,plasma creatinine analysis,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100379,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",kidney integrity trait,,RS:0000742,WKY,male,252 days to 238 days,15,,CMO:0001258,kidney fibrotic lesion area to total kidney area ratio,,,,0.75,%,0.13,0.5035,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100385,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",kidney blood vessel morphology trait,,RS:0000742,WKY,male,252 days to 238 days,15,,CMO:0002790,artery tunica media width to artery inner diameter ratio,,,,1.82,,0.15,0.5809,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100388,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",body mass,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0000012,body weight,,,,294,g,6.0,18.0,MMO:0000016,body weighing method,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101661,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",body mass,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0000012,body weight,,,,393,g,6.0,16.9706,MMO:0000016,body weighing method,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101663,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",tibia length,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0001731,tibia straight segment length,,,,35.8,mm,0.4,1.2,MMO:0000209,body length measuring method,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101665,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",tibia length,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0001731,tibia straight segment length,,,,32.5,mm,0.9,2.5456,MMO:0000209,body length measuring method,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101667,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",arterial blood pressure trait,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0000004,systolic blood pressure,undefined,,,138,mmHg,1.0,3.0,MMO:0000031,tail cuff plethysmography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101669,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",arterial blood pressure trait,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0000004,systolic blood pressure,undefined,,,221,mmHg,5.0,14.1421,MMO:0000031,tail cuff plethysmography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101671,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart pumping trait,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0000002,heart rate,,,,380,beats/min,8.0,24.0,MMO:0000031,tail cuff plethysmography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101673,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart pumping trait,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0000002,heart rate,,,,339,beats/min,11.0,31.1127,MMO:0000031,tail cuff plethysmography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101675,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart mass,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0001198,heart weight to tibia length ratio,,,,0.263,g/cm,0.006,0.018,MMO:0000005,post excision weight measurement,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101681,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricle posterior wall thickness,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0000239,heart left ventricle posterior wall thickness,,,,1.5,mm,0.02,0.06,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101711,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricle posterior wall thickness,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0000239,heart left ventricle posterior wall thickness,,,,2.06,mm,0.04,0.1131,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101713,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricle end-diastolic diameter,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0000982,heart left ventricle end-diastolic diameter,,,,7.21,mm,0.21,0.63,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101715,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricle end-diastolic diameter,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0000982,heart left ventricle end-diastolic diameter,,,,7.2,mm,0.14,0.396,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101717,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricle end-diastolic diameter,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0000985,heart left ventricle fractional shortening,,,,39.8,%,2.5,7.5,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101719,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricle end-diastolic diameter,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0000985,heart left ventricle fractional shortening,,,,47.7,%,1.9,5.374,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101721,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricle mass,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0001123,calculated heart left ventricle weight,,,,764,mg,27.0,81.0,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101723,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricle mass,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0001123,calculated heart left ventricle weight,,,,1114,mg,35.0,98.9949,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101725,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricle wall thickness,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0000988,heart left ventricle relative wall thickness,,,,44,%,2.0,6.0,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101727,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricle wall thickness,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0000988,heart left ventricle relative wall thickness,,,,57,%,2.0,5.6569,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101729,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart pumping trait,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0002504,E wave deceleration time,,,,35.4,ms,1.2,3.6,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101731,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart pumping trait,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0002504,E wave deceleration time,,,,56.9,ms,1.8,5.0912,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101733,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart muscle relaxation trait,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0001482,heart isovolumetric relaxation time,,,,24.8,ms,1.8,5.4,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101735,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart muscle relaxation trait,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0001482,heart isovolumetric relaxation time,,,,43.1,ms,1.5,4.2426,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101737,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart pumping trait,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0002556,myocardial performance index,,,,0.44,,0.01,0.03,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101739,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart pumping trait,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0002556,myocardial performance index,,,,0.61,,0.03,0.0849,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101741,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricular blood pressure trait,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0000606,left ventricular end-diastolic blood pressure,,,,2.27,mmHg,0.11,0.33,MMO:0000014,vascular transducer tipped catheter,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101743,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricular blood pressure trait,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0000606,left ventricular end-diastolic blood pressure,,,,4.43,mmHg,0.21,0.594,MMO:0000014,vascular transducer tipped catheter,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101745,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricular blood pressure trait,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0001747,time constant of left ventricular pressure decay,,,,36.2,ms,0.5,1.5,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101747,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricular blood pressure trait,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0001747,time constant of left ventricular pressure decay,,,,47.3,ms,1.5,4.2426,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101749,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricular blood pressure trait,,RS:0004552,SS.ZUC-Leprfa+/+/Slc,female,91 days,9,,CMO:0002993,heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio,,,,0.32,mmHg/mm,0.02,0.06,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101751,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart left ventricular blood pressure trait,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0002993,heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio,,,,0.63,mmHg/mm,0.05,0.1414,MMO:0000337,echocardiography,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101753,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",heart left ventricle posterior wall thickness,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,13,,CMO:0000238,heart posterior wall thickness,,,,0.206,cm,0.006,0.0216,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),101998,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",heart left ventricle wall thickness,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,13,,CMO:0000988,heart left ventricle relative wall thickness,,,,49,%,1.0,3.6056,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),102004,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",heart left ventricle end-diastolic diameter,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,13,,CMO:0000985,heart left ventricle fractional shortening,,,,47.66,%,2.43,8.7615,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),102007,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",cardiac output trait,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,13,,CMO:0000180,ejection fraction,,,,82.5,%,1.94,6.9948,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),102010,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",blood flow trait,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,13,,CMO:0002504,E wave deceleration time,,,,53.05,ms,1.48,5.3362,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),102013,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",heart muscle relaxation trait,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,13,,CMO:0001482,heart isovolumetric relaxation time,,,,40.75,ms,2.42,8.7254,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),102016,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",heart left ventricular blood pressure trait,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,13,,CMO:0001747,time constant of left ventricular pressure decay,,,,33.52,ms,1.09,3.9301,MMO:0000337,echocardiography,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),102019,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",heart left ventricular blood pressure trait,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,13,,CMO:0000606,left ventricular end-diastolic blood pressure,,,,17.65,mmHg,1.43,5.1559,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),102022,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2644,"Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4.",heart left ventricular blood pressure trait,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,male,91 days,13,,CMO:0002993,heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio,,,,2.1,mmHg/mm,0.13,0.4687,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,vehicle control condition (0.5 %) (for 28 days),102025,vehicle control condition (0.5 %) (for 28 days),,,,,,,,,, 2684,"Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.",heart left ventricle end-diastolic diameter,,RS:0003328,SS/NEisSlc,male,126 days,8,,CMO:0000982,heart left ventricle end-diastolic diameter,,,,8.7,mm,0.3,0.8485,MMO:0000002,transthoracic echocardiography,,0.0,,,,,controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days),102320,controlled sodium content diet (0.3 %) (for 42 days),,,controlled sodium content diet (8 %) (for 77 days),,vehicle control condition (for 49 days),,,,, 2684,"Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.",kidney mass,,RS:0003328,SS/NEisSlc,male,126 days,8,,CMO:0000340,both kidneys wet weight to body weight ratio,,,,5.19,g/kg,0.19,0.5374,MMO:0000005,post excision weight measurement,,0.0,,,,,controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days),102323,controlled sodium content diet (0.3 %) (for 42 days),,,controlled sodium content diet (8 %) (for 77 days),,vehicle control condition (for 49 days),,,,, 2684,"Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.",blood creatinine amount,,RS:0003328,SS/NEisSlc,male,126 days,8,,CMO:0000057,serum creatinine level,,,,0.47,mg/dl,0.04,0.1131,MMO:0000271,serum creatinine analysis,,0.0,,,,,controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days),102326,controlled sodium content diet (0.3 %) (for 42 days),,,controlled sodium content diet (8 %) (for 77 days),,vehicle control condition (for 49 days),,,,, 2684,"Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.",blood urea nitrogen amount,,RS:0003328,SS/NEisSlc,male,126 days,8,,CMO:0000587,serum urea nitrogen level,,,,33.6,mg/dl,4.1,11.5966,MMO:0000274,serum urea nitrogen analysis,,0.0,,,,,controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days),102329,controlled sodium content diet (0.3 %) (for 42 days),,,controlled sodium content diet (8 %) (for 77 days),,vehicle control condition (for 49 days),,,,, 2684,"Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.",glomerular filtration trait,,RS:0003328,SS/NEisSlc,male,126 days,8,,CMO:0000765,creatinine clearance,,,,1.9,ml/min,0.5,1.4142,MMO:0000271,serum creatinine analysis,,0.0,,,,,controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days),102332,controlled sodium content diet (0.3 %) (for 42 days),,,controlled sodium content diet (8 %) (for 77 days),,vehicle control condition (for 49 days),,,,, 2684,"Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.",urine output,,RS:0003328,SS/NEisSlc,male,126 days,8,,CMO:0000260,timed urine volume,,,,53.6,ml/d,7.1,20.0818,MMO:0000357,urine volume measurement method,,0.0,,,,,controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days),102335,controlled sodium content diet (0.3 %) (for 42 days),,,controlled sodium content diet (8 %) (for 77 days),,vehicle control condition (for 49 days),,,,, 2684,"Ishikawa M, et al., Int Heart J. 2013;54(2):98-106.",total urine protein amount,,RS:0003328,SS/NEisSlc,male,126 days,8,,CMO:0000756,urine total protein excretion rate,,,,307,mg/d,46.0,130.1076,MMO:0000334,urine protein analysis,,0.0,,,,,controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then vehicle control condition (for 49 days),102338,controlled sodium content diet (0.3 %) (for 42 days),,,controlled sodium content diet (8 %) (for 77 days),,vehicle control condition (for 49 days),,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",arterial blood pressure trait,,RS:0001366,LL/Mav,male,56 days,9,,CMO:0000004,systolic blood pressure,mean of 3 samples of undefined duration,,serial mean,115,mmHg,5.0,15.0,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition,102702,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",arterial blood pressure trait,,RS:0000556,LH/Mav,male,56 days,11,,CMO:0000004,systolic blood pressure,mean of 3 samples of undefined duration,,serial mean,134,mmHg,4.0,13.2665,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition,102704,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",urine output,,RS:0001366,LL/Mav,male,56 days,9,,CMO:0000260,timed urine volume,,,,9.1,ml/d,0.4,1.2,MMO:0000357,urine volume measurement method,,0.0,,,,,vehicle control condition,102706,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",urine output,,RS:0000556,LH/Mav,male,56 days,11,,CMO:0000260,timed urine volume,,,,8.7,ml/d,0.3,0.995,MMO:0000357,urine volume measurement method,,0.0,,,,,vehicle control condition,102708,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",total urine protein amount,,RS:0001366,LL/Mav,male,56 days,9,,CMO:0000756,urine total protein excretion rate,,,,26,mg/d,1.0,3.0,MMO:0000334,urine protein analysis,,0.0,,,,,vehicle control condition,102710,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",total urine protein amount,,RS:0000556,LH/Mav,male,56 days,11,,CMO:0000756,urine total protein excretion rate,,,,70,mg/d,9.0,29.8496,MMO:0000334,urine protein analysis,,0.0,,,,,vehicle control condition,102712,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",blood glucose amount,,RS:0001366,LL/Mav,male,56 days,9,,CMO:0000046,blood glucose level,,,,70,mg/dl,1.0,3.0,MMO:0000112,blood glucose analysis,,0.0,,,,,vehicle control condition then fasting (for 16 hours),102714,vehicle control condition,,,fasting (for 16 hours),,,,,,, 2520,"Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.",body mass,,RS:0004500,SD-Nfe2l2em1Mcwi+/+,male,11 days to 9 days,8,,CMO:0000012,body weight,,,,281,g,17.7,50.0632,MMO:0000016,body weighing method,,0.0,,,,,controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days),100733,controlled sodium content diet (0.4 %) (between 70 and 84 days),,,controlled sodium content diet (4 %) (for 6 days),,vehicle control condition (for 3 days),,,,, 2520,"Priestley JR, et al., Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H478-87. doi: 10.1152/ajpheart.00586.2015. Epub 2015 Dec 4.",body mass,,RS:0004501,SD-Nfe2l2em1Mcwi-/-,male,11 days to 9 days,4,,CMO:0000012,body weight,,,,299,g,22.2,44.4,MMO:0000016,body weighing method,,0.0,,,,,controlled sodium content diet (0.4 %) (between 70 and 84 days) then controlled sodium content diet (4 %) (for 6 days) then vehicle control condition (for 3 days),100734,controlled sodium content diet (0.4 %) (between 70 and 84 days),,,controlled sodium content diet (4 %) (for 6 days),,vehicle control condition (for 3 days),,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",kidney mass,,RS:0004555,SHRSP.WKY-(D3Mgh16-D3Wox3)/Gcrc,male,126 days,7,,CMO:0000340,both kidneys wet weight to body weight ratio,,,,3.77,g/kg,0.15,0.3969,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102161,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2761,"Issiakhem M, et al., J Cardiovasc Pharmacol. 2008 Mar;51(3):280-5. doi: 10.1097/FJC.0b013e31816299a5.",arterial blood pressure trait,,RS:0000556,LH/Mav,male,63 days,8,,CMO:0000004,systolic blood pressure,undefined,,,160,mmHg,3.0,8.4853,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition,102848,vehicle control condition,,,,,,,,,, 2761,"Issiakhem M, et al., J Cardiovasc Pharmacol. 2008 Mar;51(3):280-5. doi: 10.1097/FJC.0b013e31816299a5.",arterial blood pressure trait,,RS:0000556,LH/Mav,male,84 days,8,,CMO:0000004,systolic blood pressure,undefined,,,160,mmHg,,,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition,102849,vehicle control condition,,,,,,,,,, 2761,"Issiakhem M, et al., J Cardiovasc Pharmacol. 2008 Mar;51(3):280-5. doi: 10.1097/FJC.0b013e31816299a5.",renal blood flow trait,,RS:0000556,LH/Mav,male,84 days,8,,CMO:0001955,renal blood flow rate to kidney weight ratio,,,,5,ml/min/g,0.3,0.8485,MMO:0000228,ultrasonic flowmeter,,0.0,,,,,vehicle control condition then ketamine (20 mg/kg) and thiobutabarbital (75 mg/kg) ,102853,vehicle control condition,,,ketamine (20 mg/kg) ,thiobutabarbital (75 mg/kg) ,,,,,, 2761,"Issiakhem M, et al., J Cardiovasc Pharmacol. 2008 Mar;51(3):280-5. doi: 10.1097/FJC.0b013e31816299a5.",kidney blood vessel physiology trait,,RS:0000556,LH/Mav,male,84 days,8,,CMO:0003218,renal vascular resistance to kidney weight ratio,SBP/RBF,,,33,ml/min/g/mmHg,2.0,5.6569,MMO:0000228,ultrasonic flowmeter,,0.0,,,,,vehicle control condition then ketamine (20 mg/kg) and thiobutabarbital (75 mg/kg) ,102857,vehicle control condition,,,ketamine (20 mg/kg) ,thiobutabarbital (75 mg/kg) ,,,,,, 2622,"Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23.",heart mass,,RS:0004550,SS.ZUC-Leprfa-/-/Slc,female,91 days,8,,CMO:0001198,heart weight to tibia length ratio,,,,0.35,g/cm,0.0012,0.0034,MMO:0000005,post excision weight measurement,,0.0,,ovariectomy,42,days,bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days),101693,bilateral ovariectomy (for 42 days),,,vehicle control condition (for 35 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",kidney mass,,RS:0004557,SHRSP.WKY-(D3Mgh16-rs197649383)/Gcrc,male,126 days,N/A,,CMO:0000340,both kidneys wet weight to body weight ratio,,,,4.25,g/kg,0.7,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102124,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",kidney mass,,RS:0004558,SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc,male,126 days,N/A,,CMO:0000340,both kidneys wet weight to body weight ratio,,,,4.2,g/kg,0.62,,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102125,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",drinking behavior trait,,RS:0000760,SHRSP/Gcrc,male,126 days,17,,CMO:0000741,water drink intake rate,,,,78.62,ml/d,21.79,89.8425,MMO:0000697,metabolic cage water drinking measurement method,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102126,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",drinking behavior trait,,RS:0000761,WKY/Gcrc,male,126 days,18,,CMO:0000741,water drink intake rate,,,,53.12,ml/d,30.74,130.4188,MMO:0000697,metabolic cage water drinking measurement method,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102127,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",drinking behavior trait,,RS:0003568,SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc,male,126 days,9,,CMO:0000741,water drink intake rate,,,,58.47,ml/d,9.43,28.29,MMO:0000697,metabolic cage water drinking measurement method,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102128,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",drinking behavior trait,,RS:0004556,SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc,male,126 days,7,,CMO:0000741,water drink intake rate,,,,57.55,ml/d,15.23,40.2948,MMO:0000697,metabolic cage water drinking measurement method,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102129,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",drinking behavior trait,,RS:0004558,SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc,male,126 days,6,,CMO:0000741,water drink intake rate,,,,79.16,ml/d,16.78,41.1024,MMO:0000697,metabolic cage water drinking measurement method,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102130,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine output,,RS:0000760,SHRSP/Gcrc,male,126 days,17,,CMO:0000260,timed urine volume,,,,55.29,ml/d,15.78,65.0626,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102131,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine output,,RS:0000761,WKY/Gcrc,male,126 days,18,,CMO:0000260,timed urine volume,,,,31.8,ml/d,14.34,60.8395,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102132,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine output,,RS:0003568,SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc,male,126 days,9,,CMO:0000260,timed urine volume,,,,34.03,ml/d,7.02,21.06,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102133,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine output,,RS:0004556,SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc,male,126 days,7,,CMO:0000260,timed urine volume,,,,30.68,ml/d,11.32,29.9499,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102134,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine output,,RS:0004558,SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc,male,126 days,6,,CMO:0000260,timed urine volume,,,,55.86,ml/d,8.67,21.2371,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102135,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine sodium amount,,RS:0000760,SHRSP/Gcrc,male,126 days,17,,CMO:0000129,urine sodium level,,,,211.14,mmol/l,46.41,191.3533,MMO:0000434,urine sodium analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102136,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine sodium amount,,RS:0000761,WKY/Gcrc,male,126 days,18,,CMO:0000129,urine sodium level,,,,220.23,mmol/l,71.19,302.0336,MMO:0000434,urine sodium analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102137,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle wall thickness,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000987,heart ventricle septal wall thickness,,,,0.1,cm,0.004,0.0219,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100338,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle end-diastolic diameter,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000982,heart left ventricle end-diastolic diameter,,,,10.6,mm,0.1,0.5477,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100341,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle end-systolic diameter,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000983,heart left ventricle end-systolic diameter,,,,8.9,mm,0.2,1.0954,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100344,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle posterior wall thickness,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000238,heart posterior wall thickness,,,,0.18,cm,0.004,0.0219,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100347,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle end-diastolic diameter,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000985,heart left ventricle fractional shortening,,,,15.8,%,0.7,3.8341,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100350,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",cardiac output trait,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000180,ejection fraction,,,,37,%,1.4,7.6681,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100353,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",blood flow trait,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0002789,E/A wave ratio,,,,1.85,,0.14,0.7668,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100356,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",kidney mass,,RS:0000742,WKY,male,252 days to 238 days,15,,CMO:0000082,right kidney wet weight,,,,1.3533,g,0.0439,0.17,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100359,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",urine output,,RS:0000742,WKY,male,252 days to 238 days,7,,CMO:0000260,timed urine volume,,,,10.6,ml/d,2.2,5.8207,MMO:0000357,urine volume measurement method,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100362,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",blood creatinine amount,,RS:0000742,WKY,male,252 days to 238 days,6,,CMO:0000537,plasma creatinine level,,,,0.52,mg/dl,0.04,0.098,MMO:0000306,plasma creatinine analysis,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100365,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine sodium amount,,RS:0003568,SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc,male,126 days,9,,CMO:0000129,urine sodium level,,,,268.97,mmol/l,32.7,98.1,MMO:0000434,urine sodium analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102138,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine sodium amount,,RS:0004556,SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc,male,126 days,7,,CMO:0000129,urine sodium level,,,,260.49,mmol/l,36.69,97.0726,MMO:0000434,urine sodium analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102139,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine sodium amount,,RS:0004558,SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc,male,126 days,6,,CMO:0000129,urine sodium level,,,,169.89,mmol/l,27.46,67.263,MMO:0000434,urine sodium analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102140,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine potassium amount,,RS:0000760,SHRSP/Gcrc,male,126 days,17,,CMO:0000128,urine potassium level,,,,44.48,mmol/l,17.37,71.6183,MMO:0000435,urine potassium analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102141,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine potassium amount,,RS:0000761,WKY/Gcrc,male,126 days,18,,CMO:0000128,urine potassium level,,,,71.25,mmol/l,33.04,140.1768,MMO:0000435,urine potassium analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102142,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine potassium amount,,RS:0003568,SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc,male,126 days,9,,CMO:0000128,urine potassium level,,,,72.41,mmol/l,20.37,61.11,MMO:0000435,urine potassium analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102143,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine potassium amount,,RS:0004556,SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc,male,126 days,7,,CMO:0000128,urine potassium level,,,,80.72,mmol/l,27.0,71.4353,MMO:0000435,urine potassium analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102144,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine potassium amount,,RS:0004558,SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc,male,126 days,6,,CMO:0000128,urine potassium level,,,,28.25,mmol/l,8.59,21.0411,MMO:0000435,urine potassium analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102145,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine urea amount,,RS:0000760,SHRSP/Gcrc,male,126 days,17,,CMO:0002924,urine urea level,,,,131.16,mmol/l,57.62,237.5733,MMO:0000676,urine urea analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102146,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine urea amount,,RS:0000761,WKY/Gcrc,male,126 days,18,,CMO:0002924,urine urea level,,,,235.52,mmol/l,90.62,384.4681,MMO:0000676,urine urea analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102147,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine urea amount,,RS:0003568,SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc,male,126 days,9,,CMO:0002924,urine urea level,,,,228.93,mmol/l,62.26,186.78,MMO:0000676,urine urea analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102148,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine urea amount,,RS:0004556,SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc,male,126 days,7,,CMO:0002924,urine urea level,,,,316.61,mmol/l,113.57,300.478,MMO:0000676,urine urea analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102149,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine urea amount,,RS:0004558,SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc,male,126 days,6,,CMO:0002924,urine urea level,,,,103,mmol/l,34.23,83.846,MMO:0000676,urine urea analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102150,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine creatinine amount,,RS:0000760,SHRSP/Gcrc,male,126 days,17,,CMO:0000125,urine creatinine level,,,,6.85368,mg/dl,2.7655,11.4025,MMO:0000275,urine creatinine analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102151,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine creatinine amount,,RS:0000761,WKY/Gcrc,male,126 days,18,,CMO:0000125,urine creatinine level,,,,13.90776,mg/dl,5.2906,22.4459,MMO:0000275,urine creatinine analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102152,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine creatinine amount,,RS:0003568,SHRSP.WKY-(D3Mgh16-D3Rat114)/Gcrc,male,126 days,9,,CMO:0000125,urine creatinine level,,,,10.4208,mg/dl,1.8036,5.4108,MMO:0000275,urine creatinine analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102153,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine creatinine amount,,RS:0004556,SHRSP.WKY-(D3Mgh16-rs65433898)/Gcrc,male,126 days,7,,CMO:0000125,urine creatinine level,,,,12.38472,mg/dl,3.6072,9.5438,MMO:0000275,urine creatinine analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102154,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2646,"Koh-Tan HH, et al., J Hypertens. 2017 Feb;35(2):319-329. doi: 10.1097/HJH.0000000000001155.",urine creatinine amount,,RS:0004558,SHRSP.WKY-(D3Mgh16-D3Mit10)/Gcrc,male,126 days,6,,CMO:0000125,urine creatinine level,,,,5.37072,mg/dl,1.523,3.7307,MMO:0000275,urine creatinine analysis,,0.0,,,,,vehicle control condition (for 126 days) then sodium chloride solution (1 %) (for 21 days),102155,vehicle control condition (for 126 days),,,sodium chloride solution (1 %) (for 21 days),,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",body mass,,RS:0000731,WKY/NCrl,male,168 days,6,,CMO:0000012,body weight,,,,463,g,7.0,17.1464,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition (for 28 days),103490,vehicle control condition (for 28 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",body mass,,RS:0001299,GK,male,168 days,6,,CMO:0000012,body weight,,,,380,g,7.0,17.1464,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition (for 28 days),103492,vehicle control condition (for 28 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",drinking behavior trait,,RS:0000731,WKY/NCrl,male,175 days to 140 days,6,,CMO:0002859,water intake drink rate to body weight ratio,,,,50,ml/d/kg,1.0,2.4495,MMO:0000619,drink intake measuring method,,,,,,,vehicle control condition (between 1 and 35 days),103498,vehicle control condition (between 1 and 35 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",drinking behavior trait,,RS:0001299,GK,male,175 days to 140 days,6,,CMO:0002859,water intake drink rate to body weight ratio,,,,99,ml/d/kg,13.0,31.8434,MMO:0000619,drink intake measuring method,,,,,,,vehicle control condition (between 1 and 35 days),103500,vehicle control condition (between 1 and 35 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",blood fructosamine amount,,RS:0000731,WKY/NCrl,male,175 days,6,,CMO:0002856,serum fructosamine level,,,,153,umol/l,3.0,7.3485,MMO:0000708,serum fructosamine analysis,,0.0,,,,,vehicle control condition (for 35 days),103502,vehicle control condition (for 35 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",blood fructosamine amount,,RS:0001299,GK,male,175 days,6,,CMO:0002856,serum fructosamine level,,,,187,umol/l,9.0,22.0454,MMO:0000708,serum fructosamine analysis,,0.0,,,,,vehicle control condition (for 35 days),103504,vehicle control condition (for 35 days),,,,,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",blood glucose amount,,RS:0000731,WKY/NCrl,male,168 days,6,,CMO:0000046,blood glucose level,,,,113,mg/dl,4.0,9.798,MMO:0000165,blood glucose test strip read by electrochemical glucometer,,0.0,,,,,vehicle control condition (for 28 days) then fasting (for 16 hours),103510,vehicle control condition (for 28 days),,,fasting (for 16 hours),,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",blood glucose amount,,RS:0001299,GK,male,168 days,6,,CMO:0000046,blood glucose level,,,,122,mg/dl,8.0,19.5959,MMO:0000165,blood glucose test strip read by electrochemical glucometer,,0.0,,,,,vehicle control condition (for 28 days) then fasting (for 16 hours),103512,vehicle control condition (for 28 days),,,fasting (for 16 hours),,,,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",blood glucose amount,,RS:0000731,WKY/NCrl,male,168 days,6,,CMO:0000046,blood glucose level,,,,125,mg/dl,3.0,7.3485,MMO:0000113,oral glucose tolerance test,,0.0,,,,,vehicle control condition (for 28 days) then fasting (for 16 hours) then glucose (2 g/kg) (for 2 hours),103518,vehicle control condition (for 28 days),,,fasting (for 16 hours),,glucose (2 g/kg) (for 2 hours),,,,, 2827,"Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57.",blood glucose amount,,RS:0001299,GK,male,168 days,6,,CMO:0000046,blood glucose level,,,,278,mg/dl,20.0,48.9898,MMO:0000113,oral glucose tolerance test,,0.0,,,,,vehicle control condition (for 28 days) then fasting (for 16 hours) then glucose (2 g/kg) (for 2 hours),103520,vehicle control condition (for 28 days),,,fasting (for 16 hours),,glucose (2 g/kg) (for 2 hours),,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",body mass,,RS:0001366,LL/Mav,male,56 days,9,,CMO:0000012,body weight,,,,231,g,4.0,12.0,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition,102698,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",body mass,,RS:0000556,LH/Mav,male,56 days,11,,CMO:0000012,body weight,,,,246,g,4.0,13.2665,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition,102700,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",blood glucose amount,,RS:0001366,LL/Mav,male,56 days,9,,CMO:0000046,blood glucose level,,,,136,mg/dl,4.0,12.0,MMO:0000112,blood glucose analysis,,0.0,,,,,vehicle control condition then fasting (for 16 hours) then glucose (2 g/kg) (for 1 hours),102718,vehicle control condition,,,fasting (for 16 hours),,glucose (2 g/kg) (for 1 hours),,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",body mass,,RS:0001366,LL/Mav,male,112 days,9,,CMO:0000012,body weight,,,,364,g,6.0,18.0,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition,102722,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",body mass,,RS:0000556,LH/Mav,male,112 days,11,,CMO:0000012,body weight,,,,384,g,9.0,29.8496,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition,102724,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",blood glucose amount,,RS:0000556,LH/Mav,male,56 days,11,,CMO:0000046,blood glucose level,,,,69,mg/dl,1.0,3.3166,MMO:0000112,blood glucose analysis,,0.0,,,,,vehicle control condition then fasting (for 16 hours),102716,vehicle control condition,,,fasting (for 16 hours),,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",blood glucose amount,,RS:0000556,LH/Mav,male,56 days,11,,CMO:0000046,blood glucose level,,,,127,mg/dl,3.0,9.9499,MMO:0000112,blood glucose analysis,,0.0,,,,,vehicle control condition then fasting (for 16 hours) then glucose (2 g/kg) (for 1 hours),102720,vehicle control condition,,,fasting (for 16 hours),,glucose (2 g/kg) (for 1 hours),,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",arterial blood pressure trait,,RS:0001366,LL/Mav,male,112 days,9,,CMO:0000004,systolic blood pressure,mean of 3 samples of undefined duration,,serial mean,119,mmHg,4.0,12.0,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition,102726,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",arterial blood pressure trait,,RS:0000556,LH/Mav,male,112 days,11,,CMO:0000004,systolic blood pressure,mean of 3 samples of undefined duration,,serial mean,160,mmHg,4.0,13.2665,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition,102728,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",urine output,,RS:0001366,LL/Mav,male,112 days,9,,CMO:0000260,timed urine volume,,,,12.4,ml/d,0.6,1.8,MMO:0000357,urine volume measurement method,,0.0,,,,,vehicle control condition,102730,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",urine output,,RS:0000556,LH/Mav,male,112 days,11,,CMO:0000260,timed urine volume,,,,11.6,ml/d,0.4,1.3266,MMO:0000357,urine volume measurement method,,0.0,,,,,vehicle control condition,102732,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",total urine protein amount,,RS:0001366,LL/Mav,male,112 days,9,,CMO:0000756,urine total protein excretion rate,,,,37,mg/d,1.0,3.0,MMO:0000334,urine protein analysis,,0.0,,,,,vehicle control condition,102734,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",total urine protein amount,,RS:0000556,LH/Mav,male,112 days,11,,CMO:0000756,urine total protein excretion rate,,,,135,mg/d,21.0,69.6491,MMO:0000334,urine protein analysis,,0.0,,,,,vehicle control condition,102736,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",urine albumin amount,,RS:0001366,LL/Mav,male,112 days,9,,CMO:0000757,urine albumin excretion rate,,,,4.4,mg/d,0.3,0.9,MMO:0000406,urine albumin analysis,,0.0,,,,,vehicle control condition,102738,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",urine albumin amount,,RS:0000556,LH/Mav,male,112 days,11,,CMO:0000757,urine albumin excretion rate,,,,24,mg/d,4.6,15.2565,MMO:0000406,urine albumin analysis,,0.0,,,,,vehicle control condition,102740,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",urine creatinine amount,,RS:0001366,LL/Mav,male,112 days,9,,CMO:0000764,urine creatinine excretion rate,,,,11.1,mg/d,0.5,1.5,MMO:0000275,urine creatinine analysis,,0.0,,,,,vehicle control condition,102746,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",urine creatinine amount,,RS:0000556,LH/Mav,male,112 days,11,,CMO:0000764,urine creatinine excretion rate,,,,12.9,mg/d,0.4,1.3266,MMO:0000275,urine creatinine analysis,,0.0,,,,,vehicle control condition,102748,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",blood cholesterol amount,,RS:0001366,LL/Mav,male,112 days,9,,CMO:0000585,plasma total cholesterol level,,,,62.5482,mg/dl,4.2471,12.7413,MMO:0000284,plasma total cholesterol measurement test,,0.0,,,,,vehicle control condition,102750,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",blood cholesterol amount,,RS:0000556,LH/Mav,male,112 days,11,,CMO:0000585,plasma total cholesterol level,,,,90.3474,mg/dl,7.3359,24.3304,MMO:0000284,plasma total cholesterol measurement test,,0.0,,,,,vehicle control condition,102752,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",blood triglyceride amount,,RS:0001366,LL/Mav,male,112 days,9,,CMO:0000548,plasma triglyceride level,,,,1.4,mmol/l,0.11,0.33,MMO:0000234,plasma triglyceride analysis,,0.0,,,,,vehicle control condition,102754,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",blood triglyceride amount,,RS:0000556,LH/Mav,male,112 days,11,,CMO:0000548,plasma triglyceride level,,,,1.43,mmol/l,0.16,0.5307,MMO:0000234,plasma triglyceride analysis,,0.0,,,,,vehicle control condition,102756,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",blood creatinine amount,,RS:0001366,LL/Mav,male,112 days,9,,CMO:0000537,plasma creatinine level,,,,0.501,mg/dl,0.01,0.03,MMO:0000306,plasma creatinine analysis,,0.0,,,,,vehicle control condition,102758,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",blood creatinine amount,,RS:0000556,LH/Mav,male,112 days,11,,CMO:0000537,plasma creatinine level,,,,0.519,mg/dl,0.009,0.0298,MMO:0000306,plasma creatinine analysis,,0.0,,,,,vehicle control condition,102760,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",kidney mass,,RS:0001366,LL/Mav,male,112 days,9,,CMO:0000340,both kidneys wet weight to body weight ratio,,,,6.08,g/kg,0.07,0.21,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,102762,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",kidney mass,,RS:0000556,LH/Mav,male,112 days,11,,CMO:0000340,both kidneys wet weight to body weight ratio,,,,6.24,g/kg,0.07,0.2322,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,102764,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",heart left ventricle mass,,RS:0001366,LL/Mav,male,112 days,9,,CMO:0000530,heart left ventricle weight to body weight ratio,,,,1.88,mg/g,0.002,0.006,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,102766,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",heart left ventricle mass,,RS:0000556,LH/Mav,male,112 days,11,,CMO:0000530,heart left ventricle weight to body weight ratio,,,,2.24,mg/g,0.003,0.0099,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,102768,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",aorta mass,,RS:0001366,LL/Mav,male,112 days,9,,CMO:0003216,aorta weight to body weight ratio,,,,11.2,mg/100g,0.2,0.6,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,102770,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",aorta mass,,RS:0000556,LH/Mav,male,112 days,11,,CMO:0003216,aorta weight to body weight ratio,,,,13.5,mg/100g,0.2,0.6633,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,102772,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",glomerular filtration trait,,RS:0001366,LL/Mav,male,112 days,9,,CMO:0000765,creatinine clearance,,,,1.53,ml/min,0.07,0.21,MMO:0000306,plasma creatinine analysis,,0.0,,,,,vehicle control condition,102774,vehicle control condition,,,,,,,,,, 2721,"Emonnot L, et al., J Hypertens. 2007 Feb;25(2):429-38.",glomerular filtration trait,,RS:0000556,LH/Mav,male,112 days,11,,CMO:0000765,creatinine clearance,,,,1.6,ml/min,0.1,0.3317,MMO:0000306,plasma creatinine analysis,,0.0,,,,,vehicle control condition,102776,vehicle control condition,,,,,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle integrity trait,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000687,heart left ventricle infarction size to total heart left ventricle size ratio,,,,35.8,%,5.4,29.577,MMO:0000219,ex vivo microscopy with digital image analysis,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100264,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,56 days to 42 days,30,,CMO:0000012,body weight,,,,225,g,1.8,9.859,MMO:0000016,body weighing method,,0.0,,lad occlusion,0,days,left anterior descending coronary artery occlusion then vehicle control condition,100269,left anterior descending coronary artery occlusion,,,vehicle control condition,,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000012,body weight,,,,617,g,52.0,284.8157,MMO:0000016,body weighing method,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100272,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart mass,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000017,heart weight,,,,1.573,g,0.28,1.5336,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100278,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle mass,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000776,heart left ventricle weight,,,,0.969,g,0.079,0.4327,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100290,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",lung mass,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000097,lung wet weight,,,,2.134,g,0.13,0.712,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100299,left anterior descending coronary artery occlusion (for 196 days),,,vehicle control condition (for 182 days),,,,,,, 2499,"Finch JL, et al., Am J Physiol Renal Physiol. 2011 Sep 28.",body mass,,RS:0000681,SD,female,0 days,13,,CMO:0000012,body weight,,,,283.6,g,3.8,13.7011,MMO:0000016,body weighing method,,0.0,,unx,97,days,controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days),100632,controlled calcium content diet (0.6 %) (for 97 days),controlled content diet (0.9 %) (for 97 days),unilateral nephrectomy (for 97 days),vehicle control condition (100 ul) (for 90 days),,,,,,, 2499,"Finch JL, et al., Am J Physiol Renal Physiol. 2011 Sep 28.",blood creatinine amount,,RS:0000681,SD,female,0 days,13,,CMO:0000057,serum creatinine level,,,,1.65,mg/dl,0.14,0.5048,MMO:0000271,serum creatinine analysis,,0.0,,unx,97,days,controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days),100637,controlled calcium content diet (0.6 %) (for 97 days),controlled content diet (0.9 %) (for 97 days),unilateral nephrectomy (for 97 days),vehicle control condition (100 ul) (for 90 days),,,,,,, 2499,"Finch JL, et al., Am J Physiol Renal Physiol. 2011 Sep 28.",glomerular filtration trait,,RS:0000681,SD,female,0 days,13,,CMO:0000765,creatinine clearance,,,,0.3,ml/min,0.03,0.1082,MMO:0000271,serum creatinine analysis,,0.0,,unx,97,days,controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days),100642,controlled calcium content diet (0.6 %) (for 97 days),controlled content diet (0.9 %) (for 97 days),unilateral nephrectomy (for 97 days),vehicle control condition (100 ul) (for 90 days),,,,,,, 2499,"Finch JL, et al., Am J Physiol Renal Physiol. 2011 Sep 28.",blood parathyroid hormone amount,,RS:0000681,SD,female,0 days,13,,CMO:0002963,serum parathyroid hormone level,,,,3496,pg/ml,862.0,3107.9852,MMO:0000690,serum parathyroid hormone analysis,,0.0,,unx,97,days,controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days),100647,controlled calcium content diet (0.6 %) (for 97 days),controlled content diet (0.9 %) (for 97 days),unilateral nephrectomy (for 97 days),vehicle control condition (100 ul) (for 90 days),,,,,,, 2521,"Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13.",blood urea nitrogen amount,,RS:0001381,PCK-Pkhd1pck/CrljCrl,male,112 days,5,,CMO:0000049,blood urea nitrogen level,,,,20.6,mg/dl,1.8,4.0249,MMO:0000253,blood urea nitrogen analysis,,0.0,,,,,control condition (for 28 days) then vehicle control condition (for 84 days),100763,control condition (for 28 days),,,vehicle control condition (for 84 days),,,,,,, 2521,"Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13.",blood urea nitrogen amount,,RS:0000064,Crl:CD(SD),male,112 days,5,,CMO:0000049,blood urea nitrogen level,,,,19.3,mg/dl,2.6,5.8138,MMO:0000253,blood urea nitrogen analysis,,0.0,,,,,control condition (for 28 days) then vehicle control condition (for 84 days),100764,control condition (for 28 days),,,vehicle control condition (for 84 days),,,,,,, 2521,"Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13.",blood creatinine amount,,RS:0001381,PCK-Pkhd1pck/CrljCrl,male,112 days,5,,CMO:0000057,serum creatinine level,,,,0.51,mg/dl,0.04,0.0894,MMO:0000271,serum creatinine analysis,,0.0,,,,,control condition (for 28 days) then vehicle control condition (for 84 days),100765,control condition (for 28 days),,,vehicle control condition (for 84 days),,,,,,, 2521,"Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13.",blood creatinine amount,,RS:0000064,Crl:CD(SD),male,112 days,5,,CMO:0000057,serum creatinine level,,,,0.43,mg/dl,0.03,0.0671,MMO:0000271,serum creatinine analysis,,0.0,,,,,control condition (for 28 days) then vehicle control condition (for 84 days),100766,control condition (for 28 days),,,vehicle control condition (for 84 days),,,,,,, 2521,"Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13.",total urine protein amount,,RS:0000064,Crl:CD(SD),male,112 days,5,,CMO:0000756,urine total protein excretion rate,,,,36.7,mg/d,3.5,7.8262,MMO:0000334,urine protein analysis,,0.0,,,,,control condition (for 28 days) then vehicle control condition (for 84 days),100768,control condition (for 28 days),,,vehicle control condition (for 84 days),,,,,,, 2521,"Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13.",total urine protein amount,,RS:0001381,PCK-Pkhd1pck/CrljCrl,male,112 days,6,,CMO:0002758,urine protein level to urine creatinine level ratio,,,,12,,1.7,4.1641,MMO:0000334,urine protein analysis,,0.0,,,,,control condition (for 28 days) then vehicle control condition (for 84 days),100769,control condition (for 28 days),,,vehicle control condition (for 84 days),,,,,,, 2521,"Jia G, et al., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13.",total urine protein amount,,RS:0000064,Crl:CD(SD),male,112 days,5,,CMO:0002758,urine protein level to urine creatinine level ratio,,,,1.98,,0.31,0.6932,MMO:0000334,urine protein analysis,,0.0,,,,,control condition (for 28 days) then vehicle control condition (for 84 days),100770,control condition (for 28 days),,,vehicle control condition (for 84 days),,,,,,, 2784,"Chen YC, et al., Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R426-39. doi: 10.1152/ajpregu.00112.2016. Epub 2016 Jun 1.",arterial blood pressure trait,,RS:0001299,GK,male,16 days,5,,CMO:0000009,mean arterial blood pressure,undefined,,,118,mmHg,7.0,15.6525,MMO:0000014,vascular transducer tipped catheter,,0.0,,,,,air oxygen content (21 %) (for 28 days) then vehicle control condition (0.15 ml) (for 0.1 hours) then acetylcholine (5 ug/kg/min) (for 0.1 hours) then sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),103025,air oxygen content (21 %) (for 28 days),,,vehicle control condition (0.15 ml) (for 0.1 hours),,acetylcholine (5 ug/kg/min) (for 0.1 hours),,sodium nitroprusside (5 ug/kg/min) (for 0.1 hours),,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart pumping trait,,RS:0000811,SS/JrHsdMcwi,male,56 days,6,,CMO:0000002,heart rate,,,,358,beats/min,7.95,19.4734,MMO:0000013,vascular fluid filled catheter,,0.0,,,,,vehicle control condition,106798,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart pumping trait,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,8,,CMO:0000002,heart rate,,,,354,beats/min,12.9,36.4867,MMO:0000013,vascular fluid filled catheter,,0.0,,,,,vehicle control condition,106799,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",arterial blood pressure trait,,RS:0000811,SS/JrHsdMcwi,male,56 days,6,,CMO:0000004,systolic blood pressure,,,,115,mmHg,4.76,11.6596,MMO:0000013,vascular fluid filled catheter,,0.0,,,,,vehicle control condition,106802,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",arterial blood pressure trait,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,8,,CMO:0000004,systolic blood pressure,,,,115,mmHg,5.22,14.7644,MMO:0000013,vascular fluid filled catheter,,0.0,,,,,vehicle control condition,106803,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",arterial blood pressure trait,,RS:0000811,SS/JrHsdMcwi,male,56 days,6,,CMO:0000005,diastolic blood pressure,,,,84,mmHg,4.05,9.9204,MMO:0000013,vascular fluid filled catheter,,0.0,,,,,vehicle control condition,106806,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",arterial blood pressure trait,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,8,,CMO:0000005,diastolic blood pressure,,,,84.2,mmHg,4.96,14.029,MMO:0000013,vascular fluid filled catheter,,0.0,,,,,vehicle control condition,106807,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",arterial blood pressure trait,,RS:0000811,SS/JrHsdMcwi,male,56 days,6,,CMO:0003285,mean aortic pressure,,Mean aortic pressure,,94.4,mmHg,4.27,10.4593,MMO:0000013,vascular fluid filled catheter,,0.0,,,,,vehicle control condition,106810,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",arterial blood pressure trait,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,8,,CMO:0003285,mean aortic pressure,,Mean aortic pressure,,94.5,mmHg,5.02,14.1987,MMO:0000013,vascular fluid filled catheter,,0.0,,,,,vehicle control condition,106811,vehicle control condition,,,,,,,,,, 2339,"Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.",blood creatinine amount,,RS:0003328,SS/NEisSlc,not specified,547 days,10,,CMO:0000537,plasma creatinine level,,,,0.59049684,mg/dl,0.0498,0.1574,MMO:0000306,plasma creatinine analysis,,0.0,,,,,vehicle control condition (for 547.5 days),107421,vehicle control condition (for 547.5 days),,,,,,,,,, 2339,"Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.",total urine protein amount,,RS:0003328,SS/NEisSlc,not specified,547 days,10,,CMO:0000756,urine total protein excretion rate,,,,215.9,mg/d,15.3,48.3828,MMO:0000335,urine total protein analysis,,0.0,,,,,vehicle control condition (for 547.5 days),107437,vehicle control condition (for 547.5 days),,,,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",total life span,,RS:0000775,SHRSP/A3N,male,168 days to 147 days,25,,CMO:0003800,ratio of deaths related to chronic hypertension to total study population during a period of time,,ratio of deaths related to chronic hypertension to total study population during a period of time (CMO:0003800),,95,%,,,MMO:0000160,unspecified method,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (for 63 days) and controlled fat content diet (24.5 %) (for 63 days) and vehicle control condition (for 63 days),107518,controlled sodium chloride content drinking water (1 %) (for 63 days),controlled fat content diet (24.5 %) (for 63 days),vehicle control condition (for 63 days),,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",total urine protein amount,,RS:0000775,SHRSP/A3N,male,154 days to 119 days,N/A,,CMO:0000756,urine total protein excretion rate,,,,127,mg/d,13.0,,MMO:0000334,urine protein analysis,,86400.0,,,,,controlled sodium chloride content drinking water (1 %) (between 35 and 49 days) and controlled fat content diet (24.5 %) (between 35 and 49 days) and vehicle control condition (between 35 and 49 days),107520,controlled sodium chloride content drinking water (1 %) (between 35 and 49 days),controlled fat content diet (24.5 %) (between 35 and 49 days),vehicle control condition (between 35 and 49 days),,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",body mass,,RS:0000775,SHRSP/A3N,male,147 days to 126 days,N/A,,CMO:0000012,body weight,,,,254,g,7.0,,MMO:0000016,body weighing method,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (for 42 days) and controlled fat content diet (24.5 %) (for 42 days) and vehicle control condition (for 42 days),107527,controlled sodium chloride content drinking water (1 %) (for 42 days),controlled fat content diet (24.5 %) (for 42 days),vehicle control condition (for 42 days),,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney mass,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0000081,kidney weight,,,,2.65,g,0.1,,MMO:0000005,post excision weight measurement,kidney,0.0,,,,,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days),107531,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days),controlled fat content diet (24.5 %) (between 42 and 77 days),vehicle control condition (between 42 and 77 days),,,,,,,, 3140,"Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.",body mass,,RS:0001011,Crl:WI,male,112 days,10,,CMO:0000012,body weight,,,,391.8,g,17.2,54.3912,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition (for 28 days),109387,vehicle control condition (for 28 days),,,,,,,,,, 3140,"Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.",body mass,,RS:0000596,MWF/FubRkb,male,112 days,10,,CMO:0000012,body weight,,,,362.8,g,12.8,40.4772,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition (for 28 days),109389,vehicle control condition (for 28 days),,,,,,,,,, 3140,"Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.",tibia length,,RS:0001011,Crl:WI,male,113 days,10,,CMO:0000450,tibia length,,,,4,cm,1.0,3.1623,MMO:0000276,post excision length measurement,,0.0,,,,,vehicle control condition (for 28 days),109395,vehicle control condition (for 28 days),,,,,,,,,, 3140,"Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.",tibia length,,RS:0000596,MWF/FubRkb,male,113 days,10,,CMO:0000450,tibia length,,,,4.2,cm,1.0,3.1623,MMO:0000276,post excision length measurement,,0.0,,,,,vehicle control condition (for 28 days),109397,vehicle control condition (for 28 days),,,,,,,,,, 3140,"Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.",urine output,,RS:0001011,Crl:WI,male,114 days,10,,CMO:0000260,timed urine volume,,,,11.1,ml/d,1.3,4.111,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,,,,vehicle control condition (for 28 days),109399,vehicle control condition (for 28 days),,,,,,,,,, 3140,"Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.",urine output,,RS:0000596,MWF/FubRkb,male,114 days,10,,CMO:0000260,timed urine volume,,,,10.1,ml/d,0.4,1.2649,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,,,,vehicle control condition (for 28 days),109401,vehicle control condition (for 28 days),,,,,,,,,, 3140,"Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.",urine albumin amount,,RS:0001011,Crl:WI,male,114 days,10,,CMO:0000757,urine albumin excretion rate,,,,0.17,mg/d,0.01,0.0316,MMO:0000075,enzyme linked immunosorbent assay,,0.0,,,,,vehicle control condition (for 28 days),109403,vehicle control condition (for 28 days),,,,,,,,,, 3140,"Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.",urine albumin amount,,RS:0000596,MWF/FubRkb,male,114 days,10,,CMO:0000757,urine albumin excretion rate,,,,64.4,mg/d,5.6,17.7088,MMO:0000075,enzyme linked immunosorbent assay,,0.0,,,,,vehicle control condition (for 28 days),109405,vehicle control condition (for 28 days),,,,,,,,,, 3140,"Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.",arterial blood pressure trait,,RS:0001011,Crl:WI,male,112 days,10,,CMO:0000004,systolic blood pressure,,,,126.9,mmHg,4.0,12.6491,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition (10 mg/kg/d) (for 28 days),109407,vehicle control condition (10 mg/kg/d) (for 28 days),,,,,,,,,, 3140,"Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.",arterial blood pressure trait,,RS:0000596,MWF/FubRkb,male,112 days,10,,CMO:0000004,systolic blood pressure,,,,151.5,mmHg,9.0,28.4605,MMO:0000031,tail cuff plethysmography,,0.0,,,,,vehicle control condition (10 mg/kg/d) (for 28 days),109409,vehicle control condition (10 mg/kg/d) (for 28 days),,,,,,,,,, 3140,"Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.",heart pumping trait,,RS:0001011,Crl:WI,male,112 days,10,,CMO:0000002,heart rate,,,,355.3,beats/min,9.7,30.6741,MMO:0000031,tail cuff plethysmography,heart,0.0,,,,,vehicle control condition (for 28 days),109411,vehicle control condition (for 28 days),,,,,,,,,, 3140,"Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.",heart pumping trait,,RS:0000596,MWF/FubRkb,male,112 days,10,,CMO:0000002,heart rate,,,,352.3,beats/min,7.3,23.0846,MMO:0000031,tail cuff plethysmography,heart,0.0,,,,,vehicle control condition (for 28 days),109413,vehicle control condition (for 28 days),,,,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus size trait,,RS:0000742,WKY,male,0 days,17,,CMO:0003489,kidney glomerular tuft surface area,,,,13.2,x 10E3 um2,3.3,13.6062,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition,107511,unilateral nephrectomy (for 150 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003443,kidney tubule regeneration foci count,,,,27.3,/section,2.9,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days),107547,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days),controlled fat content diet (24.5 %) (between 42 and 77 days),vehicle control condition (between 42 and 77 days),,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003445,interstitial nephritis foci count,,,,8.5,/section,1.2,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days),107551,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days),controlled fat content diet (24.5 %) (between 42 and 77 days),vehicle control condition (between 42 and 77 days),,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",blood cholesterol amount,,RS:0003766,WAG/Nov,male,180 days to 150 days,10,,CMO:0000585,plasma total cholesterol level,,,,74.4,mg/dl,4.1,12.9653,MMO:0000284,plasma total cholesterol measurement test,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107781,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",blood cholesterol amount,,RS:0001334,ISIAH,male,180 days to 150 days,10,,CMO:0000585,plasma total cholesterol level,,,,59.5,mg/dl,3.2,10.1193,MMO:0000284,plasma total cholesterol measurement test,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107784,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",blood HDL phospholipid amount,,RS:0003766,WAG/Nov,male,180 days to 150 days,10,,CMO:0001566,plasma high density lipoprotein phospholipid level,,,,47.1,mg/dl,4.1,12.9653,MMO:0000282,plasma high-density lipoprotein-cholesterol measurement test,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107787,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",blood HDL phospholipid amount,,RS:0001334,ISIAH,male,180 days to 150 days,10,,CMO:0001566,plasma high density lipoprotein phospholipid level,,,,36.2,mg/dl,2.4,7.5895,MMO:0000282,plasma high-density lipoprotein-cholesterol measurement test,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107790,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",platelet size trait,,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0001350,platelet distribution width,,,,8.7,fl,0.1581,0.5,MMO:0000174,automated hematology analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107882,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",platelet size trait,,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0001350,platelet distribution width,,,,8.6,fl,0.0316,0.1,MMO:0000174,automated hematology analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107884,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood urea nitrogen amount,serum BUN,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000587,serum urea nitrogen level,,,,35,mg/dl,0.5692,1.8,MMO:0000554,automated serum analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107887,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood urea nitrogen amount,serum BUN,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000587,serum urea nitrogen level,,,,34.5,mg/dl,0.4111,1.3,MMO:0000554,automated serum analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107889,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney mass,,RS:0000742,WKY,male,0 days,17,,CMO:0001954,left kidney wet weight to body weight ratio,,,,9.9,mg/g,0.7,2.8862,MMO:0000005,post excision weight measurement,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition,107456,unilateral nephrectomy (for 150 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",platelet size trait,,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0001348,mean platelet volume,,,,5.9,fl,0.0316,0.1,MMO:0000174,automated hematology analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107821,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",platelet size trait,,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0001348,mean platelet volume,,,,5.9,fl,0.0632,0.2,MMO:0000174,automated hematology analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107823,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",leukocyte quantity,WBC,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000365,total white blood cell count,,,,12.9,x 1000 cells/ul,0.6325,2.0,MMO:0000144,automated total white blood cell count test,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107826,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",leukocyte quantity,WBC,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000365,total white blood cell count,,,,10,x 1000 cells/ul,0.3479,1.1,MMO:0000144,automated total white blood cell count test,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107828,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood hemoglobin amount,"hemoglobin, MCH, MCHC",RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000026,blood hemoglobin level,,,,19.9,g/dl,0.6641,2.1,MMO:0000295,blood hemoglobin analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107831,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood hemoglobin amount,"hemoglobin, MCH, MCHC",RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000026,blood hemoglobin level,,,,18.9,g/dl,0.4743,1.5,MMO:0000295,blood hemoglobin analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107833,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003444,kidney total tubule cast count,,,,349,/section,45.0,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days),107555,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days),controlled fat content diet (24.5 %) (between 42 and 77 days),vehicle control condition (between 42 and 77 days),,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003446,renal fibrosis foci count,,,,16.4,/section,1.4,,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days),107559,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days),controlled fat content diet (24.5 %) (between 42 and 77 days),vehicle control condition (between 42 and 77 days),,,,,,,, 2339,"Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.",arterial blood pressure trait,,RS:0003328,SS/NEisSlc,not specified,547 days,10,,CMO:0000004,systolic blood pressure,,,,137,mmHg,3.0,9.4868,MMO:0000011,vascular indwelling catheter method,femoral artery,0.0,,,,,vehicle control condition (for 547.5 days),106791,vehicle control condition (for 547.5 days),,,,,,,,,, 2339,"Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.",heart mass,,RS:0003328,SS/NEisSlc,not specified,547 days,10,,CMO:0000074,heart weight to body weight ratio,,,,3.2,g/kg,0.1,0.3162,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (for 547.5 days),106792,vehicle control condition (for 547.5 days),,,,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,17,,CMO:0000012,body weight,,,,256,g,5.0,20.6155,MMO:0000016,body weighing method,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition,107446,unilateral nephrectomy (for 150 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",heart mass,,RS:0000742,WKY,male,0 days,17,,CMO:0000074,heart weight to body weight ratio,,,,3.5,g/kg,0.1,0.4123,MMO:0000005,post excision weight measurement,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition,107451,unilateral nephrectomy (for 150 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus size trait,,RS:0000742,WKY,male,0 days,17,,CMO:0003488,kidney glomerular surface area,,kidney glomerulus surface area (CMO:0003488),,19.3,x 10E3 um2,4.8,19.7909,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition,107461,unilateral nephrectomy (for 150 days),,,streptozotocin (35 mg/kg) ,,vehicle control condition,,,,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",cone electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,4,,CMO:0003702,photopic B wave amplitude of ERG waveform,,photopic b-wave ERG,,51,uV,,,MMO:0000616,electroretinography,cornea,0.0,,subretinal injection,30,days,vehicle control condition (2 ul) then controlled visible light condition (30 cd x s/m2) then visible light stimulus (12 cd/m2) ,108644,vehicle control condition (2 ul) ,,,controlled visible light condition (30 cd x s/m2) ,,visible light stimulus (12 cd/m2) ,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",thymus mass,,RS:0003766,WAG/Nov,male,180 days to 150 days,10,,CMO:0000612,thymus weight to body weight ratio,,,,0.77,mg/g,0.09,0.2846,MMO:0000005,post excision weight measurement,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107688,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",thymus mass,,RS:0001334,ISIAH,male,180 days to 150 days,10,,CMO:0000612,thymus weight to body weight ratio,,,,1.95,mg/g,0.77,2.435,MMO:0000005,post excision weight measurement,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107689,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",thymocyte quantity,,RS:0003766,WAG/Nov,male,180 days to 150 days,10,,CMO:0001843,thymocyte count,,,,1028.62,x10E6/organ,146.62,463.6532,MMO:0000224,isolated cell counting method,,0.0,,IP injection,1,days,vehicle control condition (2 ml/kg) (for 1 days),107693,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",erythrocyte quantity,"red blood cell count, hematocrit",RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000025,red blood cell count,,,,11,x 10E6 cells/ul,0.4111,1.3,MMO:0000146,automated blood cell counting method,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107801,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",erythrocyte size trait,"MCV, RDW%",RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000038,mean corpuscular volume,,,,47.5,fl,0.0316,0.1,MMO:0000174,automated hematology analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107806,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",erythrocyte size trait,"MCV, RDW%",RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000038,mean corpuscular volume,,,,47.5,fl,0.1897,0.6,MMO:0000174,automated hematology analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107808,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",erythrocyte quantity,"red blood cell count, hematocrit",RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000037,hematocrit,,,,52.3,%,0.9487,3.0,MMO:0000214,hematocrit analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107811,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",erythrocyte quantity,"red blood cell count, hematocrit",RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000037,hematocrit,,,,51,%,1.0436,3.3,MMO:0000214,hematocrit analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107813,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",rod electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,4,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,scotopic a-wave ERG,,142,uV,,,MMO:0000616,electroretinography,cornea,0.0,,subretinal injection,30,days,vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) ,108642,vehicle control condition (2 ul) ,,,controlled exposure to darkness (for 12 hours),,visible light stimulus (5 cd/m2) ,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus size trait,,RS:0000742,WKY,male,0 days,11,,CMO:0003489,kidney glomerular tuft surface area,,,,8.7,x 10E3 um2,2.6,8.6232,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then vehicle control condition,107510,unilateral nephrectomy (for 150 days),,,vehicle control condition,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",spleen morphology trait,,RS:0003766,WAG/Nov,male,180 days to 150 days,10,,CMO:0002117,spleen cell count,,,,707.11,x10E6/organ,150.29,475.2587,MMO:0000224,isolated cell counting method,,0.0,saline,IP injection,1,days,vehicle control condition (2 ml/kg) (for 1 days),107700,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",spleen morphology trait,,RS:0001334,ISIAH,male,180 days to 150 days,10,,CMO:0002117,spleen cell count,,,,583.56,x10E6/organ,109.7,346.9019,MMO:0000224,isolated cell counting method,,0.0,saline,IP injection,1,days,vehicle control condition (2 ml/kg) (for 1 days),107703,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",T cell development trait,,RS:0003766,WAG/Nov,male,180 days to 150 days,10,,CMO:0003521,apoptotic hypodiploid thymocyte count to total thymocyte count ratio,,,,0.45,%,0.12,0.3795,MMO:0000617,flow cytometry method,,0.0,saline,IP injection,1,days,vehicle control condition (2 ml/kg) (for 1 days),107706,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",T cell development trait,,RS:0003766,WAG/Nov,male,180 days to 150 days,10,,CMO:0003523,G0 stage diploid thymocyte count to total thymocyte count ratio,,,,93.31,%,0.93,2.9409,MMO:0000617,flow cytometry method,,0.0,saline,IP injection,1,days,vehicle control condition (2 ml/kg) (for 1 days),107709,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",T cell development trait,,RS:0003766,WAG/Nov,male,180 days to 150 days,10,,CMO:0003524,G2/M stage tetraploid thymocyte count to total thymocyte count ratio,,,,2.62,%,0.29,0.9171,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107712,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3098,"Pross M, et al., Surg Endosc. 2001 Aug;15(8):882-5. doi: 10.1007/s004640090029. Epub 2001 May 2.",body mass,,RS:0000967,WAG,male,0 days,16,,CMO:0000012,body weight,,,,272.4,g,3.35,13.4,MMO:0000016,body weighing method,,0.0,cells and vehicle injected,IP injection,21,days,CC531 cells (5 X 10E6) (for 21 days) then vehicle control condition (1 ml) (for 21 days),107872,CC531 cells (5 X 10E6) (for 21 days),,,vehicle control condition (1 ml) (for 21 days),,,,,,, 3098,"Pross M, et al., Surg Endosc. 2001 Aug;15(8):882-5. doi: 10.1007/s004640090029. Epub 2001 May 2.",peritoneum integrity trait,,RS:0000968,WAG/OlaHsd,male,0 days,16,,CMO:0003554,metastatic intraperitoneal tumor weight,abdominal lesion weight,,,7.42,g,0.2525,1.01,MMO:0000344,necropsy,,0.0,CC531 cells,IP injection,21,days,CC531 cells (5 X 10E6) (for 21 days) then vehicle control condition (1 ml) (for 21 days),107874,CC531 cells (5 X 10E6) (for 21 days),,,vehicle control condition (1 ml) (for 21 days),,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood cholesterol amount,serum total cholesterol,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000363,serum total cholesterol level,,,,40.5,mg/dl,1.7076,5.4,MMO:0000554,automated serum analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107894,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood alanine transaminase amount,serum alanine aminotransferase,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000575,serum alanine aminotransferase activity level,,,,59.2,U/l,1.9922,6.3,MMO:0000554,automated serum analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107907,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood alanine transaminase amount,serum alanine aminotransferase,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000575,serum alanine aminotransferase activity level,,,,44.8,U/l,2.9409,9.3,MMO:0000554,automated serum analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107909,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood alkaline phosphatase amount,serum alkaline phosphatase,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000577,serum alkaline phosphatase activity level,,,,476,U/l,1.5811,5.0,MMO:0000554,automated serum analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107912,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood amylase amount,serum amylase,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0003519,serum amylase activity level,,,,3096,U/l,32.2552,102.0,MMO:0000554,automated serum analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107944,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3128,"Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.",rod electrophysiology trait,,RS:0000698,Hsd:SD,both,0 days,4,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,scotopic b-wave ERG,,338,uV,,,MMO:0000616,electroretinography,cornea,0.0,,subretinal injection,30,days,vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) ,108640,vehicle control condition (2 ul) ,,,controlled exposure to darkness (for 12 hours),,visible light stimulus (5 cd/m2) ,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,11,,CMO:0000012,body weight,,,,408,g,10.0,33.1662,MMO:0000016,body weighing method,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then vehicle control condition,107445,unilateral nephrectomy (for 150 days),,,vehicle control condition,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",heart mass,,RS:0000742,WKY,male,0 days,11,,CMO:0000074,heart weight to body weight ratio,,,,2.4,g/kg,0.1,0.3317,MMO:0000005,post excision weight measurement,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then vehicle control condition,107450,unilateral nephrectomy (for 150 days),,,vehicle control condition,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",erythrocyte quantity,"red blood cell count, hematocrit",RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000025,red blood cell count,,,,10.7,x 10E6 cells/ul,0.253,0.8,MMO:0000146,automated blood cell counting method,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107803,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",thymus mass,,RS:0000698,Hsd:SD,female,84 days,10,,CMO:0000612,thymus weight to body weight ratio,,,,1.5,mg/g,0.35,1.1068,MMO:0000005,post excision weight measurement,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105884,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",thymus mass,,RS:0004674,SD-Ahrem2Sage,female,84 days,10,,CMO:0000612,thymus weight to body weight ratio,,,,1.61,mg/g,0.19,0.6008,MMO:0000005,post excision weight measurement,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105885,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",spleen mass,,RS:0000698,Hsd:SD,female,84 days,10,,CMO:0000149,spleen weight to body weight ratio,,,,0.299,%,0.027,0.0854,MMO:0000005,post excision weight measurement,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105896,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",spleen mass,,RS:0004674,SD-Ahrem2Sage,female,84 days,10,,CMO:0000149,spleen weight to body weight ratio,,,,0.286,%,0.022,0.0696,MMO:0000005,post excision weight measurement,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105897,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",brain mass,,RS:0000698,Hsd:SD,female,84 days,10,,CMO:0000139,brain weight to body weight ratio,,,,0.742,%,0.031,0.098,MMO:0000005,post excision weight measurement,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105908,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",brain mass,,RS:0004674,SD-Ahrem2Sage,female,84 days,10,,CMO:0000139,brain weight to body weight ratio,,,,0.742,%,0.044,0.1391,MMO:0000005,post excision weight measurement,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105909,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",ovary mass,,RS:0000698,Hsd:SD,female,84 days,10,,CMO:0003019,both ovaries weight to body weight ratio,,,,0.049,%,0.011,0.0348,MMO:0000005,post excision weight measurement,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105920,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",ovary mass,,RS:0004674,SD-Ahrem2Sage,female,84 days,10,,CMO:0003019,both ovaries weight to body weight ratio,,,,0.047,%,0.007,0.0221,MMO:0000005,post excision weight measurement,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105921,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",erythrocyte quantity,,RS:0000698,Hsd:SD,female,84 days,10,,CMO:0000025,red blood cell count,,,,7.47,x 10E6 cells/ul,0.21,0.6641,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105932,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",erythrocyte quantity,,RS:0004674,SD-Ahrem2Sage,female,84 days,10,,CMO:0000025,red blood cell count,,,,7.41,x 10E6 cells/ul,0.36,1.1384,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105933,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",blood hemoglobin amount,,RS:0000698,Hsd:SD,female,84 days,10,,CMO:0000026,blood hemoglobin level,,,,14.05,g/dl,0.48,1.5179,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105944,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",blood hemoglobin amount,,RS:0004674,SD-Ahrem2Sage,female,84 days,10,,CMO:0000026,blood hemoglobin level,,,,14.01,g/dl,0.62,1.9606,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105945,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",erythrocyte quantity,,RS:0000698,Hsd:SD,female,84 days,10,,CMO:0000037,hematocrit,,,,43.31,%,1.49,4.7118,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105956,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",erythrocyte quantity,,RS:0004674,SD-Ahrem2Sage,female,84 days,10,,CMO:0000037,hematocrit,,,,43.31,%,1.67,5.281,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105957,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",erythrocyte size trait,,RS:0000698,Hsd:SD,female,84 days,10,,CMO:0000038,mean corpuscular volume,,,,57.96,fl,1.26,3.9845,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105968,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",erythrocyte size trait,,RS:0004674,SD-Ahrem2Sage,female,84 days,10,,CMO:0000038,mean corpuscular volume,,,,58.44,fl,0.87,2.7512,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105969,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",blood hemoglobin amount,,RS:0000698,Hsd:SD,female,84 days,10,,CMO:0000290,mean corpuscular hemoglobin,,,,18.82,pg,0.44,1.3914,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105980,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",blood hemoglobin amount,,RS:0004674,SD-Ahrem2Sage,female,84 days,10,,CMO:0000290,mean corpuscular hemoglobin,,,,18.92,pg,0.39,1.2333,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105981,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",blood hemoglobin amount,,RS:0000698,Hsd:SD,female,84 days,10,,CMO:0000291,mean corpuscular hemoglobin concentration,,,,32.48,g/dl,0.68,2.1503,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105992,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",blood hemoglobin amount,,RS:0004674,SD-Ahrem2Sage,female,84 days,10,,CMO:0000291,mean corpuscular hemoglobin concentration,,,,32.37,g/dl,0.7,2.2136,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),105993,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",platelet size trait,,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0003526,platelet distribution width (percentage),,,,5.2,%,0.0,0.0,MMO:0000174,automated hematology analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,108146,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",platelet size trait,,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0003526,platelet distribution width (percentage),,,,8.5,%,0.0,0.0,MMO:0000174,automated hematology analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,108148,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3140,"Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.",vasodilation trait,,RS:0001011,Crl:WI,male,114 days,10,,CMO:0000731,acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,90.3,%,1.2,3.7947,MMO:0000342,wire myography,mesenteric artery,0.0,,,,,vehicle control condition (for 28 days),109431,vehicle control condition (for 28 days),,,,,,,,,, 3140,"Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.",vasodilation trait,,RS:0000596,MWF/FubRkb,male,114 days,10,,CMO:0000731,acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,82.3,%,3.0,9.4868,MMO:0000342,wire myography,mesenteric artery,0.0,,,,,vehicle control condition (for 28 days),109433,vehicle control condition (for 28 days),,,,,,,,,, 3140,"Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.",vasoconstriction trait,,RS:0001011,Crl:WI,male,114 days,10,,CMO:0003726,norepinephrine-induced blood vessel contractile force expressed as percent of force of contraction to KCL,,,,51.3,%,4.7,14.8627,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),109439,vehicle control condition (for 28 days),,,,,,,,,, 3140,"Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.",vasoconstriction trait,,RS:0000596,MWF/FubRkb,male,114 days,10,,CMO:0003726,norepinephrine-induced blood vessel contractile force expressed as percent of force of contraction to KCL,,,,77.8,%,10.2,32.2552,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),109441,vehicle control condition (for 28 days),,,,,,,,,, 3140,"Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.",vasoconstriction trait,,RS:0001011,Crl:WI,male,114 days,10,,CMO:0003727,negative logarithm of the molar concentration of norepinephrine at which the force of blood vessel contraction is half the maximum value,,,,6.7,,0.1,0.3162,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),109443,vehicle control condition (for 28 days),,,,,,,,,, 3140,"Gil-Ortega M, etal., Am J Nephrol. 2020 Feb 21:1-10. doi: 10.1159/000506275.",vasoconstriction trait,,RS:0000596,MWF/FubRkb,male,114 days,10,,CMO:0003727,negative logarithm of the molar concentration of norepinephrine at which the force of blood vessel contraction is half the maximum value,,,,6.9,,0.1,0.3162,MMO:0000342,wire myography,,0.0,,,,,vehicle control condition (for 28 days),109445,vehicle control condition (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",platelet quantity,,RS:0000698,Hsd:SD,female,84 days,10,,CMO:0000029,platelet count,,,,1308.4,x 1000 cells/ul,220.08,695.9541,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),106004,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",platelet quantity,,RS:0004674,SD-Ahrem2Sage,female,84 days,10,,CMO:0000029,platelet count,,,,1388,x 1000 cells/ul,216.06,683.2417,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),106005,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",leukocyte quantity,,RS:0000698,Hsd:SD,female,84 days,10,,CMO:0000027,white blood cell count,,,,9.42,x 1000 cells/ul,2.25,7.1151,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),106016,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",leukocyte quantity,,RS:0004674,SD-Ahrem2Sage,female,84 days,10,,CMO:0000027,white blood cell count,,,,10.8,x 1000 cells/ul,1.5,4.7434,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),106017,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",neutrophil quantity,,RS:0000698,Hsd:SD,female,84 days,10,,CMO:0000030,blood neutrophil count,,,,1.48,x 1000 cells/ul,0.85,2.6879,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),106028,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",neutrophil quantity,,RS:0004674,SD-Ahrem2Sage,female,84 days,10,,CMO:0000030,blood neutrophil count,,,,1.89,x 1000 cells/ul,0.62,1.9606,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),106029,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",lymphocyte quantity,,RS:0000698,Hsd:SD,female,84 days,10,,CMO:0000031,blood lymphocyte count,,,,7.36,x 1000 cells/ul,1.77,5.5972,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),106040,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",lymphocyte quantity,,RS:0004674,SD-Ahrem2Sage,female,84 days,10,,CMO:0000031,blood lymphocyte count,,,,8.25,x 1000 cells/ul,1.31,4.1426,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),106041,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",monocyte quantity,,RS:0000698,Hsd:SD,female,84 days,10,,CMO:0000032,blood monocyte count,,,,0.29,x 1000 cells/ul,0.14,0.4427,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),106052,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",monocyte quantity,,RS:0004674,SD-Ahrem2Sage,female,84 days,10,,CMO:0000032,blood monocyte count,,,,0.31,x 1000 cells/ul,0.09,0.2846,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),106053,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",eosinophil quantity,,RS:0000698,Hsd:SD,female,84 days,10,,CMO:0000033,blood eosinophil count,,,,0.13,x 1000 cells/ul,0.14,0.4427,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),106064,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",eosinophil quantity,,RS:0004674,SD-Ahrem2Sage,female,84 days,10,,CMO:0000033,blood eosinophil count,,,,0.18,x 1000 cells/ul,0.18,0.5692,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),106065,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",basophil quantity,,RS:0000698,Hsd:SD,female,84 days,10,,CMO:0000034,blood basophil count,,,,0.07,x 1000 cells/ul,0.03,0.0949,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),106076,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",basophil quantity,,RS:0004674,SD-Ahrem2Sage,female,84 days,10,,CMO:0000034,blood basophil count,,,,0.08,x 1000 cells/ul,0.02,0.0632,MMO:0000174,automated hematology analysis,,,,,,,vehicle control condition (5 ml/kg) (for 28 days),106077,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood cholesterol amount,serum total cholesterol,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000363,serum total cholesterol level,,,,60,mg/dl,2.2136,7.0,MMO:0000554,automated serum analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107892,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood alkaline phosphatase amount,serum alkaline phosphatase,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000577,serum alkaline phosphatase activity level,,,,620,U/l,7.2732,23.0,MMO:0000554,automated serum analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107914,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",thymocyte quantity,,RS:0003766,WAG/Nov,male,180 days to 150 days,10,,CMO:0003517,CD3+ thymocyte count,,cd3+ thymocyte,,1021.26,x10E6/organ,145.57,460.3328,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107715,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",thymocyte quantity,,RS:0003766,WAG/Nov,male,180 days to 150 days,10,,CMO:0003527,CD4+CD8- thymocyte count,,cd4+cd8- t-cell,,239.75,x 10E6/organ,50.38,159.3155,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107718,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",thymocyte quantity,,RS:0003766,WAG/Nov,male,180 days to 150 days,10,,CMO:0003528,CD4+CD8+ thymocyte count,,cd4+cd8+ t-cell,,596.53,x10E6/organ,88.59,280.1462,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107721,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",thymocyte quantity,,RS:0003766,WAG/Nov,male,180 days to 150 days,10,,CMO:0003529,CD4-CD8+ thymocyte count,,cd4-cd8+ t-cell,,74.18,x10E6/organ,11.97,37.8525,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107724,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",thymocyte quantity,,RS:0003766,WAG/Nov,male,180 days to 150 days,10,,CMO:0003530,CD4+CD25+ thymocyte count,,cd4+cd25+ t-cell,,40.63,x10E6/organ,7.77,24.5709,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107727,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",splenocyte morphology trait,,RS:0003766,WAG/Nov,male,180 days to 150 days,10,,CMO:0003537,CD4+CD25- splenocyte count to total splenocyte count ratio,,cd4+cd25- spleen,,27.9,%,0.69,2.182,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107730,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",splenocyte morphology trait,,RS:0003766,WAG/Nov,male,180 days to 150 days,10,,CMO:0003539,CD3+ splenocyte count to total splenocyte count ratio,,cd3- spleen,,30.13,%,0.75,2.3717,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107733,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",splenocyte morphology trait,,RS:0003766,WAG/Nov,male,180 days to 150 days,10,,CMO:0003540,CD11b/c+ splenocyte count to total splenocyte count ratio,,cd11b/c+ spleen,,12.4,%,0.81,2.5614,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107736,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",splenocyte morphology trait,,RS:0003766,WAG/Nov,male,180 days to 150 days,10,,CMO:0003534,CD11b/c+ splenocyte count,,cd11b/c+ spleen,,92.63,x10E6/organ,24.28,76.7801,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107739,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",splenocyte morphology trait,,RS:0001334,ISIAH,male,180 days to 150 days,10,,CMO:0003538,CD4+CD25+ splenocyte count to total splenocyte count ratio,,cd4+cd25+ spleen,,1.7,%,0.17,0.5376,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107742,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",splenocyte morphology trait,,RS:0001334,ISIAH,male,180 days to 150 days,10,,CMO:0003541,CD45RA+ splenocyte count to total splenocyte count ratio,,cd45 RA+ spleen,,34.86,%,1.36,4.3007,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107745,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",splenocyte morphology trait,,RS:0001334,ISIAH,male,180 days to 150 days,10,,CMO:0003540,CD11b/c+ splenocyte count to total splenocyte count ratio,,cd11b/c+ spleen,,8.4,%,1.11,3.5101,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107748,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",splenocyte morphology trait,,RS:0001334,ISIAH,male,180 days to 150 days,10,,CMO:0003531,CD4+CD25+ splenocyte count,,cd4+cd25+ spleen,,9.83,x10E6/organ,0.94,2.9725,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107751,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",splenocyte morphology trait,,RS:0001334,ISIAH,male,180 days to 150 days,10,,CMO:0003542,CD4-CD25+ splenocyte count,,cd4-cd25+ spleen,,3.21,x 10E6/organ,0.57,1.8025,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107754,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",splenocyte morphology trait,,RS:0001334,ISIAH,male,180 days to 150 days,10,,CMO:0003533,CD3+ splenocyte count,,cd3+ spleen,,214.09,x10E6/organ,11.49,36.3346,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107757,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",splenocyte morphology trait,,RS:0001334,ISIAH,male,180 days to 150 days,10,,CMO:0003534,CD11b/c+ splenocyte count,,cd11b/c+ spleen,,50.17,x10E6/organ,10.65,33.6783,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107760,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",thymocyte quantity,,RS:0001334,ISIAH,male,180 days to 150 days,10,,CMO:0003517,CD3+ thymocyte count,,cd3+ thymus,,716.82,x10E6/organ,91.79,290.2655,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107763,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",thymocyte quantity,,RS:0001334,ISIAH,male,180 days to 150 days,10,,CMO:0003528,CD4+CD8+ thymocyte count,,cd4+cd8+ t-cell,,419,x10E6/organ,50.57,159.9164,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107766,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 2339,"Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.",urine output,,RS:0003328,SS/NEisSlc,not specified,547 days,10,,CMO:0001968,timed urine volume to body weight ratio,,,,0.0218736,ul/min/g,0.0024,0.0075,MMO:0000357,urine volume measurement method,,0.0,,,,,vehicle control condition (for 547.5 days),107429,vehicle control condition (for 547.5 days),,,,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood triglyceride amount,serum triglyceride level,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000360,serum triglyceride level,,,,249,mg/dl,6.957,22.0,MMO:0000554,automated serum analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107899,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3028,"Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.",retina blood vessel morphology trait,,RS:0000681,SD,male,49 days to 35 days,3,,CMO:0003187,retinal uptake index of quinidine,,quinidine uptake index,,212,%,13.0,22.5167,MMO:0000238,liquid scintillation counting,,0.0,sec post excision,carotid injection,15,,tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours),106114,tritiated quinidine (10 uCi) (for 0 hours),vehicle control condition (for 0 hours),,,,,,,,, 3028,"Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.",retina blood vessel morphology trait,,RS:0000681,SD,male,49 days to 35 days,3,,CMO:0003184,retinal uptake index of digoxin,,digoxin uptake index,,24,%,5.8,10.0459,MMO:0000238,liquid scintillation counting,,0.0,sec post excision,carotid injection,15,,tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours),106117,tritiated digoxin (10 uCi) (for 0 hours),vehicle control condition (for 0 hours),,,,,,,,, 3028,"Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.",retina blood vessel morphology trait,,RS:0000681,SD,male,49 days to 35 days,3,,CMO:0003178,retinal uptake index of verapamil,,verapamil uptake index,,336,%,7.0,12.1244,MMO:0000238,liquid scintillation counting,,0.0,sec post excision,carotid injection,15,,tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours),106120,tritiated verapamil (10 uCi) (for 0 hours),vehicle control condition (for 0 hours),,,,,,,,, 3028,"Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.",retina blood vessel morphology trait,,RS:0004432,SD-Abcb1aem1Sage-/-,male,56 days to 42 days,3,,CMO:0003187,retinal uptake index of quinidine,,quinidine uptake index,,227,%,25.0,43.3013,MMO:0000238,liquid scintillation counting,,0.0,sec post excision,carotid injection,15,,tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours),106123,tritiated quinidine (10 uCi) (for 0 hours),vehicle control condition (for 0 hours),,,,,,,,, 3028,"Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.",retina blood vessel morphology trait,,RS:0004432,SD-Abcb1aem1Sage-/-,male,56 days to 42 days,3,,CMO:0003184,retinal uptake index of digoxin,,digoxin uptake index,,88,%,29.7,51.4419,MMO:0000238,liquid scintillation counting,,0.0,sec post excision,carotid injection,15,,tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours),106126,tritiated digoxin (10 uCi) (for 0 hours),vehicle control condition (for 0 hours),,,,,,,,, 3028,"Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.",retina blood vessel morphology trait,,RS:0004432,SD-Abcb1aem1Sage-/-,male,56 days to 42 days,3,,CMO:0003178,retinal uptake index of verapamil,,verapamil uptake index,,536,%,6.0,10.3923,MMO:0000238,liquid scintillation counting,,0.0,sec post excision,carotid injection,15,,tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours),106129,tritiated verapamil (10 uCi) (for 0 hours),vehicle control condition (for 0 hours),,,,,,,,, 3028,"Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.",aqueous humor morphology trait,,RS:0000681,SD,male,49 days to 35 days,3,,CMO:0003185,aqueous humor uptake index of quinidine,,quinidine uptake index,,5.95,%,0.38,0.6582,MMO:0000238,liquid scintillation counting,,0.0,sec post excision,carotid injection,15,,tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours),106132,tritiated quinidine (10 uCi) (for 0 hours),vehicle control condition (for 0 hours),,,,,,,,, 3028,"Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.",aqueous humor morphology trait,,RS:0004432,SD-Abcb1aem1Sage-/-,male,49 days to 35 days,3,,CMO:0003182,aqueous humor uptake index of digoxin,,digoxin uptake index,,55.9,%,13.2,22.8631,MMO:0000238,liquid scintillation counting,,0.0,sec post excision,carotid injection,15,,tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours),106144,tritiated digoxin (10 uCi) (for 0 hours),vehicle control condition (for 0 hours),,,,,,,,, 3028,"Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.",aqueous humor morphology trait,,RS:0004432,SD-Abcb1aem1Sage-/-,male,56 days to 42 days,3,,CMO:0003179,aqueous humor uptake index of verapamil,,verapamil uptake index,,24.8,%,1.4,2.4249,MMO:0000238,liquid scintillation counting,,0.0,sec post excision,carotid injection,15,,tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours),106147,tritiated verapamil (10 uCi) (for 0 hours),vehicle control condition (for 0 hours),,,,,,,,, 3028,"Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.",blood-brain barrier morphology trait,,RS:0000681,SD,male,49 days to 35 days,3,,CMO:0003186,brain uptake index of quinidine,,quinidine uptake index,,2.12,%,0.12,0.2078,MMO:0000238,liquid scintillation counting,,0.0,sec post excision,carotid injection,15,,tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours),106150,tritiated quinidine (10 uCi) (for 0 hours),vehicle control condition (for 0 hours),,,,,,,,, 3028,"Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.",blood-brain barrier morphology trait,,RS:0000681,SD,male,49 days to 35 days,3,,CMO:0003183,brain uptake index of digoxin,,digoxin uptake index,,0.987,%,0.35,0.6062,MMO:0000238,liquid scintillation counting,,0.0,sec post excision,carotid injection,15,,tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours),106153,tritiated digoxin (10 uCi) (for 0 hours),vehicle control condition (for 0 hours),,,,,,,,, 3028,"Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.",blood-brain barrier morphology trait,,RS:0000681,SD,male,49 days to 35 days,3,,CMO:0003177,brain uptake index of verapamil,,verapamil uptake index,,9.07,%,0.89,1.5415,MMO:0000238,liquid scintillation counting,,0.0,sec post excision,carotid injection,15,,tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours),106156,tritiated verapamil (10 uCi) (for 0 hours),vehicle control condition (for 0 hours),,,,,,,,, 3028,"Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.",blood-brain barrier morphology trait,,RS:0004432,SD-Abcb1aem1Sage-/-,male,56 days to 42 days,3,,CMO:0003186,brain uptake index of quinidine,,quinidine uptake index,,26.1,%,2.4,4.1569,MMO:0000238,liquid scintillation counting,,0.0,sec post excision,carotid injection,15,,tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition,106159,tritiated quinidine (10 uCi) (for 0 hours),vehicle control condition,,,,,,,,, 2339,"Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.",glomerular filtration trait,,RS:0003328,SS/NEisSlc,not specified,547 days,10,,CMO:0001211,creatinine clearance to body weight ratio,,,,0.38241,ml/min/100g,0.0267,0.0843,MMO:0000306,plasma creatinine analysis,,0.0,,,,,vehicle control condition (for 547.5 days),107441,vehicle control condition (for 547.5 days),,,,,,,,,, 2339,"Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.",locomotor behavior trait,,RS:0003328,SS/NEisSlc,not specified,236 days to 63 days,10,,CMO:0001037,time to first movement outside a discrete space in an experimental apparatus,,,,235,s,50.0,158.1139,MMO:0000725,passive avoidance test using a two-way shuttle box apparatus,,0.0,passive avoidance test using a two-way shuttle box apparatus (MMO:000072),electric foot shock,18,days,vehicle control condition (for 547.5 days) then tactile electric shock exposure (500 mA) (for 0 hours),107468,vehicle control condition (for 547.5 days),,,tactile electric shock exposure (500 mA) (for 0 hours),,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood bilirubin amount,serum bilirubin,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000376,serum total bilirubin level,,,,0.4,mg/dl,0.0316,0.1,MMO:0000554,automated serum analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107924,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood bilirubin amount,serum bilirubin,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000376,serum total bilirubin level,,,,0.35,mg/dl,0.1581,0.5,MMO:0000554,automated serum analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107926,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood lactate dehydrogenase amount,,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000668,serum lactate dehydrogenase activity level,,,,964,U/l,31.3065,99.0,MMO:0000554,automated serum analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107929,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood lactate dehydrogenase amount,,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000668,serum lactate dehydrogenase activity level,,,,2717,U/l,163.1735,516.0,MMO:0000554,automated serum analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107931,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3015,"Zhuang ZM, et al., Int J Clin Exp Med. 2015 May 15;8(5):6866-77. eCollection 2015.",blood interleukin-4 amount,,RS:0000681,SD,not specified,0 days,4,,CMO:0003066,serum interleukin-4 level,,error not defined,,0.14,ug/l,0.005,0.01,MMO:0000075,enzyme linked immunosorbent assay,,0.0,,,,,vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days),105411,vehicle control condition,,,acetic acid (for 0 hours),,physical restraint in tube type rodent restrainer (for 2 hours),,fasting (for 1 days),,, 3015,"Zhuang ZM, et al., Int J Clin Exp Med. 2015 May 15;8(5):6866-77. eCollection 2015.",blood interleukin-9 amount,,RS:0000681,SD,not specified,0 days,4,,CMO:0003068,serum interleukin-9 level,,error not defined,,0.1,ug/l,0.005,0.01,MMO:0000075,enzyme linked immunosorbent assay,,0.0,,,,,vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days),105415,vehicle control condition,,,acetic acid (for 0 hours),,physical restraint in tube type rodent restrainer (for 2 hours),,fasting (for 1 days),,, 3015,"Zhuang ZM, et al., Int J Clin Exp Med. 2015 May 15;8(5):6866-77. eCollection 2015.",intestine trypsin amount,,RS:0000681,SD,not specified,0 days,4,,CMO:0003072,intestine trypsin level,,error not defined,,0.17,ug/l,0.005,0.01,MMO:0000075,enzyme linked immunosorbent assay,,0.0,,,,,vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days),105419,vehicle control condition,,,acetic acid (for 0 hours),,physical restraint in tube type rodent restrainer (for 2 hours),,fasting (for 1 days),,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal outer nuclear layer morphology trait,,RS:0000064,Crl:CD(SD),male,66 days to 59 days,5,,CMO:0003086,retinal outer nuclear layer thickness,,outer nuc layer,,41,um,1.118,2.5,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,,,,,vehicle control condition (0 mg/kg) (for 5 days),105434,vehicle control condition (0 mg/kg) (for 5 days),,,,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal layer morphology trait,,RS:0000064,Crl:CD(SD),male,66 days to 59 days,5,,CMO:0003083,retinal outer layer thickness,,outer retinal layer,,142.2,um,2.6833,6.0,MMO:0000696,optical coherence tomography,,0.0,optical coherence tomography,,,,vehicle control condition (0 mg/kg) (for 5 days),105466,vehicle control condition (0 mg/kg) (for 5 days),,,,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal layer morphology trait,,RS:0000064,Crl:CD(SD),male,74 days to 67 days,5,,CMO:0003083,retinal outer layer thickness,,outer retinal layer,,138.5,um,3.3988,7.6,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,optical coherence tomography,,,,vehicle control condition (0 mg/kg) (for 13 days),105474,vehicle control condition (0 mg/kg) (for 13 days),,,,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal layer morphology trait,,RS:0000064,Crl:CD(SD),male,87 days to 80 days,10,,CMO:0003083,retinal outer layer thickness,,outer retinal layer,,136,um,3.4883,7.8,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,optical coherence tomography,,,,vehicle control condition (0 mg/kg) (for 26 days),105482,vehicle control condition (0 mg/kg) (for 26 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",liver mass,,RS:0000698,Hsd:SD,female,84 days,10,,CMO:0000141,liver weight as percentage of body weight,,,,3.647,%,0.199,0.6293,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (5 ml/kg) (for 28 days),105720,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3021,"Harrill JA, et al., J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.",liver mass,,RS:0004674,SD-Ahrem2Sage,female,84 days,10,,CMO:0000141,liver weight as percentage of body weight,,,,3.428,%,0.3,0.9487,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition (5 ml/kg) (for 28 days),105726,vehicle control condition (5 ml/kg) (for 28 days),,,,,,,,,, 3028,"Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.",blood-brain barrier morphology trait,,RS:0004432,SD-Abcb1aem1Sage-/-,male,56 days to 42 days,3,,CMO:0003183,brain uptake index of digoxin,,digoxin uptake index,,14,%,7.3,12.644,MMO:0000238,liquid scintillation counting,,0.0,sec post excision,carotid injection,15,,tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition,106162,tritiated digoxin (10 uCi) (for 0 hours),vehicle control condition,,,,,,,,, 3028,"Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.",blood-brain barrier morphology trait,,RS:0004432,SD-Abcb1aem1Sage-/-,male,56 days to 42 days,3,,CMO:0003177,brain uptake index of verapamil,,verapamil uptake index,,75,%,5.8,10.0459,MMO:0000238,liquid scintillation counting,,0.0,sec post excision,carotid injection,15,,tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition,106165,tritiated verapamil (10 uCi) (for 0 hours),vehicle control condition,,,,,,,,, 2339,"Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.",blood enzyme amount,,RS:0003328,SS/NEisSlc,not specified,547 days,10,,CMO:0003487,serum NAG activity level,,serum NAG activity level (CMO:0003487),,20.1,uU/ml,1.9,6.0083,MMO:0000723,blood NAG activity assay,,0.0,blood NAG activity assay (MMO:0000723),,,,vehicle control condition (for 547.5 days),107425,vehicle control condition (for 547.5 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",thymocyte quantity,,RS:0001334,ISIAH,male,180 days to 150 days,10,,CMO:0003529,CD4-CD8+ thymocyte count,,cd4-cd8+ t-cell,,63.99,x10E6/organ,6.25,19.7642,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107769,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",thymocyte quantity,,RS:0001334,ISIAH,male,180 days to 150 days,10,,CMO:0003530,CD4+CD25+ thymocyte count,,cd4+cd25+ t-cell,,32.19,x10E6/organ,7.15,22.6103,MMO:0000617,flow cytometry method,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107772,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",blood triglyceride amount,,RS:0003766,WAG/Nov,male,180 days to 150 days,10,,CMO:0000548,plasma triglyceride level,,,,1.1865,mmol/l,0.0915,0.2894,MMO:0000234,plasma triglyceride analysis,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107775,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",blood triglyceride amount,,RS:0001334,ISIAH,male,180 days to 150 days,10,,CMO:0000548,plasma triglyceride level,,,,1.2995,mmol/l,0.1153,0.3645,MMO:0000234,plasma triglyceride analysis,,0.0,saline,IP injeciton,1,days,vehicle control condition (2 ml/kg) (for 1 days),107778,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal outer nuclear layer morphology trait,,RS:0000064,Crl:CD(SD),male,88 days to 81 days,5,,CMO:0003086,retinal outer nuclear layer thickness,,outer nuc layer,,53.4,um,2.3255,5.2,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,,,,,vehicle control condition (0 mg/kg) (for 25 days),105442,vehicle control condition (0 mg/kg) (for 25 days),,,,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal outer nuclear layer morphology trait,,RS:0000064,Crl:CD(SD),male,144 days to 137 days,5,,CMO:0003085,retinal outer nuclear layer photoreceptor nucleus count,,nuclei per cell,,10.5,,0.4025,0.9,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,vehicle control condition (for 25 days),105462,vehicle control condition (for 25 days),,,,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal layer morphology trait,,RS:0000064,Crl:CD(SD),male,87 days to 80 days,10,,CMO:0003084,retinal inner layer thickness,,inner retinal layer,,126,um,4.0249,9.0,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,optical coherence tomography,,,,vehicle control condition (0 mg/kg) (for 26 days),105486,vehicle control condition (0 mg/kg) (for 26 days),,,,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal layer morphology trait,,RS:0000064,Crl:CD(SD),male,118 days to 111 days,5,,CMO:0003083,retinal outer layer thickness,,outer retinal layer,,132.2,um,3.7119,8.3,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,optical coherence tomography,,,,vehicle control condition (0 mg/kg) (for 25 days),105490,vehicle control condition (0 mg/kg) (for 25 days),,,,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal layer morphology trait,,RS:0000064,Crl:CD(SD),male,143 days to 136 days,5,,CMO:0003083,retinal outer layer thickness,,outer retinal layer,,129.8,um,4.0249,9.0,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,optical coherence tomography,,,,vehicle control condition (0 mg/kg) (for 25 days),105498,vehicle control condition (0 mg/kg) (for 25 days),,,,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal layer morphology trait,,RS:0000064,Crl:CD(SD),male,143 days to 136 days,5,,CMO:0003084,retinal inner layer thickness,,inner retinal layer,,123.8,um,4.8299,10.8,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,optical coherence tomography,,,,vehicle control condition (0 mg/kg) (for 25 days),105502,vehicle control condition (0 mg/kg) (for 25 days),,,,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal layer morphology trait,,RS:0000064,Crl:CD(SD),male,66 days to 59 days,5,,CMO:0003082,full retina thickness,,full retina layer,,129.7,um,3.7119,8.3,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,,,,,vehicle control condition (0 mg/kg) (for 5 days),105438,vehicle control condition (0 mg/kg) (for 5 days),,,,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal outer nuclear layer morphology trait,,RS:0000064,Crl:CD(SD),male,88 days to 81 days,5,,CMO:0003085,retinal outer nuclear layer photoreceptor nucleus count,,nuclei per cell,,11.3,,0.3712,0.83,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,vehicle control condition (0 mg/kg) (for 25 days),105450,vehicle control condition (0 mg/kg) (for 25 days),,,,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal outer nuclear layer morphology trait,,RS:0000064,Crl:CD(SD),male,144 days to 137 days,5,,CMO:0003086,retinal outer nuclear layer thickness,,outer nuc layer,,50.6,um,1.61,3.6,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,,,,,vehicle control condition (for 25 days),105454,vehicle control condition (for 25 days),,,,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal layer morphology trait,,RS:0000064,Crl:CD(SD),male,144 days to 137 days,5,,CMO:0003082,full retina thickness,,full retina layer,,191.6,um,7.5579,16.9,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,,,,,vehicle control condition (0 mg/kg) (for 25 days),105458,vehicle control condition (0 mg/kg) (for 25 days),,,,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal layer morphology trait,,RS:0000064,Crl:CD(SD),male,66 days to 59 days,5,,CMO:0003084,retinal inner layer thickness,,inner retinal layer,,131.6,um,4.8746,10.9,MMO:0000696,optical coherence tomography,,0.0,optical coherence tomography,,,,vehicle control condition (0 mg/kg) (for 5 days),105470,vehicle control condition (0 mg/kg) (for 5 days),,,,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal layer morphology trait,,RS:0000064,Crl:CD(SD),male,74 days to 67 days,5,,CMO:0003084,retinal inner layer thickness,,inner retinal layer,,128.7,um,4.9193,11.0,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,optical coherence tomography,,,,vehicle control condition (0 mg/kg) (for 13 days),105478,vehicle control condition (0 mg/kg) (for 13 days),,,,,,,,,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal layer morphology trait,,RS:0000064,Crl:CD(SD),male,118 days to 111 days,5,,CMO:0003084,retinal inner layer thickness,,inner retinal layer,,121.9,um,4.3827,9.8,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,optical coherence tomography,,,,vehicle control condition (0 mg/kg) (for 25 days),105494,vehicle control condition (0 mg/kg) (for 25 days),,,,,,,,,, 3029,"Yang F, et al., J Pharm Pharm Sci. 2014;17(3):362-70.",cerebrum integrity trait,,RS:0001696,F344-Pde4dTn(sb-T2/Bart3)2.285Mcwi,male,0 days,6,,CMO:0003169,cerebrum infarct volume to total cerebrum volume ratio,,,,20,%,9.0,22.0454,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,,cerebral ischemia,1,days,isoflurane (1.5 %) (for 4 hours) then vehicle control condition then middle cerebral artery occlusion (for 1 hours),106360,isoflurane (1.5 %) (for 4 hours),,,vehicle control condition,,middle cerebral artery occlusion (for 1 hours),,,,, 3015,"Zhuang ZM, et al., Int J Clin Exp Med. 2015 May 15;8(5):6866-77. eCollection 2015.",blood immunoglobulin E amount,,RS:0000681,SD,not specified,0 days,4,,CMO:0001542,serum total immunoglobulin E level,,error not defined,,0.2,ug/l,0.0,0.0,MMO:0000075,enzyme linked immunosorbent assay,,0.0,,,,,vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days),105407,vehicle control condition,,,acetic acid (for 0 hours),,physical restraint in tube type rodent restrainer (for 2 hours),,fasting (for 1 days),,, 3016,"Fielden MR, et al., Toxicol Pathol. 2015 Jun;43(4):581-92. doi: 10.1177/0192623314553804. Epub 2014 Oct 31.",retinal layer morphology trait,,RS:0000064,Crl:CD(SD),male,88 days to 81 days,5,,CMO:0003082,full retina thickness,,full retina layer,,177.2,um,6.2163,13.9,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,,,,,vehicle control condition (0 mg/kg) (for 25 days),105446,vehicle control condition (0 mg/kg) (for 25 days),,,,,,,,,, 3018,"Westlund KN, et al., Neuroscience. 2014 Mar 14;262:165-75. doi: 10.1016/j.neuroscience.2013.12.043. Epub 2014 Jan 3.",voluntary movement trait,,RS:0000215,F344,male,0 days,4,,CMO:0003680,measurement of the 50% threshold of mechanical stimulus needed to elicit evasive reaction,,both paws,,2.88,g,0.44,0.88,MMO:0000752,von Frey assay,,1500.0,von Frey assay (MMO:0000752),,,,vehicle control condition,105566,vehicle control condition,,,,,,,,,, 3083,"Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15.",life span trait,,RS:0002538,SHRSP/A3NCrl,male,175 days to 161 days,12,,CMO:0003630,ratio of survivors of severe albuminuria to total study population during a period of time,,ratio of survivors of severe albuminuria to total study population during a period of time (CMO:0003630),,50,%,,,MMO:0000160,unspecified method,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days),109030,controlled sodium chloride content drinking water (1 %) (for 91 days),controlled fat content diet (24.5 %) (for 91 days),,vehicle control condition (for 35 days),,,,,,, 3028,"Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.",aqueous humor morphology trait,,RS:0000681,SD,male,49 days to 35 days,3,,CMO:0003179,aqueous humor uptake index of verapamil,,verapamil uptake index,,8.46,%,0.61,1.0566,MMO:0000238,liquid scintillation counting,,0.0,sec post excision,carotid injection,15,,tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours),106138,tritiated verapamil (10 uCi) (for 0 hours),vehicle control condition (for 0 hours),,,,,,,,, 3028,"Fujii S, et al., Invest Ophthalmol Vis Sci. 2014 Jul 1;55(7):4650-8. doi: 10.1167/iovs.13-13819.",aqueous humor morphology trait,,RS:0004432,SD-Abcb1aem1Sage-/-,male,56 days to 42 days,3,,CMO:0003185,aqueous humor uptake index of quinidine,,quinidine uptake index,,12,%,0.6,1.0392,MMO:0000238,liquid scintillation counting,,0.0,sec post excision,carotid injection,15,,tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours),106141,tritiated quinidine (10 uCi) (for 0 hours),vehicle control condition (for 0 hours),,,,,,,,, 3029,"Yang F, et al., J Pharm Pharm Sci. 2014;17(3):362-70.",cerebrum integrity trait,,RS:0001013,WI,male,0 days,16,,CMO:0003169,cerebrum infarct volume to total cerebrum volume ratio,,,,23,%,3.0,12.0,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,,cerebral ischemia,1,days,isoflurane (1.5 %) (for 4 hours) then vehicle control condition then Embolism injection at middle cerebral artery (for 1 days),106358,isoflurane (1.5 %) (for 4 hours),,,vehicle control condition,,Embolism injection at middle cerebral artery (for 1 days),,,,, 3029,"Yang F, et al., J Pharm Pharm Sci. 2014;17(3):362-70.",cerebrum integrity trait,,RS:0000215,F344,male,0 days,18,,CMO:0003169,cerebrum infarct volume to total cerebrum volume ratio,,,,11,%,2.0,8.4853,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,,cerebral ischemia,1,days,isoflurane (1.5 %) (for 4 hours) then vehicle control condition then middle cerebral artery occlusion (for 1 hours),106172,isoflurane (1.5 %) (for 4 hours),,,vehicle control condition,,middle cerebral artery occlusion (for 1 hours),,,,, 3029,"Yang F, et al., J Pharm Pharm Sci. 2014;17(3):362-70.",cerebrum integrity trait,,RS:0000215,F344,male,0 days,6,,CMO:0003169,cerebrum infarct volume to total cerebrum volume ratio,,,,18,%,6.0,14.6969,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,,cerebral ischemia,1,days,isoflurane (1.5 %) (for 4 hours) then vehicle control condition then middle cerebral artery occlusion (for 1 hours),106361,isoflurane (1.5 %) (for 4 hours),,,vehicle control condition,,middle cerebral artery occlusion (for 1 hours),,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart right ventricle mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0003280,heart right ventricle weight to left ventricle plus septum weight ratio,,heart right ventricle weight to left ventricle plus septum weight ratio,,0.25,g/g,0.02,0.0529,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106536,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart right ventricle mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0003280,heart right ventricle weight to left ventricle plus septum weight ratio,,heart right ventricle weight to left ventricle plus septum weight ratio,,0.25,g/g,0.01,0.0316,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106537,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart left ventricle mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0000776,heart left ventricle weight,,,,0.641,g,0.0193,0.0511,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106538,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart left ventricle mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0000776,heart left ventricle weight,,,,0.64,g,0.0094,0.0297,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106539,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart right ventricle mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0000777,heart right ventricle weight,,,,0.162,g,0.0067,0.0177,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106540,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart right ventricle mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0000777,heart right ventricle weight,,,,0.157,g,0.0028,0.0089,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106541,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",body mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0000012,body weight,,,,261,g,6.0,15.8745,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition,106550,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",body mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0000012,body weight,,,,259,g,2.8,8.8544,MMO:0000016,body weighing method,,0.0,,,,,vehicle control condition,106551,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",tibia length,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0000450,tibia length,,,,3.64,cm,0.06,0.1587,MMO:0000276,post excision length measurement,,0.0,,,,,vehicle control condition,106554,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",tibia length,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0000450,tibia length,,,,3.64,cm,0.03,0.0949,MMO:0000276,post excision length measurement,,0.0,,,,,vehicle control condition,106555,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",lung mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0000096,lung weight,,,,1.23,g,0.05,0.1323,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106558,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",lung mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0000096,lung weight,,,,1.2,g,0.01,0.0316,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106559,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart right atrium mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0000336,right atrium weight,,,,0.0161,g,0.0012,0.0032,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106562,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart right atrium mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0000336,right atrium weight,,,,0.0149,g,0.0011,0.0036,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106563,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart left atrium mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0000335,left atrium weight,,,,0.0148,g,7.0E-4,0.0019,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106566,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart left atrium mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0000335,left atrium weight,,,,0.0164,g,0.0011,0.0035,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106567,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart right atrium mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0003191,heart right atrium weight to left atrium weight ratio,,,,1.09,,0.09,0.2381,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106570,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart right atrium mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0003191,heart right atrium weight to left atrium weight ratio,,,,0.94,,0.09,0.2846,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106571,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",liver mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0000092,liver weight,,,,10.6,g,0.42,1.1112,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106574,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",liver mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0000092,liver weight,,,,10.6,g,0.22,0.6957,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106575,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",kidney mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0000081,kidney weight,,,,2.13,g,0.05,0.1323,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106578,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",kidney mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0000081,kidney weight,,,,2.03,g,0.03,0.0949,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106579,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart right ventricle mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0000914,heart right ventricle weight to body weight ratio,,,,0.62,mg/g,0.03,0.0794,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106582,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart right ventricle mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0000914,heart right ventricle weight to body weight ratio,,,,0.61,mg/g,0.01,0.0316,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106583,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart left ventricle mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0000530,heart left ventricle weight to body weight ratio,,,,2.43,mg/g,0.05,0.1323,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106586,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart left ventricle mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0000530,heart left ventricle weight to body weight ratio,,,,2.49,mg/g,0.03,0.0949,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106587,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",lung mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0000156,lung weight to body weight ratio,,,,0.403,%,0.076,0.2011,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106590,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",lung mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0000156,lung weight to body weight ratio,,,,0.465,%,0.007,0.0221,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106591,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart right atrium mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0002952,heart right atrium weight to body weight ratio,,,,0.06,mg/g,0.01,0.0265,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106594,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart right atrium mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0002952,heart right atrium weight to body weight ratio,,,,0.06,mg/g,0.01,0.0316,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106595,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart left atrium mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0002950,heart left atrium weight to body weight ratio,,,,0.06,mg/g,0.01,0.0265,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106598,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart left atrium mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0002950,heart left atrium weight to body weight ratio,,,,0.06,mg/g,0.01,0.0316,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106599,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",liver mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0000633,liver weight to body weight ratio,,,,40.5,g/kg,1.02,2.6987,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106602,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",liver mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0000633,liver weight to body weight ratio,,,,40.9,g/kg,0.77,2.435,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106603,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",kidney mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0000622,single kidney wet weight to body weight ratio,,,,8.14,g/kg,0.11,0.291,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106606,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",kidney mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0000622,single kidney wet weight to body weight ratio,,,,7.83,g/kg,0.15,0.4743,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106607,vehicle control condition,,,,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",arterial blood pressure trait,,RS:0000775,SHRSP/A3N,male,189 days to 168 days,6,,CMO:0000004,systolic blood pressure,,,serial mean,284,mmHg,8.0,19.5959,MMO:0000031,tail cuff plethysmography,tail,0.0,average 3 week intervals for 12 weeks,,,,controlled sodium chloride content drinking water (1 %) (for 84 days) and controlled fat content diet (24.5 %) (for 84 days) and vehicle control condition (for 84 days),107499,controlled sodium chloride content drinking water (1 %) (for 84 days),controlled fat content diet (24.5 %) (for 84 days),vehicle control condition (for 84 days),,,,,,,, 3096,"Shurligina AV, et al., Bull Exp Biol Med. 2013 Aug;155(4):421-4. doi: 10.1007/s10517-013-2167-4.",leukocyte quantity,,RS:0001334,ISIAH,male,180 days to 150 days,10,,CMO:0002340,blood non-specified leukocyte count,,,,2.96,10E3/ul,0.99,3.1307,MMO:0000533,white blood cell counting method,,0.0,saline,IP injection,1,days,vehicle control condition (2 ml/kg) (for 1 days),107696,vehicle control condition (2 ml/kg) (for 1 days),,,,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney mass,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0000340,both kidneys wet weight to body weight ratio,,,,13,g/kg,0.7,,MMO:0000005,post excision weight measurement,kidney,0.0,,,,,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days),107535,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days),controlled fat content diet (24.5 %) (between 42 and 77 days),vehicle control condition (between 42 and 77 days),,,,,,,, 3090,"Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.",kidney glomerulus integrity trait,,RS:0000775,SHRSP/A3N,male,182 days to 126 days,N/A,,CMO:0003447,kidney glomerular lesion count,,,,76.5,/section,7.0,,MMO:0000561,ex vivo light microscopy with histochemistry,renal glomerulus,0.0,,,,,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and vehicle control condition (between 42 and 77 days),107539,controlled sodium chloride content drinking water (1 %) (between 42 and 77 days),controlled fat content diet (24.5 %) (between 42 and 77 days),vehicle control condition (between 42 and 77 days),,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood hemoglobin amount,"hemoglobin, MCH, MCHC",RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000290,mean corpuscular hemoglobin,,,,18,pg,0.0632,0.2,MMO:0000295,blood hemoglobin analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107836,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood hemoglobin amount,"hemoglobin, MCH, MCHC",RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000290,mean corpuscular hemoglobin,,,,17.5,pg,0.0316,0.1,MMO:0000295,blood hemoglobin analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107838,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood hemoglobin amount,"hemoglobin, MCH, MCHC",RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000291,mean corpuscular hemoglobin concentration,,,,38,g/dl,0.1265,0.4,MMO:0000295,blood hemoglobin analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107841,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood hemoglobin amount,"hemoglobin, MCH, MCHC",RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000291,mean corpuscular hemoglobin concentration,,,,37,g/dl,0.1897,0.6,MMO:0000295,blood hemoglobin analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107843,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",erythrocyte size trait,"MCV, RDW%",RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000041,red blood cell distribution width-coefficient of variation,,,,16.9,%,0.2214,0.7,MMO:0000174,automated hematology analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107846,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",erythrocyte size trait,"MCV, RDW%",RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000041,red blood cell distribution width-coefficient of variation,,,,17.7,%,0.1265,0.4,MMO:0000174,automated hematology analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107848,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",lymphocyte quantity,LYM,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000371,blood lymphocyte count to total leukocyte count ratio,,,,8.1,%,0.253,0.8,MMO:0000145,automated differential white blood cell count test,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107851,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",lymphocyte quantity,LYM,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000371,blood lymphocyte count to total leukocyte count ratio,,,,8,%,0.0949,0.3,MMO:0000145,automated differential white blood cell count test,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107853,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood triglyceride amount,serum triglyceride level,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000360,serum triglyceride level,,,,265,mg/dl,8.2219,26.0,MMO:0000554,automated serum analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107897,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood aspartate transaminase amount,serum aspartate aminotransferase,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000581,serum aspartate aminotransferase activity level,,,,139,U/l,2.5931,8.2,MMO:0000554,automated serum analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107902,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood aspartate transaminase amount,serum aspartate aminotransferase,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000581,serum aspartate aminotransferase activity level,,,,193,U/l,8.2219,26.0,MMO:0000554,automated serum analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107904,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",blood amylase amount,serum amylase,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0003519,serum amylase activity level,,,,3190,U/l,77.1596,244.0,MMO:0000554,automated serum analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107946,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart right ventricle mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0003188,heart right ventricle weight to tibia length ratio,,,,4.51,mg/mm,0.22,0.5821,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106610,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart right ventricle mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0003188,heart right ventricle weight to tibia length ratio,,,,4.33,mg/mm,0.97,3.0674,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106611,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart left ventricle mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0002787,heart left ventricle weight to tibia length ratio,,,,0.178,g/cm,0.0069,0.0183,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106614,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart left ventricle mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0002787,heart left ventricle weight to tibia length ratio,,,,0.177,g/cm,0.0027,0.0085,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106615,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",lung mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0003144,lung weight to tibia length ratio,,,,0.291,g/cm,0.0455,0.1204,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106618,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",lung mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0003144,lung weight to tibia length ratio,,,,0.33,g/cm,0.004,0.0126,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106619,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart right atrium mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0003192,heart right atrium weight to tibia length ratio,,,,0.44,mg/mm,0.036,0.0952,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106622,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart right atrium mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0003192,heart right atrium weight to tibia length ratio,,,,0.41,mg/mm,0.03,0.0949,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106623,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart left atrium mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0003193,heart left atrium weight to tibia length ratio,,,,0.41,mg/mm,0.02,0.0529,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106626,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",heart left atrium mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0003193,heart left atrium weight to tibia length ratio,,,,0.45,mg/mm,0.03,0.0949,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106627,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",liver mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0002995,liver weight to tibia length ratio,,,,29.2,mg/mm,1.28,3.3866,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106630,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",liver mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0002995,liver weight to tibia length ratio,,,,29.1,mg/mm,0.66,2.0871,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106631,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",kidney mass,,RS:0000811,SS/JrHsdMcwi,male,56 days,7,,CMO:0003145,single kidney weight to tibia length ratio,,,,0.0586,g/cm,0.0018,0.0048,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106634,vehicle control condition,,,,,,,,,, 3032,"Xu D, et al., Hypertension. 2011 Aug;58(2):303-9. doi: 10.1161/HYPERTENSIONAHA.110.166819. Epub 2011 Jul 5.",kidney mass,,RS:0001480,SS-Sod3m1Mcwi,male,56 days,10,,CMO:0003145,single kidney weight to tibia length ratio,,,,0.0556,g/cm,0.0011,0.0035,MMO:0000005,post excision weight measurement,,0.0,,,,,vehicle control condition,106635,vehicle control condition,,,,,,,,,, 2339,"Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502.",hippocampus neuron quantity,,RS:0003328,SS/NEisSlc,not specified,547 days,10,,CMO:0000328,neuron count,,,,1258,cells/mm2,32.0,101.1929,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,,,,vehicle control condition (for 547.5 days),107465,vehicle control condition (for 547.5 days),,,,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney mass,,RS:0000742,WKY,male,0 days,11,,CMO:0001954,left kidney wet weight to body weight ratio,,,,3.9,mg/g,0.1,0.3317,MMO:0000005,post excision weight measurement,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then vehicle control condition,107455,unilateral nephrectomy (for 150 days),,,vehicle control condition,,,,,,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus size trait,,RS:0000742,WKY,male,0 days,11,,CMO:0003488,kidney glomerular surface area,,kidney glomerulus surface area (CMO:0003488),,12.6,x 10E3 um2,3.8,12.6032,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then vehicle control condition,107460,unilateral nephrectomy (for 150 days),,,vehicle control condition,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",granulocyte quantity,,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000367,blood granulocyte count to total leukocyte count ratio,,,,1.2,%,0.0,0.0,MMO:0000145,automated differential white blood cell count test,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107856,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",granulocyte quantity,,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000367,blood granulocyte count to total leukocyte count ratio,,,,0.8,%,0.0,0.0,MMO:0000145,automated differential white blood cell count test,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107858,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",lymphocyte quantity,LYM,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000031,blood lymphocyte count,,,,62.8,x 1000 cells/ul,0.3162,1.0,MMO:0000145,automated differential white blood cell count test,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107861,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",lymphocyte quantity,LYM,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000031,blood lymphocyte count,,,,77.7,x 1000 cells/ul,0.6325,2.0,MMO:0000145,automated differential white blood cell count test,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107863,DHD/K12/TRb cells (1.5 X 10E6) ,,,vehicle control condition (1 ml) ,,,,,,, 3083,"Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15.",xenobiotic metabolism trait,,RS:0002538,SHRSP/A3NCrl,male,175 days to 161 days,6,,CMO:0003440,time to peak measurement of Gd-DTPA uptake by kidney cortex,,5 seconds x 10 measurements averaged x 8 regions,,14.3,s,1.2,17.98,MMO:0000718,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,cortex of kidney,400.0,5 seconds x 10 measurements averaged x 8 regions,,,,controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days),107374,controlled sodium chloride content drinking water (1 %) (for 91 days),controlled fat content diet (24.5 %) (for 91 days),,vehicle control condition (for 35 days),,,,,,, 3083,"Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15.",glomerular filtration trait,,RS:0002538,SHRSP/A3NCrl,male,175 days to 161 days,6,,CMO:0003631,multiregional glomerular filtration rate index,dCm/dt = KclCc(t),glomerular filtration rate index,,2.25,mmol/min,0.14,0.3429,MMO:0000718,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,,400.0,5 sec x 10 measurements x 8 regions,,,,controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (between 35 and 63 days),107379,controlled sodium chloride content drinking water (1 %) (for 91 days),controlled fat content diet (24.5 %) (for 91 days),,vehicle control condition (between 35 and 63 days),,,,,,, 3083,"Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15.",body mass,,RS:0002538,SHRSP/A3NCrl,male,175 days to 161 days,6,,CMO:0000012,body weight,,,,307,g,8.0,19.5959,MMO:0000016,body weighing method,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days),107382,controlled sodium chloride content drinking water (1 %) (for 91 days),controlled fat content diet (24.5 %) (for 91 days),,vehicle control condition (for 35 days),,,,,,, 3083,"Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15.",arterial blood pressure trait,,RS:0002538,SHRSP/A3NCrl,male,175 days to 161 days,6,,CMO:0000004,systolic blood pressure,,,,162,mmHg,4.0,9.798,MMO:0000031,tail cuff plethysmography,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days),107385,controlled sodium chloride content drinking water (1 %) (for 91 days),controlled fat content diet (24.5 %) (for 91 days),,vehicle control condition (for 35 days),,,,,,, 3083,"Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15.",glomerular filtration trait,,RS:0002538,SHRSP/A3NCrl,male,175 days to 161 days,6,,CMO:0000765,creatinine clearance,,,,2,ml/min,0.2,0.4899,MMO:0000275,urine creatinine analysis,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days),107388,controlled sodium chloride content drinking water (1 %) (for 91 days),controlled fat content diet (24.5 %) (for 91 days),,vehicle control condition (for 35 days),,,,,,, 3083,"Lenhard SC, etal., J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. doi: 10.1124/jpet.103.057398. Epub 2003 Oct 15.",blood urea nitrogen amount,,RS:0002538,SHRSP/A3NCrl,male,175 days to 161 days,6,,CMO:0000049,blood urea nitrogen level,,,,20.5,mg/dl,5.8,14.207,MMO:0000253,blood urea nitrogen analysis,,0.0,,,,,controlled sodium chloride content drinking water (1 %) (for 91 days) and controlled fat content diet (24.5 %) (for 91 days) then vehicle control condition (for 35 days),107391,controlled sodium chloride content drinking water (1 %) (for 91 days),controlled fat content diet (24.5 %) (for 91 days),,vehicle control condition (for 35 days),,,,,,, 3154,"Baranov P, et al., J Ocul Pharmacol Ther. 2017 Jun;33(5):412-422. doi: 10.1089/jop.2016.0121. Epub 2017 Apr 25.",cone electrophysiology trait,,RS:0000655,RCS-p+/LavRrrc,not specified,119 days,7,,CMO:0003702,photopic B wave amplitude of ERG waveform,,,,23.1,uV,1.0,2.6458,MMO:0000616,electroretinography,cornea,0.0,,intravitrial injection,98,days,vehicle control condition (2 ul) then visible light stimulus (25 cd x s/m2) ,109739,vehicle control condition (2 ul) ,,,visible light stimulus (25 cd x s/m2) ,,,,,,, 3154,"Baranov P, et al., J Ocul Pharmacol Ther. 2017 Jun;33(5):412-422. doi: 10.1089/jop.2016.0121. Epub 2017 Apr 25.",eye physiology trait,,RS:0000655,RCS-p+/LavRrrc,not specified,119 days,7,,CMO:0003729,optokinetic reflex,,,,6,s,0.27,0.7144,MMO:0000754,optokinetic reflex test method,,60.0,,intravitrial injection,98,days,vehicle control condition (2 ul) then visible light stimulus (25 cd x s/m2) ,109741,vehicle control condition (2 ul) ,,,visible light stimulus (25 cd x s/m2) ,,,,,,, 3157,"Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y.",rod electrophysiology trait,,RS:0000660,RCS/LavRrrc,not specified,35 days,4,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,,,95.22,uV,16.19,32.38,MMO:0000616,electroretinography,retina,0.0,,pbs vehicle injection,14,days,vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus,109856,vehicle control condition (2 ul) ,,,controlled exposure to darkness (for 12 hours),,visible light stimulus,,,,, 3157,"Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y.",rod electrophysiology trait,,RS:0000660,RCS/LavRrrc,not specified,77 days,4,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,,,13.01,uV,1.845,3.69,MMO:0000616,electroretinography,retina,0.0,,pbs vehicle injection,56,days,vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus,109862,vehicle control condition (2 ul) ,,,controlled exposure to darkness (for 12 hours),,visible light stimulus,,,,, 3157,"Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y.",rod electrophysiology trait,,RS:0000660,RCS/LavRrrc,not specified,49 days,4,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,,,29.44,uV,7.435,14.87,MMO:0000616,electroretinography,retina,0.0,,pbs vehicle injection,28,days,vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus,109859,vehicle control condition (2 ul) ,,,controlled exposure to darkness (for 12 hours),,visible light stimulus,,,,, 3155,"van Hoesel QG, etal., J Natl Cancer Inst. 1984 May;72(5):1141-50.",hypodermis integrity trait,,RS:0004900,LOU/MWsl,male,130 days,8,,CMO:0003700,subcutaneous tumor diameter measurement,,,,37.2,mm,1.1314,3.2,MMO:0000159,in vivo caliper method,hindlimb,0.0,mean of 3 measurements,,28,days,rat IgM immunocytoma cells (0.01 x 10E6 cells) (for 18 days) then vehicle control condition (1 ml/kg) (for 28 days),109745,rat IgM immunocytoma cells (0.01 x 10E6 cells) (for 18 days),,,vehicle control condition (1 ml/kg) (for 28 days),,,,,,, 3155,"van Hoesel QG, etal., J Natl Cancer Inst. 1984 May;72(5):1141-50.",blood albumin amount,,RS:0004900,LOU/MWsl,male,109 days,5,,CMO:0000550,serum albumin level,,,,219,g/dl,13.8636,31.0,MMO:0000100,gel electrophoresis,,0.0,,,,,rat IgM immunocytoma cells (0.01 x 10E6 cells) (for 18 days) then vehicle control condition (1 ml/kg) (for 7 days),109761,rat IgM immunocytoma cells (0.01 x 10E6 cells) (for 18 days),,,vehicle control condition (1 ml/kg) (for 7 days),,,,,,,